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Cognitive fluctuations occur in 80-90% of patients with dementia with Lewy bodies (DLB) and 
have a profound negative impact on the patient’s quality of life. However, cognitive 
fluctuations are the least well characterised of the core clinical features. The ascending 
reticular activating system (ARAS) has an important role in arousal and awareness, 
therefore, has been implicated in the aetiology of cognitive fluctuations in DLB.  
Methods 
Post-mortem tissue from components of the ARAS, locus coeruleus, pedunculopontine 
nucleus, raphe and medial prefrontal cortex (mPFC), was obtained from DLB cases with a 
clinical history of cognitive fluctuations and compared to cognitively normal control, mixed 
Alzheimer’s disease (AD)/DLB cases with cognitive fluctuations, and mixed AD/DLB and AD 
without cognitive fluctuations. Pathological burden of protein aggregates and 
neurotransmitter markers were quantified in individual cases. Immunoblots were performed 
on isolated synaptosomes from mPFC tissue to examine ARAS projection integrity. Influence 
of pathological and biochemical markers on the presence and severity of cognitive 
fluctuations were determined 
Key findings 
Neurodegenerative pathology was observed in all regions examined, with no specific pattern 
or level of pathological burden associated with the presence or absence of cognitive 
fluctuations. Alterations to the serotonergic system in DLB may relate to the severity of 
cognitive fluctuations. Synaptosomal isolation may preferentially select for intact, functional, 
synapses as neurotransmitter marker levels analysed did not differ from controls  
Conclusions 
This study identified that the severity of protein aggregates in the ARAS was not associated 
with the presence or absence of cognitive fluctuations. The results may indicate that DLB 
patients have a pathologically compromised arousal system, but that this likely acts in 
concert with other mechanisms to elicit cognitive fluctuations. As cognitive fluctuations are 
transient, one may speculate that static protein aggregates are unlikely to underlie a clinical 
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Figure 1.1. a-synuclein protein structure.                                                                                                                                                
α-synuclein is a 140 amino acid protein, with three functionally distinct sub-regions. N-
terminal region: highly conserved, contains 7, 11 residue repeats that form a helix upon 
membrane binding, the six known missense mutations that cause familial PD lie within this 
region (shown in orange). Central hydrophobic region (non-Aβ component or NAC domain): 
associated with an increased propensity of the protein to form fibrils. Acidic tail: contains 
mainly negatively charged residue and largely unfolded; all bar of the phosphorylation sites, 
serine (Ser) 87, are localised in the c-terminal domain, phosphorylation of α-synuclein at 
Ser129 (shown in green) has been found to be the predominant form of the α-synuclein in 
Lewy bodies (Wales et al., 2013). .............................................................................................. 8 
Figure 1.2. Mechanisms of a-synuclein propagation.                                                                                                                      
α-synuclein species may be transferred between neurons and induce spread of pathology to 
neighbouring brain regions. Once α-synuclein has been released from the originating cell 
into the extracellular environment, either via exosomes or non-classical exocytosis 
pathways, these α-synuclein proteins can enter other neurons in a variety of proposed ways, 
with either direct or indirect interactions between donor and recipient neurons. Indirect 
ways include through direct transfer, if there is membrane damage to the recipient neuron 
or via endocytosis. Direct mechanisms can occur through the formation of tunnelling 
nanotubes or through synaptic transmission. Figure adapted from (Wales et al., 2013). ...... 14 
Figure 1.3. The amyloid cascade hypothesis.                                                                                                                                           
The amyloid cascade hypothesis suggests that deposition of Aβ within the brain is an 
essential and crucial step that leads to AD. Autosomal dominant mutations that lead to 
familial forms of AD occur in three genes 1 presenilin 1 and 2 part of the g-secretase complex 
and 2 APP. The cascade has also been the target for therapeutics which are currently in 
clinical trials. Targets include a) g-secretase inhibitors and modulators, b) BACE inhibitors, c) 
monoclonal antibodies and compounds against monomers, oligomers and protofibrils and d) 
monoclonal antibodies and compounds preventing Aβ fibril aggregation into plaques. Figure 
adapted from (Panza et al., 2019). .......................................................................................... 18 
Figure 1.4. Common neuronal pathways altered in neurodegenerative disease.             
Common neuronal pathways that can be altered in neurodegenerative disease include: I-
protein quality control: molecular chaperones including heat shock proteins (HSP) regulate 
protein folding and ubiquitin-proteasome system (UPS) mediated degradation, while 
misfolded proteins could return to their native conformation state through interaction with 
disaggregase. II-autophagy-lysosome pathway (ALP): dysfunction to the ALP is thought to be 
a reason for the accumulation of protein aggregates and dysfunctional mitochondria within 
neurons. III-mitochondrial homeostasis: impairment of the clearance of dysfunctional 
mitochondria through mitophagy can lead to a reduction in energy production, signal for cell 
death pathways and impair proteostasis networks. IV-Protein seeding and propagation: 
prion like spread of pathological proteins could be the cause of disease progression and 
spread within the brain. V-Synaptic toxicity and network dysfunction: pathological proteins 
within pre- and post-synaptic terminals can lead to dysfunction in synaptic transmission, 
leading to network impairments. Figure adapted from (Gan et al., 2018). 28 
Figure 1.5. Wiring diagram for the ascending reticular activating system.                                                                                           
A wiring diagram summarising the nuclei and their neurotransmitter systems that form the 
ascending reticular activating system. Ventral pathway shown in orange and the dorsal 




serotonergic- dorsal raphe (DR); noradrenergic- locus coeruleus (LC). Other nuclei and 
neurotransmitter systems involved: 1) cholinergic-laterodorsal tegmental nucleus; 2) 
dopaminergic- ventral periaqueductal grey matter; 3) histaminergic- tuberomammillary 
nucleus; 4) orexinergic-hypothalamus; 5) cholinergic & GABAergic-basal forebrain. Figure 
adapted from (Saper et al., 2005). .......................................................................................... 46 
Figure 2.1. Study cohort identification and selection flow chart. * due to only 9 ‘pure’ DLB 
cases possessing CAF scores an additional 6 cases which possessed well characterised 
cognitive fluctuations although were not assessed via CAF were included in order to increase 
the n for the DLB with cognitive fluctuations group. **/*** the main aim of the study was to 
examine the role of the ARAS in cognitive fluctuations; therefore, the main priority was 
selection of DLB cases which had the best characterised fluctuations. Both the AD and 
control cases were matched as best possible to the DLB cases for age and MMSE (in the case 
of AD cases), a further AD case was removed due to identification of a brainstem infarct 
upon examination of the pons. ............................................................................................... 72 
Figure 2.2. Location and identification of the locus coeruleus.                                                                                                                                                            
Pigmented neurons of the locus coeruleus, at the level of the upper-mid pons, stained with 
haematoxylin. Image shown is of a control case. Scale bas = 500µm. ................................... 77 
Figure 2.3. Location and identification of the raphe.                                                                                                                
Tryptophan hydroxylase 2 immunohistochemistry to identify the serotonergic neurons of the 
raphe within the upper-mid pons. Image shown is of a control case. Scale bar = 1000µm, 
inset scale bar 100µm. IV- IV ventricleIV ................................................................................ 78 
Figure 2.3. Location and identification of the raphe.                                                                                                                
Tryptophan hydroxylase 2 immunohistochemistry to identify the serotonergic neurons of the 
raphe within the upper-mid pons. Image shown is of a control case. Scale bar = 1000µm, 
inset scale bar 100µm. IV- IV ventricle ................................................................................... 78 
Figure 2.4. Location and identification of the pedunculopontine nucleus.                                                                              
Choline acetyltransferase immunohistochemistry to identify the cholinergic neurons of the 
pedunculopontine nucleus within the lower midbrain. Image shown is of a control case. 
Scale bar = 1000µm, inset scale bar 100µm. IV-IV ventricle ................................................... 78 
Figure 2.5. Newcastle Brain Tissue Resource brainstem dissection protocol.                                                                                                                                                                                                              
(A) Medulla, lilac, is divided into 4 blocks AV to AT; Pons, pink, is divided into 4 blocks AS to 
AQ; midbrain, green, is divided into 2 blocks, only the lower midbrain block is shown. Blocks 
are cut with the ventral side as the cut face, apart from Block O which is cut from the dorsal 
side. (B) Formalin fixed brainstem tissue from the medulla and pons blocks AU-AQ from the 
top to the bottom. Blocks P, AQ and O were sampled for analysis within this study. ............ 79 
Figure 2.6. Example images of delineation of the brainstem nuclei for image analysis.                                                                                                                                                                                               
(A) pedunculopontine nucleus stained with choline acetyltransferase, scale bar = 1mm; (B) 
raphe nuclei stained with tryptophan hydroxylase, scale bar = 1mm; (C) locus coeruleus with 
a haematoxylin stain, scale bar = 500µm. IV- IV ventricle ...................................................... 84 
Figure 2.7. Analysis of immunoreactivity.                                                                                                                                            
Images taken at x100 magnification had the nuclei of interest delineated, as shown in figure 
2.6. A colour threshold was then applied which detected only the immunoreactivity labelled 
by the DAB chromogen within the delineated region of interest but does not detect non-
specific background staining. Representative image shows a small section of the raphe from 
an Alzheimer’s disease case with AT8 immunohistochemistry, both with and without the 
red-green-blue colour threshold. Scale bar = 100µm. ............................................................ 85 
Figure 2.8. Example manually stitched image of immunofluorescent double labelling.                                                                                         
Manually stitched immunofluorescence image for tryptophan hydroxylase 2 and pS129 α-




Figure 2.9. Colocalisation between Tryptophan hydroxylase 2 and α-synuclein.                                                                     
Tryptophan hydroxylase 2 positive neurons containing α-synuclein (red arrow) and with no 
α-synuclein present (green arrow). Image shown is of a DLB case. ........................................ 87 
Figure 2.10. Newcastle Brain Tissue Resource frozen tissue dissection protocol.                        
Brodmann area 12 relating to the medial prefrontal cortex was sampled either from block 4 
or 5 of the dissection protocol. ............................................................................................... 88 
Figure 2.11. Synaptosomal fractionation protocol.                                                                                                                            
Flow chart describing the sequential centrifugation for preparation of a crude synaptosomal 
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Figure 3.1. Location and identification of the locus coeruleus.                                                                                                               
Neuromelanin containing noradrenergic neurons of the locus coeruleus located close to the 
fourth ventricle in the upper-mid pons in a fixed tissue control case section counterstained 
with haematoxylin. Scale bar = 500µm. Inset displays fixed tissue block with red arrow 
indicating the location of the locus coeruleus as can be seen with the naked eye. Inset scale 
bar = 10mm. IV-IV ventricle .................................................................................................... 97 
Figure 3.2. Pathology in the locus coeruleus.                                                                                                                                             
Representative images of A-α-synuclein (KM51), C- tau (AT8), E-Aβ (4G8).  Pathological 
burden data for B- α-synuclein, D- tau and F- Aβ. Data is shown as median with interquartile 
range. ** p<0.01 ***p<0.001 compared to controls. Scale bar 500µm, inset 100µm. 
Abbreviations: AD- Alzheimer’s disease; DLB- dementia with Lewy bodies; nLBD- 
neocortical/limbic pathologically Lewy body disease. .......................................................... 100 
Figure 3.3. Correlations between locus coeruleus tau pathology and cognitive fluctuation 
severity.                                                                                                                                                              
A and B- LC tau pathology against last CAF scores and average CAF scores respectively shown 
all cases whom experienced cognitive fluctuations during life and had at least one CAF score 
in both the DLB and nLBD groups. C and D- nLBD cases only for LC tau pathology against last 
and average CAF score respectively. E and F- DLB cases only for LC tau pathology against last 
and average CAF score respectively. Abbreviations: LC- locus coeruleus; CAF-clinical 
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Representative images of A-goat polyclonal ChAT, B- mouse monoclonal ChAT, C- rabbit 
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images are x2 the original image. ......................................................................................... 114 
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pathology.  Scale bar 1000µm, inset 100µm. ........................................................................ 118 
Figure 4.3. Pathology in the pedunculopontine nucleus.                                                                                                
Pathological burden data for A- α-synuclein, B- tau and C- Aβ in the pedunculopontine 
nucleus. Data is shown as median with interquartile range. ** p<0.01 ***p<0.001 compared 
to controls. Abbreviations: AD- Alzheimer’s disease; DLB- dementia with Lewy bodies; nLBD- 
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Figure 6.4. Serotonin reuptake transporter and vesicular monoamine transporter 2 levels.                                                                                                                                                                              
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D fluctuation groups across blots. Data is shown relative to controls with median and 
interquartile range. Abbreviations: AD- Alzheimer’s disease; CF- cognitive fluctuations; DLB- 
dementia with Lewy bodies; nLBD- neocortical/limbic pathologically Lewy body disease. . 177 
Figure 6.8. α-synuclein -5G4 pathology.                                                                                                                                                                                                                                                                            
Dot blots for A- Synaptosomal fraction, P2, and B- Soluble enzyme fraction, S2, 5G4. i 
representative dots from both blots. The two left columns are dots from the AD and DLB 
blot; the right two columns are dots from the nLBD with (+CF) and without (-CF) fluctuations 
blot. Dots representing the minimum, median and maximum are shown for the four 
fluctuation groups. Control (Con1 and Con2) show the cases with minimum (left) and 
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Chapter 1: Introduction 
1.1 Dementia 
The global population is ageing, with people living longer than at any point previously. The 
United Nations World Population Ageing Highlights have stated that the global population of 
over 60s has increased from 205 million in 1950 to 962 million in 2017, with this projected to 
reach 2.1 billion by 2050, the number of people living until they are 80 and older is also set 
to triple by 2050 (United Nations, 2017). The result in this rapid increase in the aged 
population is a rise in age-related diseases and their associated societal, economic and 
medical problems. 
Dementia is an ‘umbrella’ term used to define a group of conditions that are characterised 
by a noticeable, progressive and irreversible cognitive decline, through disease or 
dysfunction of the brain that impacts upon the independence of daily living (World Health 
Organization, 1992; American Psychiatric Association, 2013). Dementia can result from a 
number of conditions including Alzheimer’s disease (AD), dementia with Lewy bodies (DLB) 
and frontotemporal dementia (FTD). With the incidence and prevalence of dementia 
increasing with age, the ageing global population has led to an increase in the number of 
people living with dementia (Prince et al., 2014). In the United Kingdom presently there are 
approximately 850,000 individuals living with dementia, with this figure projected to rise to 
1 million by 2025 (Prince et al., 2014) . The current lack of available disease-modifying 
therapies is likely to exacerbate the impact that the rise in numbers presents. 
1.1.1 Epidemiology 
Globally the incidence and prevalence of dementia increases with age. The incidence of 
dementia increases from 0.1% at 60 to 8.6% at 90 years of age (Jorm and Jolley, 1998), with 
the overall prevalence doubling with every 5 years of age after 65 (Lobo et al., 2000). In 
more economically developed countries this is 5-10% of those over 65 years of age, with a 
larger prevalence in women than men, although this is thought to be due to an increased life 
expectancy in women as there is no difference in incidence between the sexes (Hugo and 
Ganguli, 2014).  
DLB is the second most common cause of neurodegenerative dementia after AD 
(Heidebrink, 2002), annually accounting for 3.2% of the new dementia cases (Zaccai et al., 




with this rising to 5% in those of 75 years (Jellinger and Korczyn, 2018). The prevalence of 
DLB is estimated to be 4.2-4.6% of all dementia cases within a community setting, with this 
percentage rising to 7.5% in secondary care populations (Vann Jones and O'Brien, 2014; 
Kane et al., 2018). However, post-mortem studies have suggested the prevalence of DLB was 
found to account for 20% of all dementia cases (McKeith, 2000). The disparity between 
clinical and post-mortem findings could be explained by an underdiagnosis clinically or an 





1.2 Dementia with Lewy bodies 
1.2.1 Clinical features 
DLB is characterised by the presence of cognitive decline in conjunction with core and 
supportive signs and symptoms, along with indicative and supportive biomarkers. The four 
core clinical features of DLB are cognitive fluctuations, parkinsonian extra-pyramidal 
symptoms, rapid eye movement (REM) sleep behaviour disorder (RBD), and complex visual 
hallucinations (McKeith et al., 2017). Supportive features of DLB include autonomic 
dysfunction and severe sensitivity to neuroleptics. Three indicative biomarkers are 
supportive to a clinical diagnosis of DLB: reduced dopamine transporter uptake in the basal 
ganglia demonstrated by single-photon emission computed tomography (SPECT) or positron 
emission tomography (PET); abnormal (low uptake) 123iodine- metaiodobenzylguanidine 
(MIBG) myocardial scintigraphy; polysomnographic confirmation of RBD. Two core features 
or one core feature and a positive biomarker are needed for a probable diagnosis of DLB and 
one feature or one positive biomarker for a possible diagnosis (McKeith et al., 2017). 
Recently there has been a move to try diagnosing DLB at an earlier stage, research has 
focussed on mild cognitive impairment (MCI) with Lewy bodies (MCI-LB) with new criteria 
having been developed (McKeith et al., 2020), with MCI representing the stage between the 
expected cognitive decline of normal ageing and that seen in clinical dementia (Mayo Clinic, 
2020). A number of the core and supportive features of DLB are present in the MCI-LB stage, 
including RBD, motor symptoms and autonomic symptoms (Donaghy et al., 2015; Donaghy 
et al., 2017; McKeith et al., 2020), however, it is thought that the combination of these 
features occurs less frequently than in the those with clinical dementia. The mean age for 
presentation of DLB is 75, with an average life expectancy of 3.3-4.0 years post diagnosis; 
shorter than other dementia subtypes, which may reflect a delay in diagnosis (Vann Jones 
and O'Brien, 2014; Zweig and Galvin, 2014; Price et al., 2017).  
The core features of DLB are also observed in other neurodegenerative diseases including 
Parkinson’s disease (PD) and PD with dementia (PDD). PDD and DLB possess overlapping 
clinical features, therefore for a diagnosis of DLB in a patient with parkinsonian features, the 
onset of dementia and the parkinsonism features must occur contemporaneously, defined 
for research purposes as the parkinsonism occurring within a year of the dementia (the ‘one-
year rule’). Thus, when parkinsonism precedes dementia by a year or more, a diagnosis of 




1.2.1.1 Core clinical features  
DLB is characterised by the presence of four core clinical features: cognitive fluctuations, 
parkinsonian extra-pyramidal symptoms, rapid eye movement (REM) sleep behaviour 
disorder (RBD), and complex visual hallucinations (McKeith et al., 2017).  
In DLB, fluctuating cognition, one of the four core features, has been shown to affect up to 
90% of patients (Byrne et al., 1989; McKeith et al., 2005), with 56% of those with MCI-LB 
presenting with cognitive fluctuations (Donaghy et al., 2017; McKeith et al., 2020). The 
incidence of cognitive fluctuations in DLB is in contrast to those with a diagnosis of AD, 
where they are only encountered in 10-20% of patients (McKeith et al., 1992b; McKeith et 
al., 1994; Walker et al., 2000b). Clinically fluctuating cognition in DLB manifests as 
spontaneous and transient alterations to arousal, attention and cognition (Zupancic et al., 
2011), although they have been shown to be independent to alterations in alertness (Bliwise 
et al., 2014). The manifestation of fluctuating cognition in DLB is qualitatively distinct from 
those observed in AD, which typically are associated with transient episodes of confusion 
(McKeith et al., 2005). Fluctuating cognition has a profound negative impact on the patient’s 
quality of life and ability to function day to day (Gibb et al., 1987; Yamamoto and Imai, 1988; 
Byrne et al., 1989; McKeith et al., 1992b; Zweig and Galvin, 2014). Although an important 
factor for the diagnosis of DLB, it has been found to be one of the most difficult to reliably 
identify and evaluate (Van Dyk et al., 2016). Dysfunction to cholinergic systems is associated 
with fluctuations, particularly alterations to nicotinic receptors in the temporal cortex 
(Ballard et al., 2002b; Gore et al., 2015). Furthermore, the acetylcholinesterase inhibitor 
(AChEI) donepezil, has been shown to offer a modest improvement to cognitive fluctuations, 
as measured via the Cognitive Fluctuation Inventory score, compared to placebo in a clinical 
trial (Mori et al., 2012). 
Recurrent, complex visual hallucinations are also a core clinical feature of DLB, occurring in 
up to 80% of patients and 29% of those with MCI-LB, with their presence being a frequent 
clinical signpost to diagnosis (Donaghy et al., 2017; McKeith et al., 2017). Visual 
hallucinations have also been found to occur in other neurodegenerative disorders, for 
example AD and PD. However, compared to visual hallucinations in other neurodegenerative 
disorders those in DLB appear earlier in the disease progression (Fenelon et al., 2000), are 
more prevalent (Ballard et al., 1997; Fenelon et al., 2000), have increased severity (Chiu et 




(Ballard et al., 1997). In DLB, visual hallucinations typically consist of objects including 
animals, people and faces, with frequent secondary delusional ideas, beliefs arising from and 
in an attempt to comprehend the primary hallucinations, that a stranger or intruders are in 
the home. Whereas, visual hallucinations reported by those with AD are briefer and simpler , 
where hallucinations lack a recognizable form such as shapes and patterns (Mosimann et al., 
2006; Urwyler et al., 2016). As well as visual hallucinations, other visual abnormalities also 
occur in DLB, including impaired saccadic function and impairment to complex visual tasks 
for example drawing simple objects (McKeith et al., 2005; Armstrong, 2012). However, 
although visual abnormalities occur in DLB, there is an absence of major pathological 
changes to the primary visual cortex and the lateral geniculate nucleus (Erskine et al., 2016; 
Khundakar et al., 2016), suggestive of an impairment to visual processing in the 
development of visual hallucinations. Preservation of the visual pathways may indicate a 
neurochemical origin to visual hallucinations and cholinergic deficits have also been 
associated with visual hallucinations (Perry et al., 1990b). AChEIs have been shown to be 
effective in stopping visual hallucinations in DLB, supporting the neurochemical origin of this 
clinical phenomenon (McKeith et al., 2000a).  
RBD occurs in 76% of DLB cases, compared to the phenomenon being observed in only 4% of 
non-DLB cases, prompting its recent inclusion as a core feature in the latest consensus 
guidelines (Ferman et al., 2011; McKeith et al., 2017). RBD is defined as a parasomnia 
characterised by recurrent dream enactment behaviour that includes mimicking dream 
content and absence of normal REM sleep atonia. RBD can be particularly noticeable when 
the patient or partner sustains injuries due to the violent limb movements (Postuma et al., 
2009; Ferman et al., 2011). In DLB, the onset of RBD can begin years or decades before the 
first signs of cognitive impairment (Boeve et al., 2011). 
The fourth core feature of DLB is spontaneous parkinsonian features, including 
parkinsonism; bradykinesia, rest tremor and rigidity which are common, but not invariant, in 
DLB. Approximately 60-92% of DLB patients develop parkinsonian features during their 
disease course (Ferman et al., 2011). Unlike in PD where the presence of more than one 
parkinsonian feature is required for diagnosis, DLB patients commonly only display one of 





1.2.1.2 Supportive clinical features 
There are numerous common clinical features, often present early in the disease course but 
lacking in diagnostic specificity. These supportive clinical features include severe sensitivity 
to neuroleptics, autonomic dysfunction, hypersomnia, repeated falls and depression 
(McKeith et al., 2017). A number of supportive clinical features are more common in DLB 
than in other dementias helping indicate a DLB diagnosis, especially if the features are 
present over an extended duration or in combination (McKeith et al., 2005). 
1.2.1.3 Indicative and supportive biomarkers 
The Third Consensus report of the DLB Consortium introduced reduced dopamine 
transporter uptake in basal ganglia on SPECT or PET as a biomarker along with clinical 
features (McKeith et al., 2005), with the Fourth Consensus report of the DLB Consortium 
introducing both indicative and supportive biomarkers to the diagnostic criteria for DLB 
(McKeith et al., 2017). Reduced dopamine transporter uptake in basal ganglia on SPECT or 
PET, reduced uptake on 123iodine-MIBG myocardial scintigraphy and polysomnography 
confirmation of RBD, were all included as indicative biomarkers of DLB (McKeith et al., 
2017). The presence of one indicative biomarker in conjunction with any of the core clinical 
features is necessary for a diagnosis of probable DLB (McKeith et al., 2017). There are three 
supportive biomarkers: relative preservation of medial temporal lobe structures on a 
magnetic resonance imaging (MRI) scan; generalised low uptake on SPECT/PET 
perfusion/metabolism scan, reduced occipital activity and posterior cingulate island sparing 
on fluorodeoxyglucose-PET imaging; prominent posterior slow-wave 
electroencephalography (EEG) activity with periodic fluctuations in the pre-alpha/theta 
range. The three supportive biomarkers are consistent with DLB and aid diagnosis but lack 
diagnostic specificity (Harper et al., 2016). It is an aspiration of the latest consensus report of 
the DLB consortium that genetic and fluid biomarkers should be developed to aid in the 
differential diagnosis of DLB (Guerreiro et al., 2016; McKeith et al., 2017). 
1.2.1.4 Cognitive profile of DLB vs other Neurodegenerative diseases 
Even at the MCI stage of DLB the characteristic profile of cognitive impairment observed at 
the later stages of the disease is present (Donaghy et al., 2018; Ciafone et al., 2020). The 
cognitive domains characteristic of DLB are deficits to attention, executive and visuospatial 
functions (Oda et al., 2009; Kemp et al., 2017), which are significantly more severe than 




impairments to memory, with those with MCI-AD tending to present with a more amnestic 
profile compared to those with MCI-LB (Oda et al., 2009; McKeith et al., 2016). The 
proportion of DLB patients with amnestic features is higher than that seen for Multiple 
System Atrophy or PD, likely due to the increased presence of AD pathology and 
hippocampal atrophy related to this (Goldman et al., 2014). Evidence suggests that the 
overall cognitive profile of DLB patients is prominent deficits in attention and executive 
function, particularly tasks with a visuospatial component, such as the pentagon drawing 
component on the Mini-Mental State Examination (MMSE) (Oda et al., 2009), and a relative 
preservation of memory in comparison to AD. 
1.2.1.5 Clinical Management of DLB 
Clinical management of DLB is often challenging due to the complex nature of the disease; 
key management strategies revolve around an early and accurate diagnosis, allowing for the 
correct medications and care provision to be put in place (McKeith et al., 2017; Taylor et al., 
2020). As with other dementia types there are currently no treatments that slow the 
progression of the disease, with treatment options currently limited to symptomatic relief 
(Boot, 2015). The efficacy of AChEIs has been demonstrated in DLB, with evidence for 
donepezil and rivastigmine improving cognition (Stinton et al., 2015; Wang et al., 2015), as 
well as evidence for reducing apathy and improving visual hallucinations in DLB (McKeith et 
al., 2000a). The use of neuroleptics for the management of behavioural disturbances or 
visual hallucinations is contraindicated in DLB due to the high risk of a serious sensitivity 
reaction (McKeith et al., 1992a); there is no evidence to support the use of any antipsychotic 
in DLB (Taylor et al., 2020). Levodopa/carbidopa can be used for treatment of motor 
symptoms in DLB, much like for PD, however, there is an increased risk of psychosis at higher 
doses in DLB (Goldman et al., 2008). 
1.2.2 Pathology 
DLB is neuropathologically characterised by the presence of aggregated α-synuclein, the 
major protein component of abnormal neuronal aggregates known as Lewy bodies and Lewy 
neurites (McKeith et al., 2005). Lewy bodies are spherical, dense cytoplasmic aggregates 
observed in the neuronal soma (Spillantini et al., 1997), and they appear to affect certain 
neuronal subtypes and brain regions more preferentially than others (Erskine et al., 2018), 
with Lewy neurites being found in the neuronal processes. Two types of Lewy body have 




core surrounded by a halo of radiating fibrils, which are classically observed with 
Haematoxylin & Eosin staining; and cortical Lewy bodies which are eosinophilic, rounded, 
angular or reniform structures without a halo, cortical Lewy bodies are also not readily 
detectable by Haematoxylin & Eosin (Dening and Thomas, 2013; Outeiro et al., 2019). 
Although Lewy bodies and neurites are the characteristic neuropathological feature of DLB, 
tau and amyloid-beta (Aβ) pathologies are commonly seen. 
1.2.2.1 a-synuclein 
α-synuclein is a small 14.5 kDa, 140 amino acid protein, which is divided into three 
functionally distinct sub-regions (figure. 1.1). The N-terminal, amphipathic region, amino 
acids 1-60, is highly conserved across species and contains a series of seven imperfect, 11 
amino acid, repeats containing a KTKEGV consensus motif. The presence of the consensus 
motif, is thought to form an amphipathic helix upon lipid-binding, with other membrane 
binding proteins containing a similar motif (Segrest et al., 1992; Bartels et al., 2010). All 
mutations that have been associated with familial forms of PD (figure. 1.1) are located in the 
N-terminal domain (Bendor et al., 2013). The central portion of the α-synuclein protein is 
termed the non-Aβ-component (NAC) domain, following its discovery when it was isolated 
from Aβ plaques as the non- Aβ element of plaques (Uéda et al., 1993). The central, 
hydrophobic, NAC domain, amino acids 61-95, is responsible for the aggregational 
properties of the protein (Wales et al., 2013). The C-terminal, acidic, region, amino acids 96-
140 is composed of mainly negatively charged amino acid residues (George, 2002). α-

















Figure 1.1. a-synuclein protein structure.                                                                                                                                                
α-synuclein is a 140 amino acid protein, with three functionally distinct sub-regions. N-terminal region: highly conserved, 
contains 7, 11 residue repeats that form a helix upon membrane binding, the six known missense mutations that cause 
familial PD lie within this region (shown in orange). Central hydrophobic region (non-Aβ component or NAC domain): 
associated with an increased propensity of the protein to form fibrils. Acidic tail: contains mainly negatively charged 
residue and largely unfolded; all bar of the phosphorylation sites, serine (Ser) 87, are localised in the c-terminal domain, 
phosphorylation of α-synuclein at Ser129 (shown in green) has been found to be the predominant form of the α-synuclein 




modification, with the most common being phosphorylation at serine 129 in the C-terminal 
domain (Wales et al., 2013) . The function of the acidic tail region is unknown, with many 
hypothesised functions including mechanism of membrane binding regulation and 
conferring chaperone-like activity (Wales et al., 2013) and it is the least conserved of the 
three sub-domains across species (Bendor et al., 2013). 
α-synuclein is an intrinsically disordered protein, although the protein is generally thought to 
be unstructured several structures for the native α-synuclein protein under certain 
conditions have been reported, including alpha-helix formation upon interaction with lipid 
membranes (Wales et al., 2013; Meade et al., 2019). Such dynamic structural characteristics 
have made determining the normal structure and related function of α-synuclein difficult. 
Recombinantly expressed α-synuclein, as well as α-synuclein isolated from the human brain 
has been suggested to have an unfolded monomeric structure in the native state (Weinreb 
et al., 1996; Bertoncini et al., 2005; Fauvet et al., 2012; Bendor et al., 2013). However, it has 
also been suggested that α-synuclein may remain helical in solution due to macromolecular 
crowding within the cell (McNulty et al., 2006), and that a natively unfolded state had been 
identified due to the procedural methods utilised (Bartels et al., 2011; Wang et al., 2011). It 
has been reported that native α-synuclein behaves as a helical tetramer that can resist 
aggregation (Bartels et al., 2011). Though, the debate over the native conformation of α-
synuclein is still ongoing, with more recent studies focussing on α-synuclein isolated from 
human brain samples (Wales et al., 2013; Meade et al., 2019). 
The physiological function of α-synuclein, like its native structure, is not entirely understood, 
with numerous functions proposed (Emamzadeh, 2016). The current main proposed 
function for α-synuclein is the involvement of the protein in neurotransmitter release, due 
to its location within presynaptic terminals and its propensity to bind to small spherical 
vesicular membranes (Bendor et al., 2013; Wales et al., 2013). It has been hypothesised that 
α-synuclein binds to the synaptic vesicles to modulate vesicular trafficking within the 
synapse (Emamzadeh, 2016), with the possible role of regulating the amount and speed of 
vesicular recycling within synapses and the presynaptic area. α-synuclein is also 
hypothesised to have chaperone functions, through both its N- and C-terminal domains, 
including for the SNARE proteins which are required for synaptic vesicle exocytosis (Burre et 
al., 2010). Further reported functions for α-synuclein include chaperoning of heat shock 




synuclein has been shown to translocate to the nucleus of neurons, but there is no 
consensus on the putative role that the protein may play in the nucleus; however it has been 
reported that it may have a role in transcriptional regulation (Wales et al., 2013; Pinho et al., 
2019).  
Although the presence of intraneuronal α-synuclein aggregates (i.e. Lewy bodies) is the 
characteristic finding required for the neuropathological diagnosis of DLB, its role in the 
aetiology of the disease remains uncertain. However, α-synuclein is thought to be central to 
the pathogenesis of Lewy body diseases (LBD) (Kalia and Kalia, 2015), since mutations to the 
α-synuclein gene are causative for familial PD (Polymeropoulos et al., 1997), as well as α-
synuclein being the core component of Lewy bodies and neurites. The factors that underlie 
the conversion from native state α-synuclein into an aggregated state are not well 
understood. However, it is generally hypothesised that an imbalance between the normal 
proteostasis mechanisms that regulate α-synuclein synthesis, aggregation and clearance 
may favour the conversion of native to aggregated state (Kragh et al., 2012). Polymorphisms 
in the α-synuclein promoter have been identified as a potential risk factor for sporadic PD 
(Maraganore et al., 2006), which supports the hypothesis that increased levels of α-
synuclein are sufficient to lead to the formation of Lewy bodies, in conjunction with 
multiplication of the α-synuclein gene leading to familial forms of PD (Lashuel et al., 2013). 
Increased α-synuclein levels could more easily lead to oligomer formation which in turn form 
the characteristic neuropathological hallmark, Lewy bodies (Conway et al., 2000a; Conway et 
al., 2000c). This theory in regard to increased α-synuclein, has been further supported by 
Mittal et al. (2017) who identified that salbutamol, which interacts with the β2-
adrenoreceptor which is a regulator of the α-synuclein gene, reduces the risk of developing 
PD. An increased propensity to form aggregated species is found with a number of familial 
PD mutations, including the A53T mutation (Bendor et al., 2013). However, not all PD-
associated α-synuclein mutations increase the aggregation propensity of the protein, with 
the G51D form being more resistant to aggregation than wildtype protein but is still 
associated with severe neurodegeneration implying α-synuclein aggregation independent 
mechanisms of neurodegeneration (Fares et al., 2014). The N-terminal domains propensity 
to form a helical secondary structure can be disrupted or reduced in familial PD mutations, 
with some swinging to a more favoured beta sheet secondary structure (Wales et al., 2013). 




C terminus of the α-synuclein protein which can destabilise the native form leading to a 
higher propensity to aggregate (Conway et al., 2000b). The destabilisation and subsequent 
aggregation of α-synuclein as seen through the mutations in α-synuclein that lead to PD 
further support the role for α-synuclein in the pathogenesis of synucleinopathies. 
1.2.2.2 Proposed neurodegenerative mechanisms of α-synuclein 
There have been a number of mechanisms proposed through which α-synuclein can elicit 
neurodegeneration (Wales et al., 2013; Bartels, 2019; Meade et al., 2019). These 
mechanisms include different species of α-synuclein, interplay with cellular organelles and 
disruption to synaptic processes.  
Different conformers of α-synuclein have been associated with protein aggregation and 
pathogenesis in DLB (Lashuel et al., 2013). It is hypothesised that oligomeric species are 
more neurotoxic than fibrillar forms and may be the major causative agent for 
neurodegeneration in synucleinopathies (Winner et al., 2011); although, recent evidence 
from Mahul-Mellier et al. (2020) implies that it is the transition from fibrillar to the 
formation of the Lewy body that is one of the major drivers of neurodegeneration. However, 
it is currently unclear whether it is a toxic gain or loss of function that underlies the 
neurodegenerative effects of α-synuclein oligomerisation and subsequent aggregation 
(Cookson, 2006; Ghiglieri et al., 2018).   
A large body of research has looked into how structurally altered or oligomeric α-synuclein 
can confer toxicity through interactions with membranes. Recent studies have found that 
the centre of Lewy bodies once thought to be composed of amyloid fibrils of α-synuclein are 
now thought to be mainly formed of membrane lipids from mis-trafficked vesicles 
(Shahmoradian et al., 2019), with vesicle clustering thought to be neurotoxic (Bartels, 2019). 
The importance of membranes and trafficking in synucleinopathies is further highlighted by 
glucocerebrosidase mutations being a risk factor for DLB, with homozygous mutations 
leading to Gaucher disease, a disorder characterised by lysosomal dysfunction (Shiner et al., 
2016; Rongve et al., 2019). Lysosomal and autophagy impairment has been observed in 
post-mortem studies of synucleinopathies (Arotcarena et al., 2019). Alterations to the 
autophagy-lysosomal pathway has been associated with the accumulation of α-synuclein in 
both PD and DLB (Alvarez-Erviti et al., 2010; Crews et al., 2010) with the results suggestive of 
an accumulation through defective clearance of autophagosomes in these disorders 




PD and DLB is thought to increase the accumulation of α-synuclein, further exacerbating the 
neurodegenerative processes occurring within neurons (Arotcarena et al., 2019).  
α-synuclein oligomers have been shown to permeabilise membranes, altering ion 
permeability for the neuron (Volles et al., 2001; Danzer et al., 2007), interrupting the 
endoplasmic reticulum membrane leading to a disruption in calcium (Ca2+) homeostasis that 
can promote changes to mitochondria (Wales et al., 2013). As well as the reported affects to 
mitochondria downstream of α-synuclein impairment to the endoplasmic reticulum 
membrane, mitochondrial dysfunction has been shown to occur through direct contact with 
the α-synuclein protein (Bendor et al., 2013; Wales et al., 2013).  
Mitochondrial involvement in synucleinopathies, especially PD, has been extensively studied 
in recent years, and it has been suggested that mitochondrial impairment is a major pathway 
for α-synuclein mediated neurodegeneration. A number of mutations that lead to familial 
forms of PD have been shown to induce mitochondrial fragmentation, including A53T (Park 
et al., 2018). As well as mutations located in proteins essential for mitochondrial dynamics, 
including parkin and PINK1, leading to parkinsonian symptoms, although not always in the 
presence of Lewy body formation. Together the identification of mitochondrial dysfunction 
both directly and indirectly by mutations linked to Parkinson’s disease gives further backing 
to a key mitochondrial role in the neurodegenerative processes associated with 
synucleinopathies especially PD (Ishihara-Paul et al., 2008; Dawson and Dawson, 2010; 
Vives-Bauza and Przedborski, 2011). Although commonly thought a cytoplasmic protein, 
recent studies have shown that α-synuclein associates with mitochondria (Hu et al., 2019; 
Wang et al., 2019). α-synuclein has been shown to bind to complex I, part of the electron 
transport chain, inhibiting its function and leading to a decrease in ATP production within 
the cell and mitochondrial dysfunction (Schapira et al., 1989; Wales et al., 2013).  
In the early stages of synucleinopathies it has been suggested that α-synuclein acts pre-
synaptically on proteins related to mitochondria, for example heat shock protein 10, by 
sequestering the protein in the cytosol preventing it from translocating to the mitochondria 
(Leverenz et al., 2007; Szego et al., 2019). A recent study has shown in a cell model the 
sequestering of mitochondria during the formation of Lewy bodies, with different alterations 
to mitochondrial functions, including reduction in energy production, observed during the 
stages of α-synuclein fibrillisation and Lewy body formation (Mahul-Mellier et al., 2020). The 




mechanism for α-synuclein toxicity not just related to mitochondrial proteins (Yang and Hu, 
2016; Choi et al., 2018). Specific post-translationally modified species of α-synuclein have 
been shown to have an increased binding propensity to mitochondrial membranes 
compared to the native form which is thought to have a low affinity for mitochondrial 
membranes (Wang et al., 2019), further post translational modifications for example C-
terminal truncation and phosphorylation can increase membrane binding affinity furthering 
α-synuclein toxicity (Lashuel et al., 2013). The alterations to mitochondria through direct and 
indirect α-synuclein mechanisms can lead to fragmentation of the mitochondria within the 
cell (Wales et al., 2013). Mitochondrial fragmentation can lead to cellular damage though a 
number of mechanisms including increasing reactive oxygen species production, oxidative 
stress and inducing mitochondrially mediated apoptotic pathways (Wales et al., 2013). 
Increased levels of reactive oxygen species and oxidative stress is thought to further lead to 
protein folding abnormalities perpetuating the cellular distress (Bendor et al., 2013; Wales et 
al., 2013). The data so far suggests that it is both a loss of normal function and a gain of toxic 
function as a result of abnormal α-synuclein that causes neuronal death through many 
hypothesised pathways. 
1.2.2.3 Pathological Staging 
Lewy body pathology in DLB is neuropathologically diagnosed according to its severity and 
topographical distribution in the brain and several stages are distinguished: neocortical, 
limbic, brainstem, amygdala-predominant and olfactory bulb only. The majority of DLB cases 
fall in either limbic or neocortical stage (McKeith et al., 2017). α-synuclein within Lewy 
bodies and neurites is also associated with other intracellular proteins including 
intermediate filaments and chaperone proteins, similar to neuronal inclusions found in other 
neurodegenerative disorders (McNaught et al., 2002; Tanaka et al., 2004). α-synuclein is also 
the pathological hallmark of PD and PDD, and is central to the pathogenesis of the LBD 
spectrum (Jellinger, 2003; Kim et al., 2014). Mild Lewy body pathology, is referred to as 
incidental Lewy body disease, and suggested to be more prevalent with increasing age (Saito 
et al., 2004; Erskine et al., 2020). 
In LBDs, Lewy bodies are thought to follow a stereotypical temporal and topographic 
pattern, originating in the brainstem and spreading to the neocortex through the limbic 
system throughout the course of the disease (Braak et al., 2003; McKeith et al., 2005). The 




(Yamamoto et al., 2005), with limbic or neocortical predominant pathology required for a 
diagnosis of DLB (McKeith et al., 2005). There have been a number of staging criteria 
proposed for α-synuclein pathology in LBDs, including, Braak et al. (2003) for PD and PDD 
and McKeith et al. (2005) for DLB. Braak et al. (2003) suggests the topographical spread of α-
synuclein pathology is formed of 6 stages, initiating in the medulla oblongata with 
pathological progression through the brainstem and into limbic and neocortical regions. The 
stereotypical spread of α-synuclein pathology within the brain has been proposed to be 
caused by propagation of α-synuclein in a prion-like manner, with transfer of disease related 
protein into functionally connected regions inducing native α-synuclein to undergo 
conversion into the disease like state (figure 1.2) 
Although DLB and PDD are indistinguishable based upon the topographical location of 
terminal pathology (Ruffmann et al., 2016), α-synuclein pathology in DLB is thought to 
progress in a different manner to the ascending pattern observed in the stages of PD 
pathology. The differences in topographical spread between DLB and PDD could underlie the 
different sequence of features seen clinically between the two disorders. Previous research 
into the pattern of α-synuclein deposition in DLB have proposed origins in the amygdala 












Figure 1.2. Mechanisms of a-synuclein propagation.                                                                                                                      
α-synuclein species may be transferred between neurons and induce spread of pathology to neighbouring brain 
regions. Once α-synuclein has been released from the originating cell into the extracellular environment, either via 
exosomes or non-classical exocytosis pathways, these α-synuclein proteins can enter other neurons in a variety of 
proposed ways, with either direct or indirect interactions between donor and recipient neurons. Indirect ways include 
through direct transfer, if there is membrane damage to the recipient neuron or via endocytosis. Direct mechanisms 
can occur through the formation of tunnelling nanotubes or through synaptic transmission. Figure adapted from 




pattern of spread has been supported by the fact not all DLB patients have an abnormal 
dopamine transporter scan (DaTSCAN), suggestive of differential spread or differences in 
severity burdens between DLB cases (van der Zande et al., 2016). A recent study by Raunio 
et al. (2019) identified two common α-synuclein patterns of spread in a Finnish cohort. The 
group identified that cases with high levels of AD-type pathology were associated with an 
amygdala-based spread of pathology, rather than the caudo-rostral progression suggested 
by Braak et al. (2003) (Raunio et al., 2019). Brainstem nuclei are affected in nearly all cases 
of LBD, although the severity of the pathology is highly variable (McKeith et al., 2005).  
1.2.2.4 Concomitant pathologies 
Although DLB is characterised by the presence of α-synuclein aggregates, 50-80% of patients 
have concomitant AD type pathology in the form of extracellular Aβ plaques, intracellular 
neurofibrillary tangles (NFT), neuropil threads and neuritic plaques consisting of a focal core 
of Ab surrounded by a distended halo of tau-positive neurites (Halliday et al., 2011; 
McKhann et al., 2011; Attems, 2017) (as discussed in 1.3.2). Although the presence of AD 
type pathology is not required for a neuropathological diagnosis of DLB, concomitant AD 
type pathology in DLB is thought to contribute to a faster cognitive decline (Howlett et al., 
2015; McKeith et al., 2017), with tau co-pathology thought to underlie some of the 
heterogeneity observed in clinical impairment in Lewy body disorders (Coughlin et al., 2019). 
Recent studies have identified that Lewy body disorder patients with concomitant AD 
pathology have higher levels of neocortical α-synuclein pathology than those without 
concomitant AD pathology (Coughlin et al., 2019). The concomitant tau pathology within 
these Lewy body disorder cases was also found to diverge from the neocortical 
topographical pattern observed in AD and appeared to map more closely with the 
distribution of α-synuclein pathology, the pattern of Aβ pathology was found to be similar in 
both AD and Lewy body disorder cases (Coughlin et al., 2019). Interactions between α-
synuclein and tau proteins have been reported in in vitro studies (Giasson et al., 2003), 
suggesting a possible reason why those with higher concomitant AD-type pathologies may 
have a faster cognitive decline and the divergence in tau’s topographical pattern observed in 
AD (as discussed in more detail in 1.4 and 1.5).  
Other pathologies have been described in DLB. Transactive response DNA-binding protein 43 
(TDP-43) pathology is a hallmark of amyotrophic lateral sclerosis and a subtype of FTD, and 




(Ou et al., 1995; Higashi et al., 2007). TDP-43 has also been recently found to be the 
pathological hallmark for a newly discovered type of dementia, Limbic-predominant age-
associated TDP-43 encephalopathy (LATE) (Nelson et al., 2019). LATE has been described to 
mimic AD clinical features due to the accumulation of TDP-43 and damage to the 
hippocampus (Nelson et al., 2019), which can occur in combination with AD and DLB-type 
pathology. However, the proposal of LATE as a distinct clinicopathological entity has been 
contested (Josephs et al., 2019). TDP-43 can form intracytoplasmic inclusions under 
pathological conditions. Aggregation of TDP-43 occurs after the translocation of TDP-43 into 
the cytoplasm, where it is cleaved into C-terminal fragments that are abnormally 
hyperphosphorylated (Ou et al., 1995). TDP-43 has been shown to affect structures that are 
vulnerable to Lewy bodies, such as the amygdala (Josephs et al., 2016). Within TDP-43 
positive DLB cases the severity of TDP-43 pathology is similar to that seen in cognitively 
intact controls and seems to be more associated with the concomitant AD-type pathology 
that the characteristic α-synuclein pathology (McAleese et al., 2017). As well as TDP-43, 
further pathologies are present in DLB including microvacuolation and vascular pathologies 
although relatively few neuropathological studies have been conducted in this area (McKeith 
et al., 1996). However, there is emerging evidence that supports the contribution of vascular 
changes that could exacerbate Lewy-body induced neuropathology (Raz et al., 2016), 
however, risk factors that are associated with vascular changes are associated more with AD 
than DLB or PDD (Chan et al., 2018). There are also a number of studies that suggest that 
vascular changes, such as white matter hyperintensities viewed on MRI, are associated with 
AD-type pathology in DLB and not the α-synuclein pathology (Joki et al., 2018). Further 
research is required to fully understand the role that concomitant vascular changes play in 






1.3.2 Clinical features 
AD is the leading cause of neurodegenerative dementia, accounting for 50-80% of all cases 
(Blennow et al., 2006; Mayeux and Stern, 2012). Clinically AD is characterised by a 
progressive and irreversible decline in cognition, which overtime substantially impairs the 
patient’s ability to perform activities of daily living (McKhann et al., 1984). Although AD is 
primarily considered to be an amnestic disorder, impairments to visuospatial and language 
function are also commonly present (McKhann et al., 2011). Impairments to memory are 
characterised by deficits in learning and recall of recent information, due to deficient 
episodic memory (McKhann et al., 2011; Dubois et al., 2014). AD patients have also been 
found to have cognitive fluctuations, although at a lower prevalence, 10-20%, than those 
seen in DLB (Lee et al., 2012). Although cognitive fluctuations are clinically characterised by 
alterations to cognition, in AD and DLB the cognitive domains that are affected differ, with 
those observed in AD thought to reflect a reduced capacity to cope with the cognitive 
demands of the environment (Bradshaw et al., 2004) (further discussed in 1.6). 
1.3.3 Pathology 
AD-type pathology consists of extracellular Aβ plaques, intracellular aggregates of 
hyperphosphorylated tau (NFTs and neuropil threads) and neuritic plaques consisting of a 
focal core of Ab surrounded by dystrophic tau-positive neurites (Halliday et al., 2011; 
McKhann et al., 2011; Attems, 2017). 
1.3.2.1 Ab  
Aβ plaques are accumulations of the 4kDa Aβ fragment, cleaved from the membrane bound 
amyloid precursor protein (APP), that form in the parenchyma (Murphy and LeVine, 2010). 
Formation of the Aβ fragments, in AD, is due to sequential proteolytic cleavage of the APP 
molecule by two secretases, β- and g-secretase (Selkoe, 2001b). Dependent on the cleavage 
site of g-secretase, two major isoforms of Aβ are present in the brain Aβ40 and Aβ42 with the 
variation in the C-terminus of the fragment (Murphy and LeVine, 2010) (figure 1.3).  
Deposition of Aβ plaques within the brain are thought to be the result of a gradual and 
chronic imbalance in the production and clearance of Aβ from the brain (Selkoe, 2001a). The 
physiological role of Aβ is widely debated, with putative roles suggested in immunology, 




(Pearson and Peers, 2006; Brothers et al., 2018). The lack of consensus on the putative role  
of Aβ, has been further supported by adverse effects observed in AD clinical trials that aim 
to reduce Aβ levels (Schneider et al., 2014; Mehta et al., 2017; Aisen et al., 2020). Although 
the physiological role for Aβ is still elusive, Aβ has played a central role in AD research in the 
past 20 years, with the amyloid cascade hypothesis. The Aβ cascade hypothesis states that 
the production and deposition of Aβ within the brain parenchyma is the primary event which 
can initiate a sequence of events leading to formation of NFTs and eventually neuronal cell 
death (Hardy and Higgins, 1992).  
Support for the amyloid cascade hypothesis has been shown through familial forms of AD 
whom have mutations, typically at or around the cleavage sites, or increased copy numbers 
of APP, as well as, in the secretases Presenilin 1 and 2, which form part of the g-secretase 
complex (Rocchi et al., 2003; Rosenberg et al., 2016; Selkoe and Hardy, 2016). With 
additional support for the hypothesis from Down’s syndrome, trisomy 21. The APP gene is 
located on chromosome 21, meaning those with Down’s syndrome to possess an extra copy 
Figure 1.3. The amyloid cascade hypothesis.                                                                                                                                           
The amyloid cascade hypothesis suggests that deposition of Aβ within the brain is an essential and crucial step that leads 
to AD. Autosomal dominant mutations that lead to familial forms of AD occur in three genes 1 presenilin 1 and 2 part of 
the g-secretase complex and 2 APP. The cascade has also been the target for therapeutics which are currently in clinical 
trials. Targets include a) g-secretase inhibitors and modulators, b) BACE inhibitors, c) monoclonal antibodies and 
compounds against monomers, oligomers and protofibrils and d) monoclonal antibodies and compounds preventing Aβ 









of the gene, as well as an increased expression of β-secretase homologues, also present on 
the chromosome (Head and Lott, 2004). The increase in Aβ production due to the increased 
expression causes detectable AD-type pathology in Down’s patients from the age of 40 
(Annus et al., 2016). Although there is an array of evidence to support the role of Aβ in 
familial AD and Down’s syndrome, the role that the amyloid cascade plays in sporadic AD is a 
subject of continuing debate. This is evidenced by the knowledge that cognitively intact 
brains can have high levels of Aβ present (Maarouf et al., 2011; Kovacs et al., 2013), and that 
considerable amounts of NFTs can be observed in the absence of Aβ in the brain (Crary, 
2016); along with the evidence that Aβ load does not correlate with cognitive impairment 
(Serrano-Pozo et al., 2016). 
1.3.2.2 Tau 
NFTs and neuropil threads are aggregations of the microtubule-associated protein tau, a 
protein that under physiological conditions stabilises the microtubule network within axons 
(Mandelkow and Mandelkow, 2012). To stabilise the microtubule network whilst allowing 
for the dynamics of the network including axonal transport, tau is in a constant state of flux 
between phosphorylated/off and non-phosphorylated/on states (Brandt et al., 2005). Under 
pathological conditions there is dysregulation of the phosphorylation/dephosphorylation 
cycle, leading to an accumulation of abnormally phosphorylated tau that disassociates from 
microtubules and aggregates within the neuron (Grundke-Iqbal et al., 1986; Mandelkow and 
Mandelkow, 2012). In AD there is an over 300% increase in phosphorylation of tau in AD 
brains compared to normal physiological levels (Köpke et al., 1993). Mutations, differential 
exon splicing, and increased expression levels (Myers et al., 2007), have been associated 
with several dementias. These findings provide evidence for tau dysfunction playing a key 
role in tauopathies, including FTD, progressive supranuclear palsy and corticobasal 
degeneration (Poorkaj et al., 1998; Spillantini et al., 1998; Hardy and Singleton, 2008; 
Mandelkow and Mandelkow, 2012). As with Aβ pathology, tau pathology is commonly seen 
in aged individuals, both cognitively intact and impaired (Tomlinson et al., 1970), although 
this is significantly less widespread than that seen in AD cases (Knopman et al., 2003). 
1.3.2.3 Pathological Staging 
AD pathology has been shown to follow a classical topographical pattern of deposition 
within the brain, with a number of staging criteria developed in order to chart pathological 




course of the disease, initially affecting the neocortex (Phase 1), before progressing to the 
allocortex (Phase 2), basal ganglia and basal forebrain (Phase 3) before finally being 
deposited in the brainstem (Phase 4) and cerebellum (Phase 5) (Thal et al., 2002).  
The stepwise topographical spread of tau pathology is divided into VI stages (Braak and 
Braak, 1991b; Braak et al., 2006). Tau pathology originates in the trans-entorhinal cortex 
(Stage I), with pathology progressing to the hippocampus (Stage II), temporal neocortex 
(Stage III), insular cortex (Stage IV), superior temporal gyrus (Stage V) before spreading to 
the occipital cortex (Stage VI) in its final stages (Braak and Braak, 1991b; Braak et al., 2006; 
Alafuzoff et al., 2008). The severity of the pathology within affected brain regions increases 
with Braak stage, with severe tau pathology visible in the trans-entorhinal cortex in brains 
with Braak stage VI (Walker et al., 2017). Braak stage has also been demonstrated, in several 
studies, to correlate with clinical severity of AD (Bancher et al., 1996; Gertz et al., 1996; Gold 
et al., 2000). As well as staging criteria for both tau and Aβ individually, there is criteria to 
semi-quantitively assess neuritic plaque pathology in AD cases (Mirra et al., 1991). Neuritic 
plaques, a convergence between the two AD pathologies, are a necessary feature for a 
neuropathological diagnosis of AD (Attems, 2003). The semi-quantitative scale assesses 
neuritic plaque pathology in the middle frontal gyrus, superior/middle temporal gyri and 
inferior parietal lobe, as either sparse moderate or frequent (Mirra et al., 1991). All three 
staging criteria are combined to suggest an overall level of AD neuropathological change 
within the brain, either high, medium or low (Hyman et al., 2012; Montine et al., 2012).  
1.3.2.4 Concomitant Pathologies 
As with other common neurodegenerative disorders, AD brains also possess concomitant 
pathologies, alongside the hallmark deposition of Aβ and tau. Previous neuropathological 
studies have shown that cerebrovascular disease occurs commonly in ageing with up to 84% 
of those over 80 years old possessing vascular pathologies (Petrovitch et al., 2005; Attems 
and Jellinger, 2014). Vascular pathology is common in AD cases, with 30% containing some 
cerebrovascular pathology and nearly all cases exhibiting some form of vascular lesion, 
including cerebral amyloid angiopathy and small vessel disease (Kalaria and Ballard, 1999; 
Yip et al., 2005); with vascular pathology in AD more extensively investigated than that 
observed in DLB (Raz et al., 2016), see 1.2.2.4. The interaction between vascular and AD 
pathologies are of great interest and it has been suggested that the combination of the two 




Jellinger, 2014). AD patients with lower levels of Aβ and tau with concomitant vascular 
pathologies have been shown to be more severely cognitively impaired than those with 
comparable AD-type pathology without vascular pathology (Zekry et al., 2002). 
AD brains also contain neuropathological lesions commonly associated with other 
neurodegenerative disorders including TDP-43, found in 33-40% of cases and α-synuclein, 
discussed more in 1.4.2., found in 41-55% of AD cases (Robinson et al., 2018). TDP-43, as 
discussed in 1.2.2.3, is the key hallmark for a subtype of FTD and the newly discovered LATE. 
TDP-43 pathology is found in 33-40% of AD cases, which increases to 75% in cases with the 
























1.4 Mixed AD/DLB 
Neurodegenerative dementia had for a long time thought to have been caused by discrete 
diseases, which clinically manifest due to selective neuronal loss and dysfunction in 
distinctive anatomical regions by abnormal accumulations of endogenous proteins (Rahimi 
and Kovacs, 2014). Typically, a diagnosis of a neurodegenerative disease is based upon a 
clinico-pathological consensus, where neuropathological and clinical information is 
combined to form a definitive clinico-pathological diagnosis (Walker et al., 2015). However, 
as previously described in sections 1.2 and 1.3, characteristic neuropathological deposits are 
not the only type of pathological lesion that can be found in the brain of dementia cases, 
concomitant pathologies usually characteristic of another neurodegenerative disorder can 
be found (Rahimi and Kovacs, 2014; Spires-Jones et al., 2017). Mixed dementia was for a 
long time thought to apply, mainly, to a mixture of vascular and AD pathologies in the brain 
underlying the clinical symptoms. However, over the past few decades, the observation of 
concomitant pathologies across the neurodegenerative disease spectrum is increasingly 
recognised (Armstrong et al., 2005; Jellinger, 2007; Jellinger and Attems, 2007; Kovacs et al., 
2008; Kovacs et al., 2013), this has led to the updating of clinical and neuropathological 
criteria (Rahimi and Kovacs, 2014; Josephs et al., 2016; McKeith et al., 2017).  
Numerous post-mortem and community-based studies have been undertaken with the aim 
to establish the rates of mixed pathologies within the ageing brain (Rahimi and Kovacs, 
2014). A large, 1500 cases, post-mortem cohort from Vienna found that only 52% of the 
cases examined were ‘pure’ AD and 2% ‘pure’ vascular dementia (VaD) (Jellinger and Attems, 
2007). 27.4-31.4% of the cases were either AD with additional vascular lesions or with 
additional α-synuclein pathology (Jellinger and Attems, 2007), however, there was no 
mention of whether the levels of the additional pathologies were likely to be symptomatic. 
In a larger multi-centre study led by BrainNet Europe, 3303 brains from 9 centres were 
analysed for the presence of co-occurring pathologies (Kovacs et al., 2008). 55.3% of the 
cases examined in this multi-centre cohort were found to possess more than one pathology 
associated with a neurodegenerative disease including AD, vascular pathologies and 
synucleinopathies. The findings from the study also showed that multiple pathologies were 
found most frequently in PD (92%) with additional pathologies also found Lewy body 
dementias (61%) and AD (43%), highlighting the high frequencies of mixed pathologies 




suggesting that 89% of DLB cases had some level of AD pathology (Dugger et al., 2014). 
Several community-based studies have also furthered the realisation that there is an under 
appreciation for mixed pathologies in neurodegenerative disorders (Schneider et al., 2007; 
Kovacs et al., 2013).  
There are a number of hypotheses have been proposed to explain the co-pathologies found 
in neurodegenerative disorders. One hypothesis is that similarly to the incidence of 
neurodegenerative pathologies, age is associated with the accumulation of multiple co-
occurring pathologies within the brain, with a brain from an older person more likely to 
possess more mixed pathologies (Jellinger and Attems, 2010; Kovacs et al., 2013; Filfan et al., 
2017; Robinson et al., 2018). Another hypothesis is that the primary pathology could seed 
the accumulation of a secondary pathology, this would suggest that cases with a more 
severe primary pathology would have an increased number or severity of co-pathologies 
(Clinton et al., 2010). Along with the seeding of pathologies that are thought to associate 
with co-pathologies, genetic risk factors including apolipoprotein E e4 that have been 
associated with specific neurodegenerative disorders are thought to also increase the levels 
of co-pathologies across neurodegenerative diseases, as shown with an increase in AD-type 
pathology in DLB cases with the apolipoprotein E e4 allele (Robinson et al., 2018). Although 
there has been an increased interest in how the co-pathologies occur and how they may 
affect the clinical phenotype (Irwin et al., 2017; Kapasi et al., 2017; Robinson et al., 2018), 
the initial clinical diagnosis of mixed dementia, specifically mixed AD/DLB, is rare, with only a 
small percentage having a revised diagnosis of mixed AD/DLB dementia within their lifetime 
(Thomas et al., 2018).  
1.4.1 Clinical features 
The clinical identification of mixed AD/DLB is of current interest due to the possible future 
development of protein targeted treatments, as well as the correct stratification in their 
clinical trials. Clinically, a diagnosis of mixed AD/DLB is uncommon, especially at baseline 
where it has hypothesised that the secondary pathology may not be advanced enough to 
elicit clinical symptoms (Thomas et al., 2018). However, some initial diagnoses may be 
revised later on in the disease course, although this is mainly at specialist centres, with the 
vast majority not being identified until post-mortem (Nelson et al., 2010; Lebouvier et al., 




Clinically mixed AD/DLB can present with clinical features of both AD or DLB, with this having 
been shown to be dependent upon which pathology occurs first within the brain (Walker et 
al., 2015). It is currently unknown whether there is a different clinical course for those with 
initial AD-type and DLB-type dementia that then go onto develop mixed AD/DLB (Malek-
Ahmadi et al., 2019). Although clinically difficult to identify, clinicopathological studies have 
shown that DLB and mixed AD/DLB have a differing clinical presentation in regard more 
severity of impairments and a speed of decline, with mixed AD/DLB having both greater than 
pure DLB (Kraybill et al., 2005; Nelson et al., 2010). With Studies showing that the presence 
of mixed pathologies, including mixed AD/DLB have a great change in MMSE and Dementia 
Rating Scale scores per year that those with pure AD or pure DLB (Kraybill et al., 2005).  
In patients which present with a primarily AD-like dementia, studies have shown that an 
initial presentation which includes impairment to visuospatial and executive function is 
indicative of mixed AD/DLB, as this cognitive impairment is more commonly present in 
mixed AD/DLB than in pure AD cases (Hansen et al., 1990; Weiner et al., 2003; Malek-
Ahmadi et al., 2019). These mixed AD/DLB cases also tend to have a worse depression and 
Trail-Making A test score compared to pure AD cases, even though the neuropsychological 
scores do not differ (Malek-Ahmadi et al., 2019). However, these differences between mixed 
AD/DLB and pure AD, done retrospectively, are not useful for clinical diagnosis. One third of 
mixed AD/DLB case present with a clinical DLB phenotype, which includes impairments to 
visuospatial function, this would thus lead to cases being diagnosed as DLB and not the 
correct mixed AD/DLB (Thomas et al., 2018). Mixed AD/DLB, retrospectively, have also been 
shown to have an initial verbal memory and confrontational naming deficit that is more 
severe than those with pure DLB, however, again this does not help to discriminate against 
those with pure AD (Kraybill et al., 2005), excluding a third of those with mixed AD/DLB that 
present with AD-like dementia (Thomas et al., 2018). The majority of studies that have been 
undertaken so far into understanding the clinical aspects of mixed AD/DLB have focussed 
almost exclusively on retrospective analysis. In order for more thorough longitudinal 
research to be conducted, and the eventual ability to identify and diagnose mixed AD/DLB 
biomarkers for both AD and DLB-type pathology would need to be developed and utilised 





Pathologically mixed AD/DLB is defined by the presence of both high neuropathologic 
change AD pathology, further described in 1.3.2, and neocortical DLB pathology, further 
described in 1.2.2, where the pathological criteria for both AD and DLB are met (Walker et 
al., 2015). Although this criterion pathologically defines mixed AD/DLB dementia, a number 
of research studies have used varying definitions for mixed AD/DLB. These definitions 
include AD cases with α-synuclein pathology that does not meet the pathological criteria for 
DLB, as well as DLB cases with only mild AD pathology. This variation in what is defined as 
mixed AD/DLB has further reduced the small number of studies which look into the 
pathology and underlying mechanisms of mixed AD/DLB. 
There have been a small number of clinicopathological studies which have tried to 
understand the pathological underpinning of certain clinical symptoms observed in mixed 
AD/DLB. EEG studies in DLB with and without AD pathology, not necessarily meeting the 
criteria for a diagnosis of mixed AD/DLB, compared to pure AD, found that severity and 
presence of AD pathology did not alter the EEG changes observed. This suggests that the 
EEG changes observed could be related to α-synuclein pathology present, rather than the 
AD-type pathology (van der Zande et al., 2018). Studies similar to this have shown that both 
global and regional atrophy seen in mixed AD/DLB is more similar to that seen in AD than 
DLB brains, with the level of atrophy seen correlating with the severity of AD-type pathology 
(Nedelska et al., 2015). Further studies examining the relationship of pathology on clinical 
symptoms have found that the amount of quantitative pathology does seem to reflect the 
clinical diagnosis, for example a clinically AD mixed AD/DLB will have a higher level of tau 
and Aβ compared to α-synuclein pathology (Walker et al., 2015).  
Currently it is unknown whether the initiation and spread of the secondary pathology is 
independent of the primary pathology. However, cases with higher levels of α-synuclein 
pathology tend to have higher amounts of AD-type pathology and a shorter clinical course 
suggesting that there is synergy between the two pathologies (Nelson et al., 2009; Irwin et 
al., 2017; Malek-Ahmadi et al., 2019), further discussed in 1.5. This has been further 
evidenced by a study showing that there were no changes in MMSE score with varying α-
synuclein pathology when AD-type pathology was controlled for in mixed AD/DLB, 
suggesting that the pathologies are additive (Nelson et al., 2009). As with other dementia 




that could impact upon the cognitive impairment seen clinically (Kapasi et al., 2017). Some 
studies have suggested that there could be changes to the topographical spread of the 
pathologies when they are present together in the brain, with higher tau and α-synuclein 
levels in neocortical areas compared to the hippocampus (Malek-Ahmadi et al., 2019). As 
with the clinical aspect of mixed AD/DLB research, further studies need to be undertaken to 


























1.5 Pathological mechanisms of neurodegenerative disorders 
Neurodegenerative diseases lead to a progressive loss of cognitive function, producing a 
spectrum of clinical syndromes. The majority are sporadic with the aetiology thought to be 
multifactorial with genetic, epigenetic, environmental and age-related factors (Jellinger, 
2010). Although neurodegenerative diseases have a diverse array of clinical manifestations, 
and the initial event and genetic underpinning may vary among the diseases, it is thought 
common neurodegenerative pathways are shared between them (Santiago et al., 2017). 
There have been a number of processes and pathways that have been proposed to be 
shared amongst neurodegenerative diseases, however, the basic molecular mechanisms and 
their pathogenic role in these common neurodegenerative pathways are not yet fully 
understood (Jellinger, 2010; Gan et al., 2018).  
Neurons are unique compared to other cell types in the central nervous system. Along with 
their terminally differentiated state (Frade and Ovejero-Benito, 2015), neurons face 
additional challenges that can make them susceptible to neurodegenerative processes. Due 
to the functional role that neurons play, trafficking of molecules and organelles over large 
distances, along axons and processes, as well as rapid endo-/exocytosis of molecules 
requires a continuous demand for high energy levels; impairment to the pathways involved 
in these functions are proposed to lead to neurodegeneration (Gan et al., 2018). Currently 
the major basic processes that have been implicated in neurodegenerative pathways include 
(figure 1.4): abnormal protein dynamics, through impairment in the ubiquitin-proteasome 
system and autophagy-lysosomal pathway, and protein aggregation; oxidative stress, the 
formation of free radical and impaired bioenergetic through mitochondrial dysfunction; 
neuroinflammatory processes, with changes to extra-neuronal populations; disruption to 
neuronal transport and synaptic toxicity (Gitler et al., 2017; Soto and Pritzkow, 2018).  
Although the hallmark pathological proteins are different, in distinct neurodegenerative 
diseases, it is thought that the process of misfolding, aggregation and neuronal death, are 
similar (Soto and Pritzkow, 2018). The native, monomeric structures of these proteins are 
thought to misfold to form aggregates, that are rich in beta-sheet motifs, with intermediary 
oligomeric and protofibril structures (Soto, 2003; Ross and Poirier, 2004). Although in 
previous years it has been proposed that the large aggregates were toxic, recent data has 






Figure 1.4. Common neuronal pathways altered in neurodegenerative disease.             
Common neuronal pathways that can be altered in neurodegenerative disease include: I-protein quality control: molecular chaperones including heat shock proteins (HSP) regulate 
protein folding and ubiquitin-proteasome system (UPS) mediated degradation, while misfolded proteins could return to their native conformation state through interaction with 
disaggregase. II-autophagy-lysosome pathway (ALP): dysfunction to the ALP is thought to be a reason for the accumulation of protein aggregates and dysfunctional mitochondria within 
neurons. III-mitochondrial homeostasis: impairment of the clearance of dysfunctional mitochondria through mitophagy can lead to a reduction in energy production, signal for cell death 
pathways and impair proteostasis networks. IV-Protein seeding and propagation: prion like spread of pathological proteins could be the cause of disease progression and spread within 
the brain. V-Synaptic toxicity and network dysfunction: pathological proteins within pre- and post-synaptic terminals can lead to dysfunction in synaptic transmission, leading to network 





the oligomeric intermediates (Jellinger, 2010). In addition to researchers proposing that the 
formation of large aggregates, such as Lewy bodies, could be either protective for the 
neuron or a neutral component within the pathways to neuronal death (Gan et al., 2018). 
The underlying mechanisms of the neurotoxic effects of the pathological proteins are still 
not completely understood. There have been three main mechanisms proposed; i) loss of 
function, ii) gain of function and iii) inflammatory mechanisms (Jellinger, 2010) and it is 
likely that a combination of these mechanisms occurs within the brain during 
neurodegenerative diseases, dependent on the protein sequence, cellular location and 
biophysical properties of the misfolded protein (Soto and Pritzkow, 2018).  
The understanding of these pathways is confounded by the fact that the same 
neurodegenerative processes and pathways can be affected in different ways, in different 
neurodegenerative diseases. Neurodegenerative pathways can be associated with a variety 
of clinico-pathological phenotypes and vice versa identical phenotypes can be associated 
with a number of different neurodegenerative pathways (Golde, 2009; Sabir and Scholz, 
2019). With the extensive pre-clinical phase seen in the neurodegenerative diseases, the 
elucidation of the role of these pathways is thought to be a critical step in order to locate 
drug targets for these diseases, as targeting the trigger may be too late at the point of 
clinical presentation, as well as the changes to neurodegenerative processes throughout the 
diseases progression (Golde, 2009; Kikuchi et al., 2013).  
1.5.1 Interactions between pathologies 
Neurodegenerative diseases are characterised by the presence of distinct lesions, which are 
the prerequisite for its clinical development and later diagnosis (Spires-Jones et al., 2017). 
However, the simultaneous accumulation of misfolded protein aggregates, both 
characteristic of and non-characteristic of the clinical disease is a common feature in 
neurodegenerative diseases (Badiola et al., 2011). For example over 70% of DLB cases in a 
large multi-centre study where identified to have medium-high levels of AD pathology at 
post-mortem (Irwin et al., 2017; Irwin and Hurtig, 2018). In the majority of instances the co-
occurrence of pathologies is observed in different anatomical regions and cellular 
populations, although sometimes the proteins can be located within the same aggregates 
(Badiola et al., 2011), for example tau and a-synuclein in Lewy bodies in DLB (Galloway et 




co-pathologies is thought to possibly be coincidental or, more likely, have an impact on 
disease progression or clinical presentation (Spires-Jones et al., 2017). Research is currently 
focused upon whether there is a direct or indirect synergy between the co-pathologies 
when they are present within the same brain. Synergy and interaction between the proteins 
could be due to cross-seeding of the proteins or whether enhanced cellular vulnerability, 
impairments to proteostasis mechanisms result in an indirect synergy through an increased 
likelihood for protein misfolding (Soto and Pritzkow, 2018).  
1.5.1.1 Tau and a-synuclein 
Tau is frequently found as a co-pathology in neurodegenerative diseases, such as in DLB. 
From this observation research into the possible interactions between tau and a-synuclein 
have been undertaken and are ongoing. Giasson et al. (2003) were amongst the first to 
demonstrate that interactions between a-synuclein and tau can promote cross-fibrilization 
and could drive the formation of pathological inclusions. From their study it was found that 
when a-synuclein and tau were incubated together, a-synuclein may enhance a rate-
limiting step in the initiation and early stages of tau fibrilization (Giasson et al., 2003). 
Badiola et al (2011) provided further evidence for the interaction between tau and a-
synuclein, reporting that tau enhanced a-synuclein aggregation and toxicity, in human 
neuroglioma cells and mouse cortical neurons. The study further identified that the 
presence of tau leads to smaller a-synuclein aggregates but with enhanced toxicity (Badiola 
et al., 2011). The finding that smaller a-synuclein aggregates, have an enhanced toxicity, is 
consistent with human post-mortem findings that identified that presynaptic small a-
synuclein aggregates associated with dendritic loss in the postsynaptic area, in DLB patients 
(Kramer and Schulz-Schaeffer, 2007). Human post-mortem brain tissue has supported the 
interaction between a-synuclein and tau with oligomeric forms located within the same 
aggregates using immunofluorescent techniques (Sengupta et al., 2015). Not only has the 
interaction between tau and a-synuclein been shown to enhance aggregation, the 
interaction between the proteins has been shown to enhance phosphorylation of tau, 
utilising cellular and mouse models (Moussaud et al., 2014; Li et al., 2016). It has been 
proposed that a-synuclein can interact with glycogen synthase 3 beta to promote the 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced phosphorylation of tau (Duka et al., 




mortem techniques. An increase in phosphorylated tau within neurons could therefore lead 
to increased microtubule instability, impairing intraneuronal trafficking and increasing the 
rate of neurodegenerative processes within the neuron. 
1.5.1.2 Aβ and a-synuclein 
a-synuclein was first identified as the NAC of Aβ plaques in AD (Uéda et al., 1993), 
suggesting that a-synuclein and Aβ could interact (Chen, 2016). Studies have been 
undertaken to understand the interaction of a-synuclein and Aβ (Masliah et al., 2001; 
Compta et al., 2011; Marsh and Blurton-Jones, 2012). Cross seeding between a-synuclein 
and Aβ has been observed in vitro (Ono et al., 2012), and a-synuclein has been shown to 
interact with Aβ oligomers to form hybrid oligomers in AD brains (Guerrero-Muñoz et al., 
2014). Within double transgenic mouse models, the presence of Aβ exacerbates a-synuclein 
accumulation and neuronal deficit (Masliah et al., 2001). Aβ has also been shown to induce 
phosphorylation of a-synuclein at Serine 129 (pS129) in vitro, with the insoluble level of this 
post-translationally modified a-synuclein in brain homogenates related to the level of 
soluble and insoluble Aβ, with other studies suggesting that the concentration of ps129 is 
directly related to Aβ (Swirski et al., 2014). An increase in pS129 levels, through interactions 
with Aβ, have been proposed to feed into a number of neurodegenerative mechanisms, 
including interactions with mitochondria (Oueslati, 2016). Wang et al. (2019) utilising 
primary rodent neuronal cultures and post-mortem brain tissue identified that pS129 
preferentially accumulated in the mitochondria, compared to physiological a-synuclein 
which was found to not to be associated. The preferentially accumulation of pS129 in 
mitochondria was associated with defects in mitochondrial activity (Wang et al., 2019), with 
further studies in rat brains identifying reduced protein import into the mitochondria due to 
pS129 interaction with Tom20 (Bernal-Conde et al., 2019). Reduction to the import of 
proteins from the cytosol into the mitochondria could lead to alterations in energy 
production and excessive production of reactive oxygen species (Suhane et al., 2013). The 
increased levels of reactive oxygen species could trigger apoptotic pathways leading to 
neuronal death. 
1.5.1.3 Aβ and tau 
The relationship between Aβ and tau has been extensively examined in the context of the 




unidirectional whereby the accumulation of Aβ induces hyperphosphorylation of tau (Chen, 
2016). Although the link between tau and Aβ is clearly evidenced, for example their 
convergence in neuritic plaques in AD (Spires-Jones et al., 2017), the exact species or 
conformations of Aβ that are responsible for this interaction is currently under debate 
(Chen, 2016). Many studies have suggested that species of Aβ interact indirectly via kinases 
with tau to enhance phosphorylation, leading to increased microtubule instability 
(Takashima et al., 1993; Greenberg et al., 1994; Ma et al., 2009), with a few suggesting 
direct interactions (Jin et al., 2011). The mechanistic link between Aβ and tau can be further 
supported by familial forms of AD, where genetic mutations which underlie alterations to 
Aβ processing not only leading to the formation of Aβ pathology but also leading to the 
production of tau pathology (Spires-Jones et al., 2017). While there is an abundance of 
studies suggesting how Aβ exacerbates tau pathology, there have been fewer that have 
supported a role for tau in Aβ pathology (Chen, 2016; Spires-Jones et al., 2017). 
1.5.1.4 a-synuclein, Aβ and tau 
Within mixed AD/DLB all three pathological proteins as discussed in 1.5.1 are present, 
although there has been a lack of studies that investigate all three pathological proteins 
together. As plaques, tangles and Lewy bodies occur in a way that cannot be merely 
explained by pure statistical overlap it is thought that the three proteins can promote the 
accumulation of one another, further necessitating the requirement to study the three 
together (Giasson et al., 2003; Clinton et al., 2010). The presence of a-synuclein pathology 
in AD is also associated with a more aggressive disease course and accelerated dysfunction 
(Kraybill et al., 2005), highlighting a clinical need for the interaction for the three proteins to 
be investigated. Clinton et al. (2010) tried to address this by creating a DLB-AD mouse which 
exhibited all three pathological lesions. Data from the study supported the idea that a-
synuclein, Aβ and tau interact in vivo leading to aggregation and accelerated cognitive 
decline. Within the study Clinton et al. (2010) also found an increase in the levels of 
insoluble Aβ at 12 months in the DLB-AD mice compared to AD-only mice, with the DLB-AD 
mice also possessing more plaques. Future work both in vitro, in vivo and using human post-





1.5.2 Selective vulnerability  
The clinical manifestation of neurodegenerative diseases is defined by the affected brain 
regions and neuronal subpopulations (Fu et al., 2018; Jaunmuktane and Brandner, 2019). 
The selective loss of specific neuronal populations is thought to be due to these populations 
being more vulnerable to dysfunction or death in response to pathological states (Saxena 
and Caroni, 2011; Mattsson et al., 2016), due to their intrinsic anatomy and biochemistry 
(Fu et al., 2018). Although it has been known for a long time that specific neuronal 
populations are affected in different neurodegenerative diseases, the mechanisms 
underpinning this selective vulnerability have been difficult to uncover (Fu et al., 2018).  
Several hypotheses for selective vulnerability have been proposed, including the stressor-
threshold model (Saxena and Caroni, 2011). The model hypothesises that the neurons that 
are selectively vulnerable in neurodegenerative diseases, on the background of 
environmental and genetic stress, have increased sensitivity to particular intrinsic stressors, 
organelle and energy homeostasis, which can combine to create a vicious cycle of increasing 
stressor load and lead to neuronal degeneration (Saxena and Caroni, 2011). A number of 
stressor pathways/mechanisms that were proposed to be involved in the model include 
enhanced physiological demands such as neuronal excitability, calcium fluxes and 
endoplasmic reticulum stress. Although the main neurodegenerative disease are 
characterised by the accumulation of misfolded proteins into aggregates, there has been 
research to say that this process alone is not sufficient to cause disease and that additional 
factors are required (Saxena and Caroni, 2011). 
A number of mechanisms have been suggested that together or individually could underpin 
the selective vulnerability observed in neurodegenerative diseases (Fu et al., 2018). Many of 
these mechanisms have been identified by studies that have mainly focused on a 
comparison of vulnerable neurons to their non-vulnerable neighbours, for example 
comparison of the dopaminergic neurons in the vulnerable substantia nigra (SN) and the 
non-vulnerable ventral tegmental area (VTA) in PD (Surmeier et al., 2017b; Fu et al., 2018).  
Susceptibility to mitochondrial dysfunction has been implicated in selective vulnerability in 
PD (Surmeier et al., 2010; Bolam and Pissadaki, 2012). Morphologically SN dopaminergic 
neurons have longer, sparsely myelinated axonal arbours and a higher number of synapses 




differences are thought to result in a redistribution of mitochondria within the neuron 
towards the axonal terminals, leading to elevated energy demands and increasing the 
susceptibility to dysfunction in neuronal energy production (Surmeier et al., 2010; Bolam 
and Pissadaki, 2012). The lower mitochondrial mass within SN dopaminergic neurons may 
mean that they are closer to mitochondrial failure than other neurons (Fu et al., 2018), 
suggesting that they would be selectively vulnerable to neuronal insults that lead to 
mitochondrial dysfunction. It has been suggested that certain post-translationally modified 
species of a-synuclein, such as pS129, possess different properties than the physiological 
form. pS129 has been found to associate with mitochondria, leading to disruption of 
mitochondrial processes (Wang et al., 2019), this could lead neurons that are more 
susceptible to changes in energy demands selectively vulnerable, including the SN in PD 
(Abbate, 2019; Lau et al., 2019; Mrdjen et al., 2019). 
Furthermore, differential expression and levels of Ca2+ buffer proteins have been implicated 
in the selective vulnerability in PD (Fu et al., 2018). The morphology of SN neurons, in 
combination with the pace-making oscillations, expression of different Ca2+ conductance 
channels and low Ca2+ buffering is what is currently thought to make these dopaminergic 
vulnerable compared to their VTA neighbours, with this leading to Ca2+ toxicity and 
mitochondrial stress and dysfunction (Sulzer, 2007; Brichta and Greengard, 2014; Surmeier 
et al., 2017a; Fu et al., 2018). The vulnerability conferred by the tonic pace-making activity 
and high branched axons are also observed in the cholinergic basal forebrain projection 











1.6 Cognitive fluctuations 
Cognitive fluctuations, are one of the least well characterised and understood of the four 
core clinical features of DLB, even though they have a prevalence of 80-90%, (McKeith et al., 
2000b; Ballard et al., 2001; Matar et al., 2019). Clinically defined as spontaneous variations 
in functional ability, cognition, attention and arousal, lasting from minutes to hours, as well 
as longer periods of weeks or months, cognitive fluctuations are thought to have no obvious 
environmental or situational cause (Walker et al., 2000b; Ballard et al., 2001; Escandon et 
al., 2010; Lee et al., 2012; Mainland, 2015). With cognitive fluctuations described as periods 
of inattention, behavioural confusion, hypersomnolence, appearing to be ‘switched off’ and 
incoherent speech alternating with periods of lucidity and ‘normal’ cognition, resembling a 
delirious state (Sin et al., 2015), without acute motor or sensory loss; these fluctuations are 
thought to occur without an identifiable cause for the change in mental status and do not 
tend to follow a strict rhythm (Ballard et al., 2001; Ferman et al., 2004; McKeith et al., 2017; 
Matar et al., 2019). In DLB, fluctuations in cognition have been shown to be independent of 
alertness (Escandon et al., 2010; Bliwise et al., 2014). 
Although cognitive fluctuations are a core feature of DLB, they have also been shown to 
affect those with VaD and AD, though with substantially lower prevalence than in DLB, 35-
50% and 10-20% respectively compared to 80-90% (Lee et al., 2012). While this is a feature 
found in a number of dementia subtypes, the cognitive domains affected can differ. 
Bradshaw et al (2004) found that in DLB, cognitive fluctuations tended to result in 
impairments to the flow of awareness and attention. Whereas, cognitive fluctuations 
observed in AD tended to reflect a reduced capacity to cope with the cognitive demands of 
the surrounding environment (table 1.1). It has also been suggested that fluctuations in DLB 
are more transient than those observed in AD, with caregivers stating that there were 
substantial changes in cognitive state on a daily basis (Bradshaw et al., 2004). The 
differences in affected cognitive domains in fluctuations between AD and DLB could 
underlie the reportedly decreased quality of life in DLB compared to AD (Bostrom et al., 
2007).  
The most obvious symptoms in those with neurodegenerative dementias is the loss of 
cognitive ability, however, it is the patient’s ability to live an independent life that can have 




2012). The ability to be independent and perform fundamental activities of daily living, as 
well as their decision-making capacity, impacts not only the patient’s quality of life, but the 
timing of possible institutionalisation and what degree of care they require (Jefferson et al., 
2006). Previous studies have demonstrated that cognitive fluctuations make a significant 
and independent contribution to the level of activities of daily living impairment (Ballard et 
al., 2001; Sun et al., 2018) and their decision-making capacity (Trachsel et al., 2015). 
Cognitive fluctuations not only affect the ability of the patient to complete everyday tasks, 
but they can also contribute to increased caregiver burden (Ballard et al., 2001; Zweig and 
Galvin, 2014). Several studies have investigated the impact of dementia subtype diagnosis 
and cognitive symptoms on the mental and physical demands of their caregiver (Kleinman 
et al., 2004; Lee et al., 2013; Zweig and Galvin, 2014). Studies have consistently found that a 
diagnosis of DLB or PDD resulted in a higher level of caregiver burden, even when compared 
with dementias such as AD or VaD, irrespective of age, gender and cognitive ability (Lee et 
al., 2013). The increased caregiver burden resulting from cognitive fluctuations could largely 
be due to the unpredictability of the care requirements and level of support required over 
the course of the day (Mainland, 2015). 
Table 1.1. Care Giver Descriptions of Fluctuating Cognition.                                                                                                    
Carer’s answers to the questions 'Has the patient had a period or periods today when they seemed to be confused and 
muddled and then a period or periods when they seemed to be improved and functioning better? Give examples of 
the worst and best period of function.’ Taken from the One Day Fluctuation Assessment Scale (Adapted from 







Cognitive fluctuations are highly disabling, above and beyond existing cognitive impairment, 
and can occur in varying frequencies both between subjects and within the same individual, 
from infrequent to several times a day (Ballard et al., 2001; Mainland et al., 2017). The wide 
variation in the clinical presentation of fluctuations presents the diagnostic challenge of how 
to accurately assess the feature whilst conveying all their characteristics, especially in the 
later stages of disease progression when cognitive fluctuations may be hidden by severe 
cognitive impairment (McKeith et al., 1996). The presence of fluctuations can also impact 
upon other cognitive tests, such as MMSE, making it difficult to obtain a reliable and 
accurate assessment (Mainland, 2015; Izuhara et al., 2019). The inability to accurately 
assess and characterise cognitive fluctuations seen clinically can provide difficulties when 
undertaking clinico-pathological correlative studies. Without an accurate assessment of 
cognitive fluctuations, it is not possible to correlate changes seen within brain regions to the 
severity of fluctuations.  
Although the presence of cognitive fluctuations has been established in a variety of 
dementia subtypes and is of key diagnostic relevance in DLB, there is still little known about 
the changes that underlie this phenomenon (Matar et al., 2019). Studies mainly utilising EEG 
and MRI in DLB patients have been undertaken in order to help understand what changes 
may underlie the aetiology of cognitive fluctuations. Bonanni and colleagues (2008) found 
that on EEG, DLB compared to AD patients tended to display an increase in slow wave 
activity posteriorly. Furthermore, in DLB patients the EEG frequency fluctuates in periodic 
patterns, particularly posteriorly, with such transient changes correlating with the frequency 
and severity of the fluctuating cognition (Walker et al., 2000b). Research from Schumacher 
et al. (2019a; 2019b; 2019c) using a combination of MRI and EEG has investigated 
alterations to brain dynamics as well as the possible network underpinning of cognitive 
fluctuations. In Lewy body dementia patients it was found that there was an alteration to 
microstate dynamics compared to AD and controls, with a correlation found between the 
severity of the cognitive fluctuations and the microsite abnormalities, suggesting a less 
dynamic brain is related to cognitive fluctuations (Schumacher et al., 2019c). However, the 
ability to change from low to high inter-network connectivity states as seen by functional 
MRI did not correlate with cognitive fluctuations, as measured by clinical assessment of 




to fluctuating cognition are still unknown, with no obvious structural changes having been 
associated with the phenomenon (Taylor et al., 2013). Further studies have found 
volumetric reductions to the hypothalamus in DLB, which have been suggested to relate to 
the alterations in attention and arousal seen clinically in DLB (Whitwell et al., 2007). In DLB, 
alterations have been observed in cells responsible for cortical activation and the generation 
of wakefulness, including alterations to nicotinic receptor binding (Ballard et al., 2002b; 
Pimlott et al., 2006), that could influence cognitive fluctuations (Ferman et al., 2004). 
Functional neuroimaging studies have associated fluctuations with changes in neural 
networks involving cholinergic and dopaminergic transmitter systems within the thalamus 
(Pimlott et al., 2006; Peraza et al., 2014; Delli Pizzi et al., 2015). On the basis of these 
studies, a number of theories have been postulated, discussed further in 1.6.1, as well as 
the hypothesis that cognitive fluctuations result from alterations in networks, rather than 
obvious single structural changes (Taylor et al., 2013). 
In spite of the fact that there is a limited understanding of the underlying causes of cognitive 
fluctuations, there have been a number of studies that have investigated possible 
symptomatic treatments (O'Dowd et al., 2019). Mori et al (2012) investigated the effect of 
donepezil, an AChEI, on cognitive fluctuations and found that it ameliorated fluctuating 
cognition on the Cognitive Fluctuation Inventory score and associated EEG abnormalities, 
compared to placebo. The efficacy of other currently licenced dementia drugs, including 
rivastigmine and memantine is less certain (O'Dowd et al., 2019). Studies looking at deep 
brain stimulation of regions involved in attentional networks, including the nucleus basalis 
of Meynert have been contradictory in their ability to treat cognitive fluctuations (Freund et 
al., 2009; Gratwicke et al., 2018).  
Although research has been undertaken to attempt to understand the aetiology of 
fluctuating cognition, it is understudied relative to other aspects of DLB and 
neurodegenerative dementias. The paucity of research is reflected in the limited 
reproducible biomarkers and lack of new major insights into the aetiology of cognitive 
fluctuations, as well as explaining the lack of treatments available that target this clinical 




1.6.1 Theories behind cognitive fluctuations 
Various brain regions have been implicated, through a variety of techniques including 
SPECT, diffusion and resting state MRI, and EEG, that could play a role in the generation of 
cognitive fluctuations. The identification and implication of these regions has in turn led to a 
number of mechanistic theories being posited (Matar et al., 2019; O'Dowd et al., 2019).  
1.6.1.1 Theory of attentional dysfunction 
One of the major theories for cognitive fluctuations in the disruption to attentional systems, 
with disruption in attentional processing thought to be an early feature of fluctuations 
(Matar et al., 2019). Dysfunction to the attentional systems has been hypothesised to occur 
via a number of different mechanisms, with it likely that several components together are 
affected, rather than one single pathological change (Matar et al., 2019; O'Dowd et al., 
2019). Overall the theory of attentional dysfunction suggests that in DLB the brain is less 
dynamic, with studies implicating network dysfunction and alterations to the cholinergic 
system in underlying the attentional changes. The alterations to brain dynamics could 
reduce the ability of the brain to adapt to changing loads, leading to variability within the 
attentional networks (Bradshaw et al., 2004). Without the ability to quickly and easily adapt 
to changing attentional loads this could cause lapses of inattention, observed clinically as 
fluctuations in cognition. 
Disturbances to large-scale neural networks has been implicated in the attentional 
hypothesis of cognitive fluctuations (O'Dowd et al., 2019). The default mode network, 
where activity has been linked to attentional lapses (Weissman et al., 2006), has been 
hypothesised to be involved in cognitive fluctuations, although the data in supporting this 
theory is conflicting (Franciotti et al., 2013; Lowther et al., 2014; Peraza et al., 2014; 
Schumacher et al., 2018; O'Dowd et al., 2019). Within some of the studies examining default 
mode network, it has been found that a decrease in frontoparietal network connectivity 
negatively correlated with cognitive fluctuation severity in DLB (Franciotti et al., 2013; 
Peraza et al., 2014). Although, the default mode network alone has conflicting evidence 
supporting its involvement in cognitive fluctuations, the network in combination with other 
attentional networks has been implicated in dysfunctional attention in DLB and proposed to 
be involved in fluctuating cognition (Firbank et al., 2016; Chabran et al., 2018). As well as 




which have identified a loss of global variability in DLB (Ma et al., 2019; Schumacher et al., 
2019b) and a disturbance to functional connectivity (Chabran et al., 2020), suggesting that 
the brain in DLB is more rigid which could play a role in cognitive fluctuations, as well as 
analyses which using graph-theory have found that increased path lengths correlated with 
the severity of cognitive fluctuations (Peraza et al., 2015). Alterations to the brain’s dynamic 
properties have also been studied using EEG, with alterations in dynamics having been 
shown to be associated with (Bonanni et al., 2008; Bonanni et al., 2016; Stylianou et al., 
2018) or correlating with the severity of cognitive fluctuations (Bonanni et al., 2015; 
Schumacher et al., 2019c). Together the alterations in the brain’s dynamics in DLB suggest 
that it is less able to adapt to changing loads; slower adaptations to changing loads could 
clinically be seen as durations of ‘blankness’ or an inability to focus properly (Bradshaw et 
al., 2004). 
Loss of cholinergic attentional drive has been speculated to play a role in the disruption of 
attentional networks in cognitive fluctuations (Ferman et al., 2004). Cholinergic nuclei and 
their projections have been known to play an important role in attentional processing for 
over two decades, with lesion experiments of the cholinergic basal forebrain in primates 
impacting upon attention (Voytko et al., 1994). Further studies using animal models have 
shown selective lesioning of the pedunculopontine nucleus (PPN) in rats lead to fluctuations 
in cognition (Cyr et al., 2015). Nuclei within the basal forebrain including the nucleus basalis 
of Meynert, which is functionally linked to the PPN, as well as being important in attentional 
signalling are vulnerable to a-synuclein pathology in synucleinopathies (Liu et al., 2015), 
with neuronal loss in the region having been shown to be correlated with a reduction in 
cortical choline acetyltransferase (ChAT) levels in DLB (Lippa et al., 1999). Volumetric 
changes in cholinergic regions including, the substantia innominata a cholinergic nuclei 
within the basal forebrain (Colloby et al., 2017), and midbrain, prefrontal cortex and 
thalamus overlapping with cholinergic systems (Chabran et al., 2020) have been shown to 
correlate with fluctuating cognition in DLB utilising imaging techniques. Along with imaging 
and histopathological studies, support for a loss of cholinergic attentional drive underlying 
cognitive fluctuations comes from clinical (Mori et al., 2012; Kazui et al., 2017) and 
mechanistic (Onofrj et al., 2003) studies that have examined the improvements to cognitive 




The thalamus is one of the main structures involved in the dorsal pathway of the ascending 
reticular activating system (ARAS), further discussed in 1.7.1, where thalamocortical 
projections, controlled from brainstem inputs, mediate cortical activation and consciousness 
(Jang and Kwak, 2017). Due to its role in consciousness it has been speculated that thalamic 
dysfunction could be a possible mechanism involved in the attentional dysfunction 
hypothesis of cognitive fluctuations (O'Dowd et al., 2019). α-synuclein pathology is readily 
located in the thalamic relay nuclei that from part of the ARAS (Braak et al., 2003). 
Cholinergic denervation and higher choline levels in these thalamic sub-nuclei have been 
observed in DLB (Kotagal et al., 2012b; Delli Pizzi et al., 2015), with the ratio of total choline 
to total creatinine, a neuronal marker of energetic metabolism, in these regions correlating 
with severity of fluctuations, further supporting a mechanistic role of the thalamus in 
cognitive fluctuations. Imaging studies have also identified atrophy within thalamic nuclei of 
DLB patients (Watson et al., 2017), which was more pronounced in those with cognitive 
fluctuations (Delli Pizzi et al., 2015) and related to attentional deficits (Watson et al., 2017). 
Within these studies a decrease in thalamic activity was also found, which was noted to be 
more marked in those with fluctuations (O'Brien et al., 2005; Galvin et al., 2011); as well as 
bilateral alteration of activity in DLB in thalamic regions known to project to prefrontal 
regions, although these alterations did not correlate with severity of cognitive fluctuations 
(Galvin et al., 2011; Delli Pizzi et al., 2015; O'Dowd et al., 2019). Decreased activity between 
thalamic and cortical networks has also been identified within EEG studies (Schumacher et 
al., 2019c). It is not only imaging studies that have identified thalamic alterations in 
cognitive fluctuations. A number of molecular studies have identified alterations to 
receptors, including cholinergic and dopaminergic, in specific attentional regions of the 
thalamus, known to be involved in the ARAS, and the cortical areas the thalamus projects to 
(Ballard et al., 2002b; Pimlott et al., 2006; Piggott et al., 2007). However, cognitive 
fluctuations are generally thought to be non-dopaminergic due to Levodopa not having a 
beneficial effect on the symptom (Molloy et al., 2006). These results further support and 
validate the idea of thalamic and cholinergic dysfunction possibly leading to attentional 




1.6.1.2 Theory of arousal/awareness dysfunction  
Arousal/awareness is the general receptivity to external stimuli and the preparedness to 
respond to them, this is generally seen as a state without a specific target or stimulus, this is 
in contrast to attention which is the ability to focus and respond to a particular stimuli 
(Whyte, 1992). Arousal specifically describes the level of consciousness during wakefulness, 
with there being a lack of arousal when asleep. Sleep-wake systems in the brain have been 
identified to mediate arousal (de Lecea et al., 2012). Alteration to arousal and awareness 
centres has already been shown in DLB (Pao et al., 2013), with alterations to this system 
being theorised to underly the cognitive fluctuations clinically observed (Matar et al., 2019; 
O'Dowd et al., 2019). Dysfunction within the centres that maintain arousal and awareness 
could lead to durations where patients appear to be unreceptive to external stimuli, as 
Susan Schneider-Williams described ‘blank, lost in confusion’ (Williams, 2016) and Bradshaw 
et al. (2004) described as ‘blank staring which the patient appeared to disengage from the 
on ongoing flow of activity or conversation’.  
A key region involved in the maintenance of sleep-wake is the hypothalamus, a key centre 
of the ventral ARAS pathway (Jang and Kwak, 2017). The hypothalamus is known to be 
affected by pathology in DLB (Benarroch et al., 2015). Wakefulness centres in the 
hypothalamus, including the histaminergic tuberomammillary nucleus are known to be 
affected through neuronal loss in DLB (Ferman et al., 2004; Benarroch et al., 2015), further 
supporting a dysfunctional arousal/awareness system in DLB possibly being associated with 
cognitive fluctuations. Whitwell et al. (2007) has found reductions in hypothalamus volume, 
which was suggested might relate to alterations in arousal/awareness, although they did 
not relate these findings to fluctuation severity (Taylor et al., 2013). Alterations to these 
systems are proposed to underly not only cognitive fluctuations but also RBD, with some 
clinical studies identifying a correlation between the two core features (Escandon et al., 
2010; Cagnin et al., 2017). This has suggested a possible universal alteration to the sleep-
wake system may underlie both clinical features (Terzaghi et al., 2013; Antelmi et al., 2016); 
which could suggest that in DLB the systems for sleep or wake are not efficient enough to 
maintain adequate levels of global arousal (Cagnin et al., 2017). Support for the 
arousal/awareness theory of cognitive fluctuation has also come from a limited number of 




research is required to fully understand the possible role the arousal/awareness system 
plays in cognitive fluctuations (O'Dowd et al., 2019).  
Although the hypotheses of attentional and arousal/awareness dysfunction are distinct 
from each other, it is likely that a globally altered level of arousal will lead to impairment of 
attention. Furthermore, studies into cognitive fluctuations have identified that cognitive 
fluctuations in DLB may comprise of an attentional and an arousal/awareness component 
(Bliwise et al., 2014; Ferman et al., 2014). This could suggest that both theories in 
combination could underly cognitive fluctuations and the clinical phenomenon is due to 
dysfunction of a distributed neural system (Matar et al., 2019; O'Dowd et al., 2019) .  
1.6.1.3 Theory of orthostatic hypotension 
A third theoretical mechanism for cognitive fluctuations stems not from dysfunction within 
the brain but from variation in autonomic processes especially blood pressure (Riley and 
Espay, 2018; O'Dowd et al., 2019). Orthostatic or paroxysmal hypotension is a supportive 
feature of DLB (McKeith et al., 2017), this feature can lead to transient cerebral 
hypoperfusion. Transient cerebral hypoperfusion could lead to times where the brain is not 
able to obtain enough oxygen to sustain full cognitive function, leading to lapses or 
fluctuations in cognition associated with blood pressure. A case study by Riley and Epsay 
(2018) examined a PDD patient with cognitive fluctuations which reversed upon alteration 
of position and treatment with midodrine, providing evidence that in this case fluctuations 
were caused by underlying variations in blood pressure. Another small study demonstrated 
that attentional measure were detrimentally affected by orthostatic hypotension in PDD 
patients (Peralta et al., 2007). Although, it is possible that orthostatic hypotension may 
underlie cognitive fluctuations in some Lewy body dementia cases, it is unlikely to be the 
cause in the majority of cases.  
1.6.2 Clinical assessment of cognitive fluctuations 
Although cognitive fluctuations are one of the four core features of DLB, there have been no 
operational criteria for defining cognitive fluctuations suggested in the consensus diagnostic 
criteria, making it the most difficult of the four core features of DLB to clinically identify and 
assess (Escandon et al., 2010; Lee et al., 2012; Kosaka, 2017; McKeith et al., 2017). The lack 
of operational criteria has meant that examination of fluctuations within research studies 




2014). Lee and colleagues (2012) undertook an extensive literature search of all available 
literature to date on cognitive fluctuations in the major neurodegenerative dementias, as 
well as the psychometric tests to assess the fluctuations, reporting a lack of information to 
guide clinicians on an accurate assessment and identification of cognitive fluctuations. 
1.6.2.1 Clinical assessment of fluctuation 
The CAF (Walker et al., 2000a) is a scale designed to be administered by experienced 
clinicians, consisting of a series of informant-directed questions regarding fluctuating 
confusion and impaired consciousness in the month prior to the assessment (Mainland, 
2015). If fluctuating confusion is present, frequency and duration of the episodes are both 
rated from 0-4, with the scores multiplied together to produce an overall severity score. A 
score of zero would represent that no cognitive fluctuations were present, twelve would 
represent severe cognitive fluctuations and sixteen would represent a continuous clouded 
state of confusion, with no fluctuations from this state. Studies have identified that a score 
over 5 would indicated clinically significant fluctuating cognition, with interrater reliability 
increasing with increasing severity of fluctuations (Bradshaw et al., 2004; Van Dyk et al., 
2016). However, due to the nature of the CAF scoring system, short duration but frequent 
fluctuations would receive the same score as longer duration, but more infrequent 
fluctuations, though it is thought that these two different fluctuation patterns may be due 
to differing underlying pathological changes (Matar et al., 2019). Further caveats of the CAF, 
including the open-ended nature of questions and reliance on administration by an expert 
clinician, suggesting it is unlikely to be widely adopted in clinics outside a clinical research 
setting (Bradshaw et al., 2004; Rongve et al., 2010; Lee et al., 2012).  
1.6.2.2 One day fluctuation assessment 
The One Day Fluctuation Assessment Scale (ODFAS) (Walker et al., 2000a) was developed 
based on a validated delirium assessment scale (Inouye et al., 1990), the Barthel index 
(Mahoney and Barthel, 1965) and the ‘fluctuation’ component of the DLB clinical diagnostic 
criteria (McKeith et al., 1996). The ODFAS is a scale designed to be given by non-clinicians, 
consisting of seven items assessing behaviours indicative of confusion, including falls, 
fluctuation, drowsiness, attention, disorganised thinking, alterations to consciousness levels 
and communication, on the day prior to the assessment. For some of the seven items there 




for cognitive fluctuation from zero to twenty-one. Studies using the OFDAS found that 
scores could be altered by medication regimes, as well as the scale not detecting fluctuating 
cognition in a DLB cohort to the prevalence levels reported (Bradshaw et al., 2004). A 
further caveat of the ODFAS is that the questionnaire relates specifically to the day prior to 
assessment which may not capture a transient clinical feature, in addition to scores being 
affected by falls which may not be related to cognitive fluctuations. The quantitative scoring 
systems utilised in both CAF and the ODFAS do not take into account any differences in the 
cognitive domains fluctuating, meaning that these scales may miss important difference 
between disease groups, such as AD and DLB (Bradshaw et al., 2004; Lee et al., 2012). 
1.6.2.3 Mayo composite fluctuations scale 
The Mayo Composite Fluctuations Scale (MCFS) was developed by Ferman and colleagues 
(2004), to ascertain whether the cognitive domains affected in the fluctuations could 
reliably distinguish DLB from AD or normal ageing (Mainland, 2015), the scale has been 
further translated into other languages (Thaipisuttikul et al., 2018). The MCFS consists of a 
nineteen-item questionnaire that is administered to informants, which aims to elucidate the 
symptoms of the fluctuations and delirium experienced by the patient over the past month. 
The decision to administer the questionnaire to a patient’s informant instead of the patient 
themselves, was supported by the fact that most family members or carers can describe the 
fluctuations in cognition or alertness that they have observed in patient (Ferman et al., 
2004). Although the MCFS would be able to score the severity of the fluctuations as seen by 
the informant, the nature of the test does not allow for examination of fluctuations to 
cognitive abilities, as such the test may be missing aspects of fluctuation that would only be 
‘visible’ through a more specific cognitive task.  
1.6.2.4 The dementia cognitive fluctuation scale 
The Dementia Cognitive Fluctuation Scale (DCFS) was developed by Lee and colleagues 
(2013), to improve upon the CAF, ODFAS and MCFS tests already published. Items from the 
MCFS which have been previously shown to reliably distinguish between disease groups 
were incorporated. Relevant items from the CAF and ODFAS were also incorporated, 
including alertness and confusion. The final version of the DCFS is comprised of 17 items in 
four sections- confusion, sleep, alertness and communication, and was capable of 




1.7 The ascending reticular activating system 
Consciousness is underpinned by two main components, arousal and awareness, of the 
environment and self (Weiss et al., 2007; Jang and Kwon, 2015a), with the ARAS responsible 
for its regulation and providing ‘context’ to conscious experience (Paus, 2000; Zeman, 2001; 
Llinás, 2002). The ARAS, is a fibre bundle that originates from various nuclei within the pons 
and midbrain, that projects to the cortex, thalamus and basal forebrain to mediate 
wakefulness and arousal through cortical activation, suppression of slow rhythms in EEG 
and synchronisation of faster frequency rhythms (Sarter, 2006; Edlow et al., 2012; Kovalzon, 
2016a) (figure 1.5). 
The identification and investigation of the ARAS has occurred within the last century. 
Original experiments identified differing EEG states during different wakefulness states 
(Berger, 1929), with later animal studies undertaken to identify the origin of these EEG 
states (Bremer, 1937). With the first full description and identification of the brainstem 
Figure 1.5. Wiring diagram for the ascending reticular activating system.                                                                                           
A wiring diagram summarising the nuclei and their neurotransmitter systems that form the ascending reticular activating 
system. Ventral pathway shown in orange and the dorsal pathway shown in red. Three main nuclei: cholinergic- 
pedunculopontine nucleus (PPN); serotonergic- dorsal raphe (DR); noradrenergic- locus coeruleus (LC). Other nuclei and 
neurotransmitter systems involved: 1) cholinergic-laterodorsal tegmental nucleus; 2) dopaminergic- ventral periaqueductal 
grey matter; 3) histaminergic- tuberomammillary nucleus; 4) orexinergic-hypothalamus; 5) cholinergic & GABAergic-basal 




structures forming the ARAS by Moruzzi and Magoun (Moruzzi and Magoun, 1949). 
Although, initially considered to be a diffuse structure, currently it is thought to be 
comprised of a number of different neurotransmitter systems and brainstem nuclei (‘waking 
centres’): cholinergic and glutamatergic PPN, noradrenergic locus coeruleus (LC), 
serotonergic dorsal (DR) and median raphe (MnR) and the dopaminergic VTA and SN 
(Zeman, 2001). The three major nuclei thought to be the core of the ARAS are the PPN, LC 
and DR/MnR (Mahaffey and Garcia-Rill, 2015), with further neurotransmitter systems 
playing a role in mediating the functioning of the ARAS, including orexin and histaminergic 
neurons (Kovalzon, 2016a). Further studies have suggested the ARAS consists of many 
ascending and descending connections to a wide range of brain regions that can mediate 
arousal and vigilance (Hyde and Garcia-Rill, 2015; Yates and Garcia-Rill, 2015).  
The ARAS is thought to have two main pathways for its ascending projections, non-thalamic 
and thalamic, as well as direct projections to the cortex, with high connectivity to the 
prefrontal cortex (PFC) (Shute and Lewis, 1967; Daube, 1986; Paus, 2000; Jones, 2003; Jang 
and Kwon, 2015b; Krone et al., 2017). The non-thalamic (ventral) pathway, contains 
noradrenergic and serotonergic projections to the basal forebrain, hypothalamus and the 
cortex, as well as the orexinergic and histaminergic neurons of the hypothalamus (Brown et 
al., 2012). Whereas, the thalamic (dorsal) pathway originates in the cholinergic nuclei of the 
PPN and projects to intralaminar thalamic nuclei and medial thalamic nuclei, inhibiting the 
reticular thalamic nuclei, and activating thalamocortical pathways to mediate cortical 
activation (Jang and Kwak, 2017). The dorsal pathway has been shown to stimulate the 
cortex up to ten times faster than the ventral pathway, and is the pathway selectively 
activated in REM sleep (Jones, 2005b; Han et al., 2014). Although the ARAS has been 
proposed to have two distinct pathways innervating the cortex, the dorsal and ventral 
pathways are not completely separate with the major nuclei of the ARAS have 
interconnecting projections (Shute and Lewis, 1967), specifically between the DR, LC and 
PPN, with this interconnectivity likely to play a vital role in the maintenance of arousal 
states (Edlow et al., 2013). The multiple systems that comprise the ARAS suggest that there 
is some level of redundancy within the system, further supported by animal lesion models, 




Current research into the ARAS has mainly been undertaken in animal models, and a 
minority of human MRI studies, due to limited feasibility of post-mortem tracking and the 
only recent implementation of High Angular Resolution Diffusion Imaging (Edlow et al., 
2012). Through imaging and lesion research the ARAS is believed to control arousal and the 
maintenance of consciousness, through its control of thalamo-cortical activity, altering the 
patterns of neuronal firing to allow for global synchronisation (De Cicco et al., 2017). With 
further experiments proposing a new ARAS model which implicates the thalamus as not 
only a relay centre but as an integral component allowing the integration of brainstem and 
cortical networks to modulate arousal (Edlow et al., 2012).  
1.7.1 Disorders of the ascending reticular activating system 
The ARAS is directly involved in mediating arousal and awareness. Lesions within the 
brainstem, corresponding to ARAS nuclei are associated with disturbances of arousal and 
coma, leading to alterations in the level of cortical activation and cognition (Parvizi and 
Damasio, 2003; van Gaal et al., 2012). Pathologies of wakefulness include coma and 
narcolepsy, the most studied area regarding the ARAS in humans, which evolve from a lack 
of drive from the ARAS to activate the cortex to produce the high frequency activity 
required for wakefulness and consciousness (Garcia-Rill and Simon, 2015). A number of 
pathologies of wakefulness can be due to changes to particular neurotransmitter pathways 
within the ARAS, for example narcolepsy can be caused through dysfunction of the 
hypocretin transmitter pathway in the lateral hypothalamus, in the ventral pathway (Siegel, 
2004). Coma or disorders of consciousness, can be caused by damage in multiple locations 
within the ARAS affecting the ascending connections to the cortex, including the source 
nuclei, their projections or target regions including regions of the thalamus (Garcia-Rill, 
2015; Jang and Lee, 2015). A case study of a patient who have suffered lesions to the ARAS, 
which have resulted in the presence of a minimally conscious state, was treated with deep 
brain stimulation (DBS) of the intralaminar thalamic nucleus, in the dorsal pathway (Schiff et 
al., 2007). Stimulation of the intralaminar thalamic nucleus improved communication 
function, which dissipated once the stimulation was stopped (Schiff et al., 2007), indicating 
that if the thalamocortical projections remain intact stimulation can be applied to increase 
cortical activation. It has also been hypothesised that subtle changes within ARAS activity 




within the ARAS could underpin other disorders of consciousness. Within patients whom 
suffer from absent mindedness following a traumatic brain injury, imaging studies have 
identified injuries dysfunction within the lower aspects of both the dorsal and ventral ARAS 
pathways, with a decrease in connectivity to the thalamus, hypothalamus and PFC observed 
(Jang and Kwak, 2017).  
The alterations and dysfunction observed in the ARAS in those with disorders of 
consciousness supports the idea that alterations due to neurodegenerative mechanisms in 
DLB could lead to the alterations in consciousness, cognitive fluctuations, observed 
clinically. 
1.7.2 Raphe 
The raphe nuclei is a heterogenous neuronal population, that borders the midline lie along 
the entire rostro-caudal aspect of the brainstem (Hornung, 2003). Serotonergic neurons are 
the main neuronal component of the raphe complex, allowing for easy identification with 
the serotonin synthesis enzyme, tryptophan hydroxylase 2 (TPH2), although other 
neurotransmitters including substance P in the DR are present (Baker et al., 1990; Baker et 
al., 1991). The raphe nuclei are comprised of a collection of sub-nuclei, defined upon their 
location within the complex as well as their main projections (Hornung, 2003). The two main 
sub-nuclei implicated in the ARAS are the DR located at the level of the oculomotor nucleus 
to the middle part of the pons, and the MnR located at the caudal end of the superior 
cerebellar peduncle to the level of the trigeminal motor nucleus, with neuronal overlap 
between the two nuclei evident in the lateral reticular formation (Hornung, 2003). The 
rostral group of subnuclei, including the DR and MnR, located in the rostral pons projects to 
cortical regions, whereas the caudal group located in the medulla oblongata have major 
connections to other brainstem regions and the spinal cord (Hornung, 2003). 
Research has found that the DR and MnR play a role in a number of different brain systems 
(Hornung, 2003). The systems that the raphe is involved in include emotional processing and 
maintenance of wakefulness, through its connectivity with cortical, limbic and ARAS 
structures (Jones, 2005b); with the main research focus being the role of the serotonergic 
system depression and anxiety (Hale and Lowry, 2011), with the majority of antidepressant 
drugs targeting serotonergic neurotransmission. However, the role of the DR within the 




The earliest demonstration that the raphe and the serotonergic system played a role in the 
maintenance of arousal was when it was identified that injection of reserpine, which 
depletes the level of serotonin within the brain was observed to have a sedative effect 
(Brodie et al., 1955). Further research, undertaken in cats, identified that lesioning of the 
total or partial lesioning of the raphe would lead to permanent wakefulness (Jouvet, 1968). 
However, a number of additional studies identified that after chronic depletion of serotonin 
that sleep would eventually return (Dement et al., 1972); as well as the DR being thought to 
fire maximally during waking and cease during REM sleep (Trulson and Jacobs, 1979; 
Mahaffey and Garcia-Rill, 2015), which would indicate that the nuclei promotes 
wakefulness. The inconsistency between these studies suggest that the serotonergic system 
has a complex role in the maintenance of arousal and the differing effects on arousal could 
be region and receptor subtype dependent. Through the studies implicating the raphe in 
both the maintenance of sleep and wakefulness, it suggests that dysfunction to the nucleus 
in a disease state could lead to not only to depressive symptoms but alterations in the 
balance between arousal and sleep.  
The DR is highly interconnected with other ARAS nuclei, receiving cholinergic inputs from 
the PPN through nicotinic receptors (Mihailescu et al., 2002) and noradrenergic inputs from 
the LC through α1-adrenergic receptors (Baraban and Aghajanian, 1981; Aghajanian, 1985); 
as well as sending reciprocal projections to these nuclei. It is thought that through this 
interconnectivity serotonin is able to attenuate cortical activation by inhibition of other 
neurons within the ARAS, including the cholinergic neurons of the PPN (Jones, 2005b). 
Dysfunction to the raphe nucleus through neurodegenerative mechanisms could alter the 
connectivity with other regions of the ARAS including the LC and PPN. Reductions or 
variability to serotonergic inhibition on cholinergic neurons in the PPN could lead to 
reductions in arousal due to activation of regions associated with sleep. Activation of sleep 
centres during wakefulness could create periods of inattention and low arousal, with 
reactivation of the serotonergic inhibitory effects leading to an increase in arousal.  
The DR and MnR nuclei provide the majority of the ascending serotonergic projections to 
the forebrain and the hypothalamus (Leander et al., 1998), in a parallel and overlapping 
manner (Beck et al., 2004). Although the projections are overlapping there are differences 




specific to each sub-nuclei (Beck et al., 2004). The DR projects to the prefrontal cortex, 
amygdala and striatum, with a high level of connectivity also observed with other nuclei of 
the ARAS (Vertes, 1991; Beck et al., 2004; Michelsen et al., 2007). In contrast, the MnR 
projects to the dorsal hippocampus, medial septum and cingulate (Molliver, 1987). Both the 
DR and MnR also receive afferent connections from similar regions, including forebrain and 
hypothalamus (Hornung, 2003), further cementing their role within the ARAS network. Both 
nuclei are involved in cognition, emotion, sleep-wake cycle and attention (Michelsen et al., 
2007; Andrade et al., 2013; Pollak Dorocic et al., 2014; Beliveau et al., 2015). 
In the DR, of rodents, the non-serotonergic neurons have similar electrophysiological 
properties to their neighbouring serotonergic neurons, in contrast to the MnR where the 
different neuronal populations have distinct characteristics (Beck et al., 2004). Beck et al. 
(2004) identified that neurons in the MnR have a longer interspike interval, slower firing 
rate, than neurons in the DR; however, DR neurons were more susceptible to 
hyperpolarisation by inhibitory 5-HT1A autoreceptors than MnR serotonergic neurons, with 
non-serotonergic neurons in the MnR not expressing 5-HT1A. DR neurons express 5HT1A 
auto-receptors on their cell bodies and dendrites (Bjorvatn et al., 1997) which can inhibit 
further release of serotonin by DR neurons, through feedback inhibition of the raphe nuclei, 
possibly adding a further layer of control to the raphe’s role in the modulation of cortical 
activity (McDevitt and Neumaier, 2011), with cortical regions known to feed back to the 
raphe (Beliveau et al., 2015). Alterations in the expression of 5HT1A auto-receptors could 
suggest dysfunction of the serotonergic projections from the DR, with a reduction to 
feedback inhibition. Although both raphe nuclei are considered to be predominantly 
serotonergic, there are other neurotransmitters, including dopamine and GABA used within 
the nuclei (Beck et al., 2004; Michelsen et al., 2007). Within the DR, serotonergic neurons 
have also been discovered to co-release neuropeptides including neuropeptide Y (Pau et al., 
1998) and substance P (Baker et al., 1990; Baker et al., 1991). The differences found in the 
electrophysiological and neurochemical properties of the raphe neurons could indicate that 
they play differing roles within the management of arousal and consciousness through the 





1.7.3 Locus coeruleus 
The LC is the largest noradrenergic nucleus in the brain (Samuels and Szabadi, 2008a). 
Located in the upper pons, close to the fourth ventricle, the LC contains up to 19,000 
neurons on each side of the brainstem, and these contain the lipoprotein pigment 
neuromelanin (Vijayashankar and Brody, 1979; Mann, 1983). Noradrenergic neurons from 
the LC are known to project to virtually all brain regions, including the basal forebrain, 
hippocampus, layer IV of the neocortex, thalamus and hypothalamic regions, as well as 
other nuclei in the ARAS (Levitt and Moore, 1978; Jones and Yang, 1985; Jones, 2005b; 
Samuels and Szabadi, 2008a; Samuels and Szabadi, 2008b), apart from the basal ganglia 
where projections are limited to the SN and the nucleus accumbens (De Cicco et al., 2017), 
with projections thought to be denser in the right hemisphere than the left (Marrocco et al., 
1994). The regions that the LC sends noradrenergic projections to can be classified upon the 
subtype of noradrenergic receptor they express. a1-adrenoceptors activation is thought to 
excite the post-synaptic cell, with the same believed to be true for b-adrenoreceptor 
expressing post-synaptic cells (Berridge and Waterhouse, 2003; Jones, 2004). However, 
neurons expressing a2-adrenoceptors are thought to be inhibited following their activation 
(Jones, 2004).  
The role of the LC has been extensively studied in regard to the promotion of wakefulness 
and arousal through both excitatory and inhibitory projections (Samuels and Szabadi, 
2008a). Increases in LC activity are known to result in increases to cortical EEG activity 
indicative of an increase in arousal and attention, with stimulation to the noradrenergic 
neurons in the LC increasing awareness and lesions increasing slow-wave sleep and REM 
(Delagrange et al., 1993). This suggests that dysfunction to the LC in a disease state could 
lead to alterations in wakefulness. Damage to the LC has been noted in the causation of 
comas in humans, consistent with the nucleus promoting wakefulness (Samuels and 
Szabadi, 2008b). The importance of the LC in the maintenance of wakefulness has been 
exemplified by research from Carter et al. (2012) whom found that orexinergic neurons 
acted through LC neurons in order to manifest waking. Through its projections and 
differential expression of receptor subtypes the LC selectively excites other systems that are 
also involved in waking whilst inhibiting those that are involved in sleep (Jones, 2005a; 




wakefulness. The LC further influences waking through regulation the neural activity of 
subsets of PPN cholinergic neurons, by exciting those involved in wakefulness or inhibiting 
those involved in REM through a1 and a2-adrenoceptor signalling respectively (Cespuglio et 
al., 1982; Kaitin et al., 1986; Delagrange et al., 1993; Hou et al., 2002; Samuels and Szabadi, 
2008b).  
The role of the LC in arousal have been examined in both humans and animals for a number 
of decades. The LC has been shown to be more active during wakefulness (Berridge and 
Foote, 1991), with GABA release into the nucleus at its lowest during waking, and increasing 
in slow-wave sleep and REM (Mahaffey and Garcia-Rill, 2015). Within the LC a local 
population of GABAergic neurons are able to modulate noradrenergic activity, this is 
thought to occur through electrical coupling, allowing neurons to fire in synchrony eliciting a 
coordinated output to regions receiving LC input (Christie et al., 1989; Aston-Jones et al., 
2004). Afferent projections onto the local GABAergic interneurons from cortical areas 
including the PFC have been shown, in mice, to alter LC noradrenergic activity leading to 
alterations in global arousal levels (Breton-Provencher and Sur, 2019). Human studies have 
also shown similar results which pharmacological depletion of global noradrenaline reducing 
abilities in attentional tasks (Robbins and Everitt, 1995). Together this data from mice and 
humans support the role of the LC in maintain global arousal levels through its connectivity 
with various brain regions. 
The LC receives input from all of the major ARAS nuclei to help maintain arousal and 
wakefulness (Mahaffey and Garcia-Rill, 2015); including excitatory cholinergic input from 
the PPN (Egan and North, 1985; Egan and North, 1986) and serotonergic input from the DR 
(Pickel et al., 1977), as well as local noradrenergic feedback (Egan et al., 1983). The 
noradrenergic neurons of the LC also receive inputs from the orexinergic neurons of the 
lateral hypothalamus, with this connection having been shown to be essential in order for 
the orexin system to be able to manifest waking (Garcia-Rill, 2015). The connectivity and 
experiments linking activity in the LC to increased arousal highlight the role the nucleus 
plays in mediating arousal/awareness; suggesting that changes to the LC, the inputs it 
receives from other ARAS nuclei or its projections to cortical and sub cortical regions could 




1.7.4 Pedunculopontine nucleus 
The PPN is a neurochemically heterogeneous nucleus, known to utilise cholinergic, 
glutamatergic and GABAergic neurotransmitters (Wang and Morales, 2009; Benarroch, 
2013). Located in the caudal pontomesencephalic tegmentum of the midbrain and upper 
pons (Jenkinson et al., 2009), with the most rostral end lying just below the red nucleus, 
dorsal to the SN, continuing until the LC at its most caudal part. The PPN is thought to 
contain 10,000 to 20,000 cholinergic neurons, with a proportion of these cholinergic 
neurons having been shown to co-express other neurotransmitters (Garcia-Rill et al., 1996). 
Within the PPN the distribution of the neuronal subtypes varies along its axis. The PPN pars 
compacta, located in the caudal half of the nucleus, is comprised of 30% cholinergic, 50% 
glutamatergic and 20% GABAergic neurons; whilst the pars dissipata, is comprised of 20% 
cholinergic, 40% glutamatergic and, 40% GABAergic neurons (Mena-Segovia et al., 2009; 
Wang and Morales, 2009). The subtype of neuronal output from the PPN also varies along 
its axis, with projections from the rostral PPN mainly GABAergic, where as those in the 
caudal PPN are mainly glutamatergic, although some projections are both cholinergic and 
glutamatergic (Martinez-Gonzalez et al., 2011; Benarroch, 2013). This non-uniform neuronal 
subtype distribution coincides with the location of sites, which, when stimulated induce fast 
EEG rhythms indicative of arousal (Moruzzi and Magoun, 1949; Steriade, 1980). Dysfunction 
to all or a part of these neuronal subtypes could lead to a change in output from the PPN 
due to a lack of output or inhibition within the nucleus to coordinate neuronal firing. 
 Research has found that the PPN plays a role in number of different brain systems (Semba 
and Fibiger, 1992; Benarroch, 2013; Gut and Winn, 2016). The systems that the PPN plays a 
part in include, arousal and behavioural state control, through its many reciprocal 
connection to the thalamus and cortex (Benarroch, 2013; Garcia-Rill and Simon, 2015; 
Mahaffey and Garcia-Rill, 2015); as well as, locomotion and muscle tone suggesting it may 
contribute to previously reported, dopamine non-responsive, gait disturbances in PD 
(Hamani et al., 2016). The PPN has been thought of as the main driver and critical cell group 
for waking and REM sleep in the ARAS (Garcia-Rill and Simon, 2015), this suggests that 
dysfunction to this nucleus in a disease state could severely affect not only locomotion but 
states of arousal. Dysfunction to the PPN has been reported in a number of clinical 




dysfunction of the PPN either through direct alteration of the PPN neurons or indirectly via 
the inputs into the PPN (Yates and Garcia-Rill, 2015). Downregulation of PPN output either 
directly or indirectly would result in excessive daytime sleepiness through a reduction in 
stimulation to the cortex (Yates and Garcia-Rill, 2015).  
The PPN is a highly interconnected structure with efferent projections, both cholinergic and 
noncholinergic, from the PPN projecting to the intralaminar and associative nuclei of the 
thalamus, SN, lateral hypothalamus and the globus pallidus internus (Shute and Lewis, 1967; 
Benarroch, 2013; Garcia-Rill and Simon, 2015). Similarly, to the raphe, the two regions of 
the PPN, the rostral and caudal ends, have been shown to not only possess different level of 
neuronal subtypes, but also project to different regions. In animal studies the rostral PPN 
has been shown to innervate the globus pallidus and SN; with the caudal aspect innervating 
the thalamus, LC and suprachiasmatic nucleus (Martinez-Gonzalez et al., 2011) and thought 
to be the region predominantly involved in arousal. To aid the PPN in modulating arousal it 
also has reciprocal connections with all of the major neurotransmitter systems involved in 
the ARAS; receiving orexin, histaminergic, serotonergic, noradrenergic and cholinergic 
afferent inputs (Benarroch, 2013; Beck and Garcia-Rill, 2015; Yates and Garcia-Rill, 2015).  
The PPN has been shown to be most active during waking and REM sleep, contributing to 
control of arousal through its ascending projections to the thalamus as well as its 
descending projections controlling behavioural responses to match the changes in cortical 
activation (Yates and Garcia-Rill, 2015). The PPN has been identified to control behavioural 
responses including changes to locomotion and postural control (Garcia-Rill and Skinner, 
1988; Garcia-Rill, 1991; Beck and Garcia-Rill, 2015), and atonia during REM sleep (Chase and 
Morales, 2005). The role of subsets of PPN cholinergic neurons in the maintenance of 
wakefulness and REM is supported by studies in humans that have identified that when 
AChEIs were administered during waking it stimulated cortical activity, however if 
administered during sleep it promotes REM sleep (Jones, 2005b). Cholinergic efferent fibres 
innervate the PPN (Velazquez-Moctezuma et al., 1989), projecting from the contralateral 
PPN and the laterodorsal tegmental nucleus (Semba and Fibiger, 1992). The modulation of 
the PPN through cholinergic input is thought to be mediated via both muscarinic and 
nicotinic receptors located on the dendrites or soma to modulate action potential discharge 




Garcia-Rill, 2015). PPN cholinergic cells express muscarinic receptors whereas non-
cholinergic cells typically express nicotinic cholinergic receptors (Lanca et al., 2000). 
Alterations to receptor populations on PPN neuronal sub-populations could suggest 
dysfunction to the ARAS as a system, with inputs received from other major nuclei in the 
system to regulate the PPNs output to generate arousal. Changes to receptor populations 
could possibly influence PPN firing and control of arousal even in the absence of pathology 
or macroscopic changes to the nucleus. 
In summary, the ARAS is a diffuse collection of neurotransmitter systems that has been 
implicated in controlling global consciousness and arousal levels. Studies examining 
pathologies of wakefulness, including coma and narcolepsy, have identified that the 
alterations to arousal and consciousness evolve from a lack of drive from the ARAS to 
activate the cortex to produce the high frequency activity required for wakefulness and 
consciousness. Furthermore, investigations into the main components of the 
neurotransmitter systems have identified how damage or dysfunction to brainstem nuclei 
or their transmitter systems could lead to alterations in global consciousness and arousal. 
The alterations and dysfunction observed in the ARAS in those with disorders of 
consciousness and from a number of animal models support the idea that alterations due to 
neurodegenerative mechanisms in DLB could lead to the alterations in consciousness and 












1.8 The brainstem in neurodegenerative dementias 
1.8.1 Brainstem pathology  
The brainstem, divided into three parts, the medulla, pons and midbrain, consists of a 
number of nuclei and neurotransmitter systems and is thought to be the integration centre 
that links peripheral inputs from the spinal cord with cortical regions (Grinberg et al., 2011). 
The brainstem's role as an integration centre allows it to play an important part in the 
regulation of several autonomic, behavioural and cognitive functions, a number of which 
have been shown to be dysfunctional in dementia disorders (Lee et al., 2015).  
Pathological lesions can affect the brainstem at an early stage of disease progression, such 
as α-synuclein and tau (Braak et al., 2003; Grinberg et al., 2009; Braak et al., 2011). For 
Braak Lewy body stages, α-synuclein pathology is proposed to progress through the 
brainstem in a rostral manner. With α-synuclein pathology affecting the medulla in Braak 
Stage 1 progressing to the midbrain in Stage 3 and then into the cortex. Unlike for Lewy 
bodies, the original tau staging criteria did not account for brainstem pathology, instead 
focusing on that within the cortical regions. However, a number of studies had identified 
pathology within brainstem regions, including the LC and DR prior to pathology in the 
transenthorinal cortex, Braak Stage I (Grinberg et al., 2009; Weinshenker, 2018). The 
identification of NFTs earlier than previously thought in AD, lead to an amendment to the 
original criteria and the addition of Stage 0 (a-b) with LC-specific tau pathology (Braak et al., 
2011; Weinshenker, 2018). Unlike tau and α-synuclein, the progression of Aβ within AD 
cases, as described in the Thal phases, is not observed in the brainstem until phase 4 (Thal 
et al., 2002).  
The LC, as previously discussed in 1.7.3, is highly involved in a number of cognitive and 
arousal functions which become altered in neurodegenerative dementias, leading to a 
number of studies investigating how pathological changes within the nucleus relate to these 
functions clinically (Samuels and Szabadi, 2008b; De Cicco et al., 2017; Kelly et al., 2017). 
Neuronal density has been observed to decrease within the LC with normal ageing 
(Vijayashankar and Brody, 1979; Tomlinson et al., 1981; Mann, 1983; Chan-Palay and Asan, 
1989b; Manaye et al., 1995); with the neuronal loss occurring uniformly throughout the 
nucleus (Samuels and Szabadi, 2008b). The reduction in LC neuronal density is thought to be 




al., 2004). This age-related decrease in neuronal density can be exacerbated by 
neurodegenerative disease such as AD, PD and DLB, this having been observed in post-
mortem investigations (Samuels and Szabadi, 2008b; Brunnstrom et al., 2011). Although tau 
pathology is detectable in the LC prior to cortical regions, studies have not been able to find 
a relationship between LC neuronal loss and NFT pathology (Weinshenker, 2018), with one 
study only finding significant neuronal loss in the LC at Braak stage III (Theofilas et al., 2017). 
This lack of relationship between AD-type NFT pathology and LC neuronal loss has also been 
observed in DLB with LC neuronal loss shown to be independent of the levels of 
concomitant AD-type pathology (Brunnstrom et al., 2011). Along with loss of neuronal 
density, alterations to the remaining LC neuronal morphology, synapses and dendrites have 
been reported (Baloyannis et al., 2006).  
Pathological lesions in a number of neurodegenerative diseases has also been observed in 
the DR and MnR (Lee et al., 2015; Seidel et al., 2015). As with the LC, tau pathology in AD is 
observed in the DR prior cortical involvement, with neuritic pathology negatively correlated 
with the loss of serotonergic cells within the region (Hendricksen et al., 2004), with similar 
results having been found in the MnR (Halliday et al., 1992). As the raphe serotonergic 
system is implicated in depression neurodegenerative changes to the nuclei in dementia 
disorders have been proposed to lead to depressive symptoms. Within AD, pathology and 
neuronal loss in the raphe was also found not to be different between those with and 
without depression (Hendricksen et al., 2004). Within LBD, the raphe is affected by α-
synuclein at Stage 2, the same timepoint as the LC (Braak et al., 2003), with detectable 
alterations to the neurotransmitters thought to be present at this stage (Boeve, 2013). 
Degeneration of both DR and MnR neurons have been reported in DLB, although this loss 
was not related to any clinical features, including depression (Benarroch et al., 2007), cell 
loss has also been observed in PD (Paulus and Jellinger, 1991).  
The PPN, similar to the LC and DR, is vulnerable to Lewy body pathology at an early stage of 
disease progression (Braak et al., 2003); however, in AD tau pathology in the PPN is thought 
to occur in the mid stages compared to the early observation of NFTs in the LC and DR 
(Dugger et al., 2011). The PPN has been extensively investigated with regard to its role in PD 
and Parkinsonian symptoms, with degeneration in the nucleus observed in both disorders 




shown in post-mortem analysis to be correlated with the degree of dopaminergic loss within 
the patient (Di Giovanni et al., 2019), with the neuronal loss found to affect cholinergic cells 
in the regions more than their non-cholinergic neighbours. 
1.8.2 Neuroimaging studies  
The brainstem and its projections to cortical and subcortical regions have been examined 
through various imaging modalities, with some, including the DaTSCAN looking at the 
dopaminergic SN projections to the striatum, having been implemented in clinical practice. 
Current imaging based studies undertaken so far have mainly been PET/SPECT ligand based 
studies, with the levels of transporters assumed to reflect the strength of connectivity and 
health of the neurotransmitter system (Stahl, 2000). A limited number of structural studies 
have been undertaken in the brainstem in neurodegenerative diseases. Structural imaging 
studies that have been published having conflicting results, likely due to the small size of the 
brainstem nuclei (Serra et al., 2018), their ill-defined borders and no standard way to 
delineate them across studies (Ji et al., 2020). With the development of stronger and higher 
resolution scanners, and standardised delineation software, it would be possible to more 
accurately assess smaller brain regions including brainstem nuclei and regions it projects to, 
including the hypothalamus, in both structural and ligand-based studies (Borgers et al., 
2013). 
A limited number of structural imaging studies have looked at the brainstem in dementia; 
however, these have often reported inconsistent results. One study, which investigated the 
brainstem in early AD observed structural loss bilaterally within the pons and left part of the 
midbrain compared to controls (Ji et al., 2020), whereas a similar study identified no 
asymmetry within the midbrain in AD (Lee et al., 2015) and another study identified no 
structural changes in the pons in AD compared to controls (Mrzilkova et al., 2012). 
Structural imaging studies have also been used to evaluate the cholinergic system in 
dementia. A structural MRI study found sub-region specific atrophy in the basal forebrain in 
DLB which was comparable to the atrophy observed in AD, with this atrophy in AD being 
associated with MMSE and in DLB associated with visuoperceptual function (Grothe et al., 
2014). A recent EEG study further identified an impairment to the alpha band reactivity, a 




to reduced cholinergic drive from the nucleus basalis of Meynert in the PDD cases 
(Schumacher et al., 2020). 
The cholinergic system within neurodegenerative diseases, and its possible role in clinical 
symptoms, has been widely examined using imaging techniques, including PET/SPECT, with 
a particular focus on AD and DLB. The main targets for cholinergic imaging are 
acetylcholinesterase (AChE) and the vesicular acetylcholine transporter (vAChT) with a 
number of ligands available for each. There are two major cholinergic projections systems 
within the brain, one originating in the basal forebrain, which provides the main cortical 
cholinergic innervations and the other projecting from the PPN to the thalamus and other 
brainstem nuclei. Reductions in cortical AChE, reflecting basal forebrain projections, have 
been shown in AD and DLB compared to controls (Bohnen et al., 2003), with cortical 
cholinergic losses increasing with disease progression in AD (Bohnen et al., 2016). DLB have 
also been shown to have greater reductions in AChE activity than AD in a number of cortical 
regions, with the largest difference reported in the posterior cingulate gyrus (Shimada et al., 
2015). There have been studies examining the PPN-thalamic cholinergic pathway within 
neurodegenerative diseases, which have identified through AChE PET that a reduction was 
found in LBDs, but not AD at a mild disease stage (Kotagal et al., 2012b). Alterations to the 
cholinergic system in neurodegenerative diseases have also been studied in regard to their 
influence upon clinical symptoms. A small number of studies have investigated the role of 
the cholinergic system in sleep disorders in AD (Pavese, 2014), with one AChE SPECT study 
found differences in perfusion between AD patients with and without sleep loss in 
Brodmann area (BA) 9 (Ismail et al., 2009). Short latency afferent inhibition studies, a 
technique allowing for in vivo assessment of cholinergic systems, have found alterations 
were associated with hallucinations in DLB and disinhibition in AD patients (Marra et al., 
2012).  
1.8.3 ARAS projections 
The ARAS consists of brainstem nuclei, as well as its projections to regions within the 
thalamus and hypothalamus. Dysfunction to the ARAS and its projections has been reported 
in neurodegenerative diseases such as PD, AD and Huntington’s disease (Luster et al., 2015). 
Dysfunction to the ARAS has already been reported to underly some of the delirium 




ARAS role in delirium through a study utilising functional MRI that identified acute reversible 
disruption between the thalamus and the nucleus basalis, two key integration centres of the 
ARAS (Middleton and Strick, 2000; Choi et al., 2018). 
The thalamus is the main relay centre for the dorsal pathway of the ARAS. The thalamus 
consists of up to 60 sub-nuclei and has been postulated to be involved in a vast array of 
networks and functions (Fama and Sullivan, 2015). With the its role in an array of networks, 
a number of studies have investigated its role within neurodegenerative disease, where 
these networks are dysfunctional (Pievani et al., 2011). The PPN has been observed in a 
number of animal models to innervate a number of thalamic nuclei, including the 
mediodorsal nucleus, intralaminar nuclei and limbic regions (Martinez-Gonzalez et al., 
2011). Within the thalamus, studies have shown that certain sub-nuclei are more afflicted 
with pathology than others. In AD the mediodorsal nucleus is vulnerable to AD-type 
pathology and neuronal loss (Braak and Braak, 1991a; Paskavitz et al., 1995). However, the 
lateral geniculate nucleus, which also receives inputs from the PPN has been shown to have 
widespread Aβ pathology but minimal tau deposition in AD (Dugger et al., 2011). In PD, 
Lewy body pathology is most frequently observed in limbic regions of the thalamus, 
however, this does not seem to be associated with neuronal loss (Xuereb et al., 1991; Rub et 
al., 2002). In DLB, the intralaminar nuclei, which are a major site of inputs from the PPN, are 
severely affected by Lewy body pathology (Brooks and Halliday, 2009). However, neuronal 
loss is not observed in all these thalamic nuclei, suggesting that neuronal loss may not be 
solely mediated by Lewy body pathology.  
The ventral pathway of the ARAS projects from the raphe and LC through the main relay, 
the hypothalamus, into the cortex. The hypothalamus, like the thalamus, consists of a 
collection of nuclei each with distinct functions (Vercruysse et al., 2018). Dysfunction to the 
hypothalamus and the neurotransmitters within the regions have been implicated in sleep 
disturbances, including daytime somnolence and cognitive fluctuations are observed in 
dementia disorders. Within AD, atrophy of the hypothalamus has been observed using 
neuroimaging techniques, with changes thought to occur early in disease progression as 
well as being a site for AD pathology (Vercruysse et al., 2018). Lewy body pathology has 
been observed within the hypothalamus in PD, with predominantly the posterolateral nuclei 




that the tuberoinfundibular nucleus of the hypothalamus, which contains a large 
concentrations of dopaminergic neurons was relatively spared from Lewy body pathology 
(Langston and Forno, 1978). Hypothalamic pathological lesions occur regularly in DLB, 
although with varying severity between patients (Londos et al., 2019). However, the 
pathology seen in DLB does not seem to appear in orexinergic neurons, in the lateral 
hypothalamus, although a significant decrease in neuronal number has been observed 
(Kasanuki et al., 2014). The orexin system has been implicated to be involved in AD and PD 
with it thought to have a role in excessive daytime sleepiness that is observed clinically (Lim 
and Szymusiak, 2015), with a reduction in orexin neurons seen in AD (Vercruysse et al., 
2018). Models of AD have also identified that sleep disturbances can also perpetuate the 
deposition of pathology (Kang et al., 2009), suggesting dysfunction to hypothalamic systems 



















1.9 The ascending reticular activating system in Lewy body diseases 
ARAS dysfunction is traditionally discussed in regard to coma and pathologies of 
wakefulness. However, within LBD, patients are frequently shown to manifest clinical 
phenotypes, including sleep (Jankovic, 2008) and mood (Boeve, 2013) disorders, that are 
thought to arise from dysfunction within ARAS and its components (Luster et al., 2015), as 
well as pathology known to affect the core three nuclei, as well as their relay nuclei at early 
stages of the disease course (McKeith et al., 2017). Alterations to specific neurotransmitter 
systems including the hypothalamic ARAS orexinergic and histaminergic systems have also 
been identified in a number of post-mortem studies (Kovalzon and Zavalko, 2013; Lim and 
Szymusiak, 2015). Dysfunction of the ARAS in LBDs, especially PD, is further supported by 
treatments such as Levodopa having been successfully utilised to treat those with 
alterations to consciousness related to ARAS dysfunction (Ciurleo et al., 2013). 
1.9.1 Locus coeruleus  
Lewy bodies and Lewy neurites are known to accumulate in the LC early in LBD disease 
progression, even before the SN in PD (Vermeiren and De Deyn, 2017), with the presence of 
Lewy body pathology in the LC being definitive for the classification of Braak stage 2. Loss of 
LC neurons has been reported in LBD with that seen in DLB reported to be irrespective of 
the levels of concomitant AD pathology (Brunnstrom et al., 2011), indicating, that this 
degeneration may be driven by a-synuclein pathology rather than concomitant AD-type 
pathology. The observed loss of noradrenergic neurons leads to noradrenergic 
deafferentation of cortical and subcortical regions, with eventual loss of projections from 
the LC, with the deafferentation hypothesised to play a role in cognitive decline observed in 
these disorders (Vermeiren and De Deyn, 2017). The hypothesised role of the LC and 
noradrenergic system in LBDs has been supported by several studies investigating the 
effects of noradrenergic drugs on cognition in PD. One study in PD identified a significant 
improvement in MMSE and excessive daytime sleepiness with atomoxetine, a selective 
noradrenaline reuptake inhibitor (Weintraub et al., 2010). The finding of a reduction in 
excessive daytime sleepiness, suggestive of a restoration of arousal maintenance during 
wakefulness, through treatments that increase noradrenergic activity at the synapse, 
further implicates the LC and its role in the ARAS in underlying this clinical symptom, and 




LBDs (Schenck et al., 1996; Boeve et al., 2013). The finding that improvements to sleep 
disturbance in PD with noradrenergic treatments also suggests that although neuronal loss 
is known to occur there are still noradrenergic neurons present that can be targeted. 
Although the LC has been extensively studied in various dementia subtypes and has been 
shown to be highly affected by pathology, it has not been evaluated in relation to the 
presence of cognitive fluctuations. Furthermore, there has not been a systematic study 
evaluating changes to the arousal system as a whole, the understanding of which could help 
understand the phenotypic consequences of such degeneration in DLB.  
1.9.2 PPN 
The PPN has been extensively examined in PD, in relation to a number of different clinical 
phenotypes, with less of a focus on the nucleus in DLB. Pathologically the PPN is affected by 
Lewy body pathology at Braak stage 3 (Braak et al., 2003; Grinberg et al., 2011), with the 
different cell types in the region more vulnerable to the accumulation of pathological 
lesions than others (Chambers et al., 2019). Further neurodegenerative changes including 
accumulation of mitochondrial DNA deletions were observed to more preferentially affect 
PPN cholinergic neurons than there non-cholinergic neighbours (Bury et al., 2017). Loss of 
cholinergic PPN neurons is observed in PD, with studies reporting a 50% reduction (Pahapill 
and Lozano, 2000), as well as a reduction in neuronal size compared with controls, (Rinne et 
al., 2008b; Jenkinson et al., 2009). Loss of cholinergic neurons in the PPN leads to a 
subsequent loss of cholinergic innervation to the thalamus (Francis and Perry, 2007).  
PD patients experience a number of clinical symptoms, including sleep disorders, akinesia 
and gait impairments, that have been proposed to be due to PPN dysfunction (Jankovic, 
2008). The collection of clinical features that patients can present with are suggestive of an 
overactive PPN in PD, as the PPN is known to have a key role in initiation of REM and for 
waking (Luster et al., 2015). This has been supported through investigation into the P50 
potential, a proxy measure of sensory gating, arousal level, ARAS functioning and PPN 
activity, in PD patients, where changes to this potential in both habituation and amplitude 
suggest overactivation of the PPN (Teo et al., 1997; Hyde and Garcia-Rill, 2015). With similar 
clinical features known to be present in DLB, including sleep disturbances this could suggest 




PPN dysfunction has been reported to play a role in disorders of the sleep-wakefulness 
system, including RBD (Yates and Garcia-Rill, 2015). PD patients with RBD have been shown 
to have decreased cholinergic innervation to the cortex and thalamus compared to those 
without (Chambers et al., 2019). Clonazepam, a benzodiazepine that enhances GABA 
receptor responses, has been shown to beneficial at reducing RBD symptoms (Schenck et 
al., 1993; Olson et al., 2000). Other non-benzodiazepine drugs that target GABA receptors, 
such as zopiclone and melatonin, have also be identified as effective in relieving the 
symptoms of RBD (Anderson and Shneerson, 2009; Taylor et al., 2020). The efficacy of drugs 
that target GABA receptors in treating RBD, suggests that RBD is a disorder of REM sleep 
atonia disinhibition (Yates and Garcia-Rill, 2015). Although the specific mechanism for 
clonazepam is unknown, it could be that a lack or dysfunction of GABA-mediated inhibition 
to the PPN neurons that modulate REM sleep atonia could be restored or enhanced by 
administration of the drug (Anderson and Shneerson, 2009). RBD is a common feature in 
synucleinopathies, and can manifest decades prior to other clinical symptoms, perhaps 
suggesting changes to the PPN occur early in the disease course (Aurora et al., 2010; 
Postuma et al., 2019). 
Direct dysfunction of the PPN has also been noted in PD, with cholinergic neuronal loss 
associated with gait-predominant parkinsonian phenotype (Benarroch, 2013), and severity 
of cholinergic loss within the PPN correlated with the severity of parkinsonian symptoms in 
PD (Zweig et al., 1989; Rinne et al., 2008b). Further support for the role of the PPN in gait 
disturbances come from a small number of clinical trials which identified a benefit of AChEI 
treatment on gait, balance or falls (Morris et al., 2019). With the PPN having been 
discovered to play a role in the generation of parkinsonian symptoms in PD, a number of 
studies have investigated whether the nucleus would be a candidate for DBS (Hamani et al., 
2016). PPN DBS has been shown to not only improve gait disturbances, of which some are 
refractory to dopaminergic treatments (Ferraye et al., 2010; Moro et al., 2010), but also 
improve sleep disturbances (Stefani et al., 2007) and executive and higher functions 
(Alessandro et al., 2010; Tykocki et al., 2011; Stefani et al., 2013). Research suggesting that 
PPN DBS can improve cognitive function, could suggest that there are salvageable neuronal 
projections that could be targeted in a less invasive manner to help improve the cognitive 




Although the PPN is one of the more well-studied nuclei in the context of arousal and motor 
control, there is a lack of research into the role of the PPN in DLB, with research mainly 
having focused on cholinergic pathways, including the nucleus basalis of Meynert, and the 
role of the PPN in PD. With the DBS of the PPN shown to have an impact on cognitive 
functions in PD, there is a legitimate question as to whether dysfunction of the PPN could 
underlie the cognitive symptoms seen clinically in DLB. 
1.9.3 Raphe  
The DR and MnR have been shown to have high levels of Lewy body pathology in LBDs, in 
PD this burden is comparable to that observed in the SN (Seidel et al., 2015). In PD, cell loss 
has been shown in the DR (Paulus and Jellinger, 1991) and MnR, with degeneration of MnR 
neurons thought to correlate with tremor severity (Halliday et al., 1990; Loane et al., 2013). 
Degeneration of both DR and MnR neurons have been reported in DLB, although this loss 
was not related to any clinical features, including depression (Benarroch et al., 2007). A 
small number of studies have attempted to look at the role of the serotonergic system in 
DLB, one study used acute tryptophan depletion to examine the loss of serotonin function 
on global cognitive status (Mace et al., 2016). However, the study failed to find a decrease in 
MMSE, or an effect upon depression, although this study utilised a small sample size.  
Within DLB there have been a limited number of pathological studies that have 
comprehensively investigated both pathological and neuronal changes and the relation of 
these to clinical features within both the DR and MnR. A larger body of research has focused 
upon examining the integrity of serotonergic projections through imaging and examination 
of the regions to which they project in DLB, with the majority of this being related to 
depression or sleep disorders.  
1.9.4 Ascending reticular activating system projections 
Within LBD a number of neuroimaging studies, utilising different techniques, have examined 
the projections from nuclei of the ARAS and their possible role in clinical features. However, 
these studies have tended to focus on the cholinergic and serotonergic neurotransmitter 
systems separately and have not examined functioning of the ARAS as a whole. 
Cholinergic projections have been widely evaluated in LBDs and have been proposed to be 
involved in a variety of clinical features, including alterations to cognition, sleep disorders 




cholinergic inputs from the PPN to the thalamus, as measured through PET, has been 
associated with an increased fall risk in PD (Bohnen et al., 2009; Di Giovanni et al., 2019). 
Reduction in brain AChE activity, measured through PET imaging, was also associated with 
the presence of RBD in PD patients, with the study further identifying that monoaminergic 
dysfunction was similar across patients with and without RBD (Kotagal et al., 2012a). The 
role of cholinergic alterations in RBD has been further supported by imaging studies that 
have identified reduction in AChE binding in a number of cortical regions in those with 
idiopathic RBD, in this study no significant reduction in pontothalamic binding was 
observed, suggesting that this pathway may be affected later in disease progression (Gersel 
Stokholm et al., 2019). A further structural imaging study identified an association between 
grey matter reductions in the PPN and thalamus with visual hallucinations in PD and PDD 
(Janzen et al., 2012). In DLB, a multimodal MRI study identified alterations to thalamic 
cholinergic levels which associated with severity and frequency of cognitive fluctuations 
(Delli Pizzi et al., 2015).  
Alterations to white matter tracts, investigated via diffusion tensor imaging, have identified 
reductions to the fractional anisotropy, suggestive of diffusion along the axons becoming 
less directionally orientated in DLB (Mak et al., 2014). Watson et al. (2012) identified 
reductions in fractional anisotropy in the pons and left thalamus in DLB when compared to 
AD, supporting the hypothesis for alterations in the pontothalamic cholinergic system in 
DLB. Alterations to other cholinergic pathways have also been identified in DLB. A recent 
study using a vAChT SPECT radiotracer evaluated the integrity of a number of cholinergic 
systems in DLB, including the pontothalamic and the innominatocortical pathways (Mazère 
et al., 2017). The study identified reductions in the non-displaceable binding potential for 
the vAChT ligand in the terminal regions of the innominatocortical pathway, the anterior 
cingulate cortex, and the inferior and superior parietal cortices, and of the pontothalamic 
pathway, the thalamus; with the data suggestive of cholinergic neuronal loss in both 
pathways (Mazère et al., 2017). However, Mazère et al. (2017) identified a relative 
preservation of another cholinergic pathway the septohippocampal, suggesting that not all 
cholinergic pathways are altered in DLB. Atrophy within the substantia innominata has also 




(Colloby et al., 2017), providing further evidence for cholinergic involvement in cognitive 
fluctuations. 
Along with cholinergic imaging studies, a limited number have aimed to examine the 
integrity of monoaminergic systems, including the serotonergic and noradrenergic systems. 
General monoaminergic and serotonergic PET studies have identified alterations to binding 
levels in the LC and raphe associated with sleep-disorders, including excessive daytime 
sleepiness and RBD (Pavese, 2014). Recently serotonergic integrity has been examined, 
utilising the DaTSCAN radioligand, which can also be utilised to image serotonin in vivo 
(Joling et al., 2018). A limited number of studies have so far been conducted evaluating the 
serotonergic system in LBDs, with the conflicting results as to whether extrastriatal 
serotonin reuptake transporter (SERT) levels are altered in DLB compared to PD (Roselli et 
al., 2010; Joling et al., 2018). Further examination of the serotonergic system using imaging 
should be undertaken to try and understand the alterations that may occur in vivo in DLB 
and how they relate to clinical features. Unlike cholinergic imaging studies there have been 
less of a focus on the monoaminergic system in relation to cognitive alterations in LBD. 
The possible dysfunction of the ARAS, and its constituent brain regions, in LBD has been 
investigated, yet a limited number of focus on cognitive fluctuations. Presently, there are no 
studies that have investigated the role of pathological lesions in regard to cognitive 
fluctuations in brainstem nuclei. However, although there are a limited number of 
pathological studies relating the ARAS or its constituent components to cognitive 
fluctuations, a number of imaging studies have identified alterations to thalamic cholinergic 
levels and connectivity changes that have been related to fluctuating cognition. 
Furthermore, a number of studies have identified associations with clinical features that 
could have similar pathological underpinnings to cognitive fluctuations, for example RBD. 
Alterations to the ARAS have been proposed to play a role in the underlying 
pathophysiology of RBD (Boeve et al., 2007), with a universal alteration to the sleep-wake, 
arousal, systems hypothesised to underlie both RBD and fluctuating cognition (Terzaghi et 
al., 2013; Antelmi et al., 2016). Together these studies suggest that ARAS dysfunction, 
possibly leading to a system that is not efficient enough to maintain adequate levels of 
global arousal, is present in LBD and therefore warrants investigation into how this 




1.10 Summary and overview 
Cognitive fluctuations are one of the core features of DLB (McKeith et al., 2017) and cause 
significant distress to caregivers (Zweig and Galvin, 2014). Despite being a core feature, the 
underlying mechanisms that elicit cognitive fluctuations have not yet been identified. 
However, the mechanisms underlying fluctuating cognition have been hypothesised to be 
disturbances in attentional or arousal systems, either individually or in combination (Matar 
et al., 2019; O'Dowd et al., 2019). The proposed theory of arousal system dysfunction has 
centred around the ARAS, consisting of a diffuse network of neurotransmitter systems. 
There is evidence from studies investigating traumatic brain injuries that alterations to the 
ARAS, the LC, PPN, raphe and its projections, can elicit alterations in cognition and 
consciousness. Despite conceptual links between the clinical phenotype of DLB and ARAS 
dysfunction (Matar et al., 2019), no study has yet evaluated the ARAS in entirety in this 
disorder. In DLB a number of studies have identified alterations to the components of the 
ARAS, with a subset relating these to the presence of cognitive fluctuations; including 
imaging studies have identified alterations to the cholinergic pathways of the ARAS that 
were associated with cognitive fluctuations (Delli Pizzi et al., 2015; Colloby et al., 2017). 
Pathological changes are known to affect the nuclei of the ARAS in the early stages of DLB. 
However, there is limited understanding about how these changes could alter the 
functioning of the ARAS in controlling arousal and awareness. The present study aimed to 
assess pathological changes within the three main ARAS nuclei, LC, PPN and raphe. The 
integrity of the projections to a cortical target of the system, the medial PFC (mPFC), was 
also additionally assessed.  
It is important that the ARAS is investigated wholly due to the large number of overlapping 
pathways present allowing for a degree of redundancy within the system (Kovalzon, 2016a). 
However, a full comprehensive examination of the entire ARAS is not feasible due to a 
number of practical limitations, not limited to tissue availability and examination of the 
wide array of receptors expressed. The overall aim of the study was to evaluate whether 






1.11 Research aims 
The present study aims to investigate pathological changes within the different nuclei of the 
ARAS, and the integrity of their connections to a target region, within DLB. Alterations could 
provide an understanding into arousal deficits related to cognitive fluctuations in DLB. 
The hypothesis of this study is that some, or all, of the assessed ARAS regions, possess a 
distinct pattern of neurodegenerative pathology and/or alterations to neuronal populations 
in DLB and mixed AD/DLB with cognitive fluctuations compared to AD, mixed AD/DLB 
without cognitive fluctuations and control cases.  
This study aims to: 
• To relate the burden of pathological lesions, a-synuclein, tau and Aβ, in the LC, using 
quantitative histological techniques, to the presence and severity of cognitive 
fluctuations (Chapter 1) 
• To investigate the burden of a-synuclein, tau and Aβ within the PPN using 
quantitative histological techniques in relation to the presence of cognitive 
fluctuations and the parkinsonian subtype (Chapter 2) 
• To determine the burden and neuronal location of pathological accumulations, in 
the raphe, using quantitative histological and immunofluorescent techniques. In 
addition to investigating the association to the presence of cognitive fluctuations 
(Chapter 3) 
• To assess the neuronal location of pathological burden and innervation to the mPFC 





Chapter 2: Materials and Methods 
2.1 Introduction 
This chapter describes the histological, immunohistochemical and biochemical techniques 
that were performed on fixed and frozen human post-mortem brains. For fixed tissue it will 
outline the dissection methods and storage of the tissue, histological and 
immunohistochemical methods to stain tissues, and the assess pathological and neuronal 
changes. For frozen tissue, it will outline the acquisition of frozen tissue specimens, 
synaptosomal fractionation and the proteomic assay methods utilised to quantify protein 
expression in tissue. 
2.2 Study Cohort 
Cases were selected for inclusion in the present study on the basis that they fulfilled the 
clinical and neuropathological criteria for DLB (McKeith et al., 2005), AD (Montine et al., 
2012), PDD (Emre et al., 2007) or both AD and LBD, with the latter group being classified as 
mixed AD/DLB (figure 2.1). In most cases, DLB cases were included on the basis of a clinical 
history of cognitive fluctuations. Mixed AD/DLB cases without the clinical presentation of 
fluctuating cognition, fulfilling the pathological criteria for both AD and DLB, were included 
to provide a neocortical/limbic pathologically LBD (nLBD) control group without cognitive 
fluctuations. Within the nLBD group without cognitive fluctuations were a number of DLB 
cases which had no history of cognitive fluctuations. An AD group was included in the study, 
as a group with well-defined cognitive decline and neurodegenerative pathology, but 
without the presence of cognitive fluctuations to account for the role of AD-type pathology 
within the Mixed AD/DLB group. A second mixed AD/DLB, nLBD, group with clinical 
presence of cognitive fluctuations was included to assess whether any changes related to 
cognitive fluctuations in DLB were reflected in another neurodegenerative disease group. 
Control cases were included on the basis of an absence of neurological disorders during life 
and an absence of low neuropathological change on post-mortem analysis. Study 









Table 2.1. PhD 
study cohort 
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Figure 2.1. Study cohort identification and selection flow chart. * due to only 9 ‘pure’ DLB cases possessing CAF scores an 
additional 6 cases which possessed well characterised cognitive fluctuations although were not assessed via CAF were 
included in order to increase the n for the DLB with cognitive fluctuations group. **/*** the main aim of the study was to 
examine the role of the ARAS in cognitive fluctuations; therefore, the main priority was selection of DLB cases which had the 
best characterised fluctuations. Both the AD and control cases were matched as best possible to the DLB cases for age and 
MMSE (in the case of AD cases), a further AD case was removed due to identification of a brainstem infarct upon examination 





 Table 2.2. PhD study cohort characteristics.                                                                                                                                                                                                                                                                     
Cohort characteristics for the PhD study. Abbreviations: AD-Alzheimer’s disease; CERAD- Consortium to Establish a Registry for Alzheimer’s disease; CFs- cognitive fluctuations; DLB- dementia 













2.3 Clinical Assessment 
Cases underwent neuropsychological testing intra vitam. MMSE was gathered as a measure 
of cognitive function, if more than one MMSE measurement was available then rate of 
cognitive decline was determined as previously described (Olichney et al., 1998). CAF scores 
were collected in order to quantify the degree of severity of the cognitive fluctuations 
experienced (Walker et al., 2000b). If multiple CAF scores were collected, last, average and 
maximal values were calculated. Cognitive fluctuations are a transient, that appear to vary 
in severity throughout the disease course. Utilising the last, average and maximal CAF values 
should produce a clearer picture on the severity of a transient clinical phenomenon. 
Especially as CAF scores rate the severity of the fluctuations in the preceding month, 
meaning analysis with only one score could omit critical information. This is supported by 4 
cases which were identified as having cognitive fluctuations during life had a last CAF score 
of 0, suggestive of no fluctuations. 
2.4 Tissue Preparation 
2.4.1 Tissue preparation at the Newcastle Brain Tissue Resource 
Human post-mortem brain tissue was obtained from the Newcastle Brain Tissue Resource 
(NBTR), ethical approval was granted by the Newcastle and North Tyneside Research Ethics 
Committee (ref: 08/H0906/136).  
At post-mortem, brains were removed and time interval from death noted. The left 
hemisphere, brainstem and cerebellum was sliced into approximately 1cm slices and snap 
frozen at -120oC between copper plates. The right hemisphere, brainstem and cerebellum 
was fixed in 10% neutral-buffered formalin for 6 weeks, however in the cohort there are 
cases which vary from the routine protocol with fixation lengths ranging 3-45 weeks. After 
fixation the tissue is dissected into 7mm coronal blocks. From the coronal slices a pre-
defined number of sections were sub-dissected into blocks used for diagnosis and research. 
All fixed brain tissue then underwent processing, to dehydrate and clear the tissue, before 
being embedded into paraffin wax.  
Cases were neuropathologically assessed using standardised diagnostic guidelines (Braak 
and Braak, 1991b; Mirra et al., 1991; Thal et al., 2002; Braak et al., 2003; McKeith et al., 
2017), by a neuropathologist, with neuropathology data combined with clinical data 




2.4.2 Locus coeruleus 
The LC is a small nucleus, located 1mm below the fourth ventricle and 3mm from the 
midline, extending from the level of the widest portion of the fourth ventricle, at its most 
caudal, to the inferior colliculus, at its most rostral (German et al., 1988; Fernandes et al., 
2012). The LC is easily identifiable due to the presence of neuromelanin within the 
noradrenergic neurons (figure 2.2). Sections for analysis were taken from the upper mid 
pons, Block P on the NBTR dissection protocol (figure 2.5). 
2.4.3 Raphe nucleus 
The raphe nucleus is a large heterogenous collection of serotonergic neurons, within this 
study both the DR and MnR were examined. The DR extends from the mid pons, caudally, to 
its rostral end at the level of the oculomotor nucleus, with the MnR extending from the level 
of the trigeminal motor nucleus to the decussation of the superior cerebellar peduncle at its 
rostral limit (Hornung, 2003). Sections for analysis were taken from the upper mid pons, 
Block P on the NBTR dissection protocol (figure 2.5). The nuclei were visualised utilising 
TPH2 immunohistochemistry (IHC) (figure 2.3). 
 
 
Figure 2.2. Location and identification of the locus coeruleus.                                                                                                                                                            
Pigmented neurons of the locus coeruleus, at the level of the upper-mid pons, stained with haematoxylin. Image shown is 





2.4.4 Pedunculopontine nucleus 
The PPN is a large nucleus located in the upper pons and midbrain. It is commonly accepted 
that the PPN extends from its caudal limit at the level of the retrorubral field to its rostral 
end at the level of the SN pars reticulata (Hamani et al., 2016). Sections for analysis were 
taken from the lower midbrain, Block O on the NBTR dissection protocol (figure 2.5). The 




















Figure 2.5. Location and identification of the pedunculopontine nucleus.                                                                              
Choline acetyltransferase immunohistochemistry to identify the cholinergic neurons of the pedunculopontine nucleus 
within the lower midbrain. Image shown is of a control case. Scale bar = 1000µm, inset scale bar 100µm. IV-IV ventricle  
Figure 2.4. Location and identification of the raphe.                                                                                                                
Tryptophan hydroxylase 2 immunohistochemistry to identify the serotonergic neurons of the raphe within the upper-























































Figure 2.6. Newcastle Brain Tissue Resource brainstem dissection protocol.                                                                                                                                                                                                              
(A) Medulla, lilac, is divided into 4 blocks AV to AT; Pons, pink, is divided into 4 blocks AS to AQ; midbrain, green, is divided into 2 blocks, only the lower midbrain block is shown. Blocks 
are cut with the ventral side as the cut face, apart from Block O which is cut from the dorsal side. (B) Formalin fixed brainstem tissue from the medulla and pons blocks AU-AQ from the 




2.4.5 Tissue sectioning 
Blocks containing the regions of interest were sectioned using a rotary microtome 
(ThermoFisher Scientific HM355S). 7µm sections for histological analysis were mounted 
onto charged glass slides (Superfrost Plus, Thermo Scientific, UK). Mounted sections were 
then dried at 37°C for 48 hours.  Once dried sections were stored at room temperature prior 
to staining. Tissue sectioning was completed by NBTR technicians. 
2.5 Immunohistochemistry  
IHC was undertaken on 7µm formalin-fixed tissue section. Samples for each region 
underwent IHC in as few batches as possible to minimise any variability within the staining. 
IHC was conducted to visualise pathological proteins and to locate specific neuronal 
populations.  
Paraffin-embedded sections containing the region of interest were placed in a 60°C oven for 
45 minutes, to aid dewaxing and adhesion of the tissue to the slides, prior to immersion in 
two changes of xylene (10 minutes each). Sections were then rehydrated through a series of 
ethanol concentrations (99%, 99%, 95%, 70% for 5 minutes each) through to water. 
Following tissue rehydration, sections underwent antigen retrieval to reveal epitopes that 
had been cross-linked due to the fixation process. The technique for antigen retrieval varied 
dependent upon the antibody utilised. Citrate buffer antigen retrieval was performed by 
pre-heating 0.1M trisodium (Sigma-Aldrich, Dorset, UK), pH 6.0, in an 800-watt microwave 
(SLS, Hessle, UK) until ‘bubbling’, before immersing slides into the buffer and heating on full 
power for 10 minutes. Slides were then cooled in the buffer solution at room temperature 
for 20 minutes, before being rinsed in water. Formic acid antigen retrieval was performed 
by immersing the tissue slides in room temperature 99% formic acid (Sigma-Aldrich, Dorset, 
UK) for antibody specific duration, before slides being rinsed in water. Ethylenediamine 
tetra-acetic acid (EDTA) antigen retrieval was performed by heating 1mM EDTA buffer 
(Sigma-Aldrich, Dorset, UK), pH 8.0 in a pressure cooker until boiling, before immersing 
tissue sections in the EDTA buffer for two minutes at high pressure. Following 
depressurisation, sections were rinsed in water. 
Following antibody specific antigen retrieval all slides were quenched for endogenous 
peroxidase activity incubation in 3% H2O2 (Sigma-Aldrich, Dorset, UK) solution in water for 




buffered saline (TBS) (Fisher Scientific, Waltham, MA, USA), pH7.6, twice for 5 minutes 
followed by a 1-minute rinse in TBS with Tween20 (VWR, Lutterworth, UK) (TBS-T), pH 7.6. 
Tissue sections were outlined using an ImmEdge hydrophobic barrier pen (Vector 
Laboratories, Burlingame, CA, USA). Sections were subsequently incubated with primary 
antibody, at an antibody specific optimal dilution, suspended in TBS, for one hour at room 
temperature. Slides were then rinsed twice in TBS (5 minutes each) and once in TBS-T (1 
minute) before application of the universal probe, from the Menarini MenaPath kits 
(Menarini, diagnostics, Berkshire, UK), for 30 minutes at room temperature. Sections were 
then washed as previously described prior to application of the polymer solution, 
conjugated to horseradish peroxidase (Menarini MenaPath), for 30 minutes at room 
temperature. Tissue sections were then washed twice in TBS (5 minutes each). To visualise 
antibody binding, tissue sections were incubated in 3’ diaminobenzidine (DAB) chromogen 
in DAB substrate buffer (Menarini MenaPath), 1 drop (32µl) per ml, for 3 minutes at room 
temperature. Sections were then washed thoroughly under running water for 15 minutes. 
A haematoxylin counterstain was applied to the tissue sections to identify cellular nuclei. 
Tissue sections were counterstained by immersion in haematoxylin solution (700mls of 
distilled water: 0.5g sodium iodate, 50g aluminium potassium sulphate, 5g haematoxylin, 
40mls acetic acid and 300mls glycerine) for 30 sections, before rinsing in water. Tissue 
sections were then differentiated quickly with 1% acid alcohol, before washing in water and 
then immersed in 1% ammonia water until the nuclei turned blue.  
Following counterstaining sections were dehydrated through a series of ethanol 
concentrations (70%, 95%, x2 99%) before clearing in xylene and being mounted with DPX 
and coverslipped. 
2.6 Histological staining: Luxol Fast Blue/Haematoxylin & Eosin 
Luxol Fast Blue (LFB)/ Haematoxylin & Eosin (H&E) histological staining was undertaken on 
slides from the upper pons and midbrain to help locate the correct brainstem level for the 
PPN, prior to ChAT IHC. LFB stains myelin/myelinated axons, with haematoxylin staining cell 
nuclei and eosin staining the extracellular matrix and cytoplasm within formalin fixed post-
mortem brain tissue. Following dewaxing and rehydration up to 95% alcohol, as outlined in 




Sections were then rinsed in 95% alcohol and then water. LFB was differentiated in a weak 
lithium carbonate solution, followed by further differentiation in 70% alcohol until the grey 
and white matter were clearly distinguishable. Sections were counterstained with H&E. 
Firstly, sections were incubated in haematoxylin for 5 minutes before rinsed in water and 
differentiated as outline in 2.5. Followed by incubation in eosin for 3 minutes, before being 
rinsed in water and dehydrated and cleared in xylene and mounted with a coverslip using 
DPX (CellPath, Newtown, UK).  
LFB staining solution was prepared by combining 500ml 95% alcohol with 0.5g Luxol Fast 
Blue (Fisher Scientific, Waltham, MA, USA) and 2.5ml 10% acetic acid. Haematoxylin was 
prepared as outlined in 2.5. Eosin was prepared by combing 1000ml 20% alcohol with 10g 
Eosin Y, 0.25g Phloxine and 0.25g Erythrosin. 
2.7 Immunofluorescence 
Immunofluorescence was undertaken on 7µm formalin-fixed tissue section containing the 
DR and MnR. Samples for the DR and MnR were stained in batches to ensure that there was 
limited variability in time from completion of immunofluorescence to imaging. 
Immunofluorescence was conducted to visualise the expression levels of neurotransmitter-
specific markers and to visualise colocalization of pathological lesions in neuronal 
subpopulations.   
Tissue sections containing the DR and MnR were dewaxed and rehydrated and underwent 
citrate antigen retrieval, as previously described in 2.5. Sections were rinsed twice in TBS (5 
minutes each) then in TBS-T (1 minute). Tissue sections were outlined with an ImmEdge 
hydrophobic barrier pen, before blocking in 3% normal goats’ serum (NGS) in TBS for 1 hour 
at room temperature. Block was tipped off before incubation in primary antibody serum. 
Primary mouse and rabbit antibodies were diluted in 3% NGS in TBS, at an antibody specific 
dilution. Primary antibody serum was incubated for 21 hours at 4°C. Following two rinses in 
TBS-T (5 minutes each) and one in TBS (2 minutes), tissue sections were incubated in 
secondary antibody serum in the dark for 1 hour at room temperature. Secondary 
antibodies, Alexa Fluor® 488 Goat Anti-Mouse IgG (Invitrogen, Waltham, MA, USA), 
fluoresces green and Alexa Fluor® 594 Goat Anti-Rabbit IgG (Invitrogen, Waltham, MA, 
USA), fluoresces red, were diluted both 1:200, in 3% NGS in TBS. Sections were then rinsed, 




in water. Tissue sections were quenched for autofluorescence by incubation with Sudan 
Black. Sections were dipped in 70% ethanol, to prevent precipitation, before being covered 
with Sudan Black (Sigma Aldrich, Dorset, UK) (1% Sudan Black in 70% ethanol) and incubated 
for 10 minutes at room temperature. Sections were then dipped in 70% ethanol and 
immersed in water prior to being mounted with UltraCruz hardset mounting medium 
containing DAPI (4’,6 diamino-2-phenylindole) (Santa Cruz, Heidelberg, Germany) to 
visualise all neuronal nuclei, and cover slipped. 
Sections were then covered, to block light, and stored at 4°C before being imaged the 
following day. 
2.8 Image analysis 
2.8.1 Analysis of immunoreactivity 
Analysis assessed the percentage area stained by an antibody within the LC, PPN and 
DR/MnR. Multiple adjacent single images were captured at x100 magnification using a 
Nikon 90i microscope, with a fully motorised stage, and DsFi1 camera microscope coupled 
to a PC. The multiple adjacent images were stitched together, by NIS-Elements AR3.2 
software (Nikon, Surrey), to create one large image which covered the whole region of 
interest. For the LC the large image was formed of 5x5 single images image representing an 
area of 10.1 mm2, for the DR and MnR an 8x14 image was taken representing an area of 
46.1mm2 and for the PPN a 10x10 image was taken representing an area of 41.5mm2.  
The brainstem nuclei were delineated prior to calculation of immunoreactivity (figure 2.6). 
For DR and MR nuclei were delineated on the pathology slides by comparison to a 
consecutive TPH2 slide; for the PPN the comparison was made with a consecutive ChAT 
slide. The images were analysed using a standardised red-green-blue threshold on NIS 
elements AR3.2 software, determined separately for each antibody, to selectively detect 
only immunopositive signals without detection of non-specific background (figure 2.6). In 
addition to the red-green-blue thresholds for 4G8 analysis, a size threshold was also applied, 
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Figure 2.7. Example images of delineation of the brainstem nuclei for image analysis.                                                                                                                                                                                               
(A) pedunculopontine nucleus stained with choline acetyltransferase, scale bar = 1mm; (B) raphe nuclei stained with tryptophan hydroxylase, scale bar = 1mm; (C) locus coeruleus with a 





the 4G8 antibody also detects was not included. Percentage area stained was calculated for 
all regions analysed, the DR and MnR were combined to give a total percentage area stained 
for the raphe. 
2.8.2 Analysis of immunofluorescence  
Sections that underwent immunofluorescence staining had multiple single adjacent images 
at x100 magnification captured using a Nikon 90i microscope, with a fully motorised stage, 
and DsQi1Mc camera microscope coupled to a PC. Images were taken of DAPI (excitation 
Figure 2.8. Analysis of immunoreactivity.                                                                                                                                            
Images taken at x100 magnification had the nuclei of interest delineated, as shown in figure 2.6. A colour threshold was 
then applied which detected only the immunoreactivity labelled by the DAB chromogen within the delineated region of 
interest but does not detect non-specific background staining. Representative image shows a small section of the raphe 
from an Alzheimer’s disease case with AT8 immunohistochemistry, both with and without the red-green-blue colour 




358 nm and emission 461nm), FITC (excitation 495 nm and emission 519nm) and TRITC filter 
(excitation 544 nm and emission 570nm). The multiple adjacent images were then manually 
stitched together based upon overlapping landmarks, to create a large image of the entire 
region of interest (figure 2.8). 
2.8.2.1 Intensity analysis of immunofluorescence 
Individual TPH2-positive neuron intensity was assessed within the raphe utilising FIJI 
software (Schindelin et al., 2012). The intensity was measured on an individual neuron basis 
following the methods as outlined by Fitzpatrick (2014). Large stitched images of the FITC 
(green) channel only, were altered to greyscale, in order to make the background pixels 
have a value close to zero. Individual TPH2-positive neurons were delineated and the area 
integrated intensity and mean grey value were measured. Background measurements from 
30-40 areas within the raphe were taken provide an average background measurement for 
the region of interest. The corrected TPH2 intensity for each individual TPH2-positive 
neuron was calculated using the following formula:  
integrated	density	–	(area	of	selected	cell	x	mean	fluorescence	of	background	readings)
area	of	selected	neuron  
The median corrected TPH2 intensity for all assessed TPH2-positive neurons was calculated 
for each individual section analysed.   
Figure 2.9. Example manually stitched image of immunofluorescent double labelling.                                                                                         
Manually stitched immunofluorescence image for tryptophan hydroxylase 2 and pS129 α-synuclein double labelling, with 





2.8.2.2 Analysis of co-localisation  
Manually stitched images, of all three fluorescence channels merged, were assessed for the 
presence α-synuclein aggregates, Lewy bodies, within TPH2-positive neurons (figure 2.9). 
Total number of TPH2-positive within the section were counted and the percentage bearing 
α-synuclein calculated. Through comparison of the merged image to the green only, CTCF 
adjusted for area was calculated for the TPH2-positive neurons containing Lewy bodies. 
Lewy body-containing neurons were also delineated, excluding the Lewy body, to calculate 
the CTCF adjusted for area of the TPH2-positive neuron that did not include the Lewy body.  
 
2.9 Biochemical techniques 
2.9.1 Acquisition of frozen tissue 
Frozen tissue was acquired from 10 DLB with cognitive fluctuations, 9 AD, 10 Mixed AD/DLB 
without cognitive fluctuations, 10 Mixed AD/DLB with cognitive fluctuations and 10 
controls. Tissue was taken from the mPFC, levels 4 and 5 on the NBTR dissection protocol 
(figure 2.10) corresponding to BA12.  
Figure 2.10. Colocalisation between Tryptophan hydroxylase 2 and α-synuclein.                                                                     
Tryptophan hydroxylase 2 positive neurons containing α-synuclein (red arrow) and with no α-synuclein present (green 





Figure 2.11. Newcastle Brain Tissue Resource frozen tissue dissection protocol.                        
Brodmann area 12 relating to the medial prefrontal cortex was sampled either from block 




Frozen tissue was brought to -20°C and tissue containing the mPFC was removed. 
Approximately 250mg tissue was dounce homogenised, 10 strokes, in ice cold lysis buffer at 
a tissue weight:volume ratio of 1:6. Lysis buffer, pH 7.5 was prepared containing 0.32M 
sucrose (Sigma Aldrich, Dorset, UK), 5mM HEPES (Sigma Aldrich, Dorset, UK), cOmplete 
MiniTM protease inhibitor (Sigma Aldrich, Dorset, UK) (1 tablet per 10ml) and phosphatase 
inhibitor cocktail (Roche, Mannheim, Germany) (1 tablet per 10ml), made up in deionised 
water. Homogenised aliquots were then put on ice to undergo synaptosomal fragmentation. 
2.9.2 Synaptosomal fragmentation 
Homogenised aliquots underwent synaptosomal fragmentation by sequential centrifugation 
(figure 2.11) as previously described by Wirths (2017), immediately after tissue 
homogenisation. Tissue homogenate was centrifuged at 1,000 x g for 10 minutes at 4°C in a 
1.5ml Eppendorf tube.  Following the first centrifugation the supernatant was transferred 
into a new 1.5ml tube, and the pellet, pellet 1 (P1) containing nuclei, was resuspended in 
500µl of 0.01M Phosphate buffered saline (PBS) (Sigma-Aldrich, Dorset, UK). The 
supernatant was then centrifuged at 12,000 xg for 20 minutes at 4°C. Following the second 
centrifugation the supernatant (S2), containing microsomes and soluble enzymes, was 
removed and transferred to a new 1.5ml tube. The pellet was then resuspended in the lysis 
buffer, pellet weight:volume ratio of 1:5, and recentrifuged at 12,000 xg for 20 minutes at 
4°C, in order to wash the pellet, following the removal of the wash supernatant the pellet 
was again washed, in lysis buffer with a pellet weight:volume ratio of 1:5. After the second 
wash of pellet 2 (P2), the crude synaptosomal fraction, the pellet was resuspended in 250µl 
PBS. All fractions were then stored at -80°C until further use.  
2.9.2.1 Fractionation validation 
Fractionation was validated by assessing the levels of nuclear, mitochondrial and synaptic 
markers within the three fractions via western blotting. 
Protein quantification of each frozen tissue fraction was performed using Bradford assay. 
Quantification of protein concentration was undertaken prior to every blot undertaken. 
Protein standards (1000, 800, 600, 400, 200, 100, 50 µg/ml BSA) were prepared in both 
0.01M PBS for pellet fractions and lysis buffer for supernatant fractions. 10µl of relevant 




200µl of Bradford reagent was then added to each well (Sigma-Aldrich, Dorset, UK). A visual 
inspection of the wells to ensure a colour change from brown (470nm) to blue (595nm) had 
occurred was done prior to absorbance readings. 96-well plates were loaded into FLUOstar 
Omega (BMG Labtech, Aylesbury, UK) and absorbance was read at 37oC at 595nm. 
Absorbances were measured within 10 minutes of Bradford reagent being added to the 
wells. Average absorbance values from the protein standards were plotted to create a 
protein standard curve. A linear line of best fit was fitted to the protein standard curve, with 
an R-value calculated to show the strength of the best fit line. Any R-value below 0.95, was 
deemed not to be sufficient and the Bradford assay was performed again. Using the 
equation of the protein standard curve the concentration (µg/µl) of the tissue samples was 
calculated. These concentration values were then used to prepare the 10µg samples loaded 
onto the blots. Samples were prepared for sodium dodecyl sulphate (SDS) polyacrylamide 
gel electrophoresis (PAGE) by adding sample buffer (4x Novex NuPAGE LDS sample buffer, 
Invitrogen, Waltham, MA, USA), a reducing agent (10x NuPAGE sample reducing agent, 
Invitrogen, Waltham, MA, USA) and made up to 0.5 µg/µl with deionised water.  
Tissue Homogenate 
 
1,000xg 10 minutes 
Supernatant 1 
 
Pellet 1: nuclei 12,000g 20 minutes 
 
Supernatant 2: microsomes 
and soluble enzymes 
Pellet 2: Cruse synaptosomal 
and mitochondrial fraction 
Figure 2.12. Synaptosomal fractionation protocol.                                                                                                                            




Samples were then heated for 10 minutes at 70°C, before being returned to ice and briefly 
centrifuged in a benchtop centrifuge, to ensure all sample was at the bottom of the tube 
following heating. Prepared samples were loaded onto a NuPAGE 4-12% Bis-Tris gel 
(Invitrogen, Waltham, MA, USA), 10µg of sample was loaded per well.  Gels were run at 
200V constant voltage for 35 minutes, with SDS NuPAGE MOPS Running Buffer (Invitrogen, 
Waltham, MA, USA). All blots were run with the SeeBlueTM protein ladder (ThermoFisher, 
Waltham, MA, USA) to ensure correct molecular weight of the protein bands. Proteins were 
transferred to a nitrocellulose membrane via IBlot2 (Invitrogen, Waltham, MA, USA), 20mV 
for 7 minutes. 
Proteins within the nitrocellulose membranes where then detected following the protocol 
outlined in 2.9.3. Size and intensity of the protein bands on the blots was quantified using 
FIJI (Schindelin et al., 2012) with the target protein expression normalised to glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) expression within the fractions. Target proteins were 
normalised to GAPDH to remove variations due to experimental errors, for example unequal 
loading of the three fractions into the blot. Furthermore, GAPDH was utilised over other 
proteins due to its ubiquitous expression throughout the neuron, therefore it should not be 
preferentially identified in any one of the fractions 
2.9.3 Immunoblots 
Dot blots were undertaken to assess the levels of a number of different proteins within the 
synaptosomal, P2, and soluble enzyme fragment, S2. Prior to all blots protein quantification 
was undertaken to obtain the concentration of total protein within each sample fraction via 
Bradford assays (as described in 2.9.2.1).  
Samples from both fractions analysed were adjusted to 1µg/µl with distilled water and 
directly dotted in duplicate onto 0.2µm nitrocellulose membrane (10µl per sample, 10µg 
per dot). Sample dots were allowed to dry prior to incubation in TBS-T. Optimisation of the 
protocols identified one antibody, NDuFB8, that required sample pre-treatment where 
lysates were heated at 100°C for 5 minutes prior to being dotted. All blots had samples 
added in a randomised order to remove any experimental differences between the first and 
last blotted samples. 
All immunoblots, both dot and western blots, were washed three times in TBS-T (5 minutes 




After blocking immunoblots were washed three times in TBS-T (5 minutes each). 
Immunoblots were then incubated with primary antibody at 4°C overnight under continuous 
agitation. Primary antibody solution was prepared in TBS-T, 5% BSA (Sigma-Aldrich, Dorset, 
UK) and 0.05% of sodium azide in a 50ml tube, with the primary antibody dilution having 
been empirically determined. Following incubation with primary antibody, immunoblots 
were washed three times with TBS-T (5 minutes each) prior to incubation with an 
appropriate, goat anti-mouse or goat anti-rabbit horseradish peroxidase conjugated 
secondary antibody (both 1:5000, Merk Millipore, Watford, UK) diluted in 5% milk powder 
in TBS-T. Immunoblots were incubated with secondary antibody for 1 hour at room 
temperature. All immunoblots were then washed in TBS-T (x3 5 minutes) prior to 
visualisation with enhanced chemiluminescence (1.25 mM Luminol, 30 µM coumaric acid, 
0.015 % H2O2). Processed blots were subsequently stained for total protein measurements 
utilising ponceau (Sigma-Aldrich, Dorset, UK) total protein stain (0.1% ponceau in 5% acetic 
acid). Images were captured using a Fuji LAS 4000 with imaging software (Fuji LAS Image, 
Raytek, Sheffield, UK) at 8-bit for illustration and 16-bit for analysis. 
To ensure specificity of the detected signal, appropriate secondary antibody control dot 
blots were undertaken, in which the primary antibody was excluded. For heat treated and 
soluble enzyme fraction immunoblots a small detectable immunoreactive signal was 
observed, following an exposure time comparable to the primary treated immunoblot. Non-
specific immunoreactive signal was subtracted from the signal detected on the primary 
incubated immunoblot. No other immunoblots possessed a detectable non-specific 
immunoreactive signal at an exposure time comparable to the primary incubated blot. 
2.9.4 Blot analysis 
Immunoreactivity was quantified from 16-bit digitised images utilising FIJI (Schindelin et al., 
2012) based on area under curve measurements normalised to total protein load 
established via area under the curve for ponceau processed blots, as previously described 
by Koss et al (2016). Immunoblot intensity data were normalised within blot using total 





2.10 Statistical analysis 
Statistical analysis was conducted using SPSS v.26 (IBM). All data were assessed for 
normality by the Shapiro-Wilk test and inspection of histograms and Q-Q plots, prior to 
statistical analysis of significance between groups.  Immunohistochemistry and immunoblot 
data did not fulfil normal distribution criteria; therefore, Kruskal-Wallis tests were employed 
to determine overall group differences. A paired t test (Mann-Whitney U) was used to 
determine differences between two clinical groups. Spearman’s rank correlation co-efficient 
was used to determine associations between variables. Corrections such as Bonferroni were 
not applied due to the fact that there is not a true null hypothesis because of the 
classification of neurogenerative diseases, for example AD will have higher levels of AD-type 







Chapter 3: Pathological studies in the locus coeruleus 
3.1 Introduction 
Cognitive fluctuations are one of the four core clinical features of DLB (McKeith et al., 2017). 
Despite this they are one of least understood and most difficult to assess clinically, with the 
underlying pathophysiological framework poorly understood (Matar et al., 2019). Imaging 
studies have demonstrated connectivity alterations in the basal ganglia and thalamus which 
have been associated with cognitive fluctuations (Schumacher et al., 2019c); as well as 
dysconnectivity within the ARAS, having been shown to lead to alterations in consciousness 
in other disorders (Siegel, 2004; Jang and Lee, 2015). Regions that form part of the ARAS, 
including the thalamus (Braak et al., 2003), basal ganglia (Liu et al., 2015) and hypothalamus 
(Benarroch et al., 2015) are known to be vulnerable to the accumulation of pathological 
proteins in DLB and are hypothesised to play a role in the pathophysiology of cognitive 
fluctuations. However, there have been a limited number of studies that have examined 
how these accumulations could relate to the presence and severity cognitive fluctuations 
(Matar et al., 2019; O'Dowd et al., 2019).  
The LC, the largest source of noradrenergic projections in the brain, has been extensively 
studied in in respect to its role in the maintenance of arousal and wakefulness (Samuels and 
Szabadi, 2008a). Activity within the LC is known to relate to cortical EEG levels (Berridge and 
Foote, 1991), indicative of arousal, with the nuclei thought to control this through selective 
excitement of systems that are also involved in waking, whilst inhibiting those that are 
involved in sleep (Jones, 2005a; McKenna et al., 2017). A number of studies have 
investigated the LC in neurodegenerative diseases. Age-related neuronal loss in the LC has 
been shown to be exacerbated by neurodegenerative changes, which in DLB seem to be 
driven by α-synuclein pathology and not concomitant AD-type pathology (Samuels and 
Szabadi, 2008b; Brunnstrom et al., 2011). Accumulation of α-synuclein pathology in the LC is 
thought to occur early in DLB (Vermeiren and De Deyn, 2017). Tau pathology has also been 
shown to be located in the LC prior to the transenthorinal cortex (Weinshenker, 2018). 
Although the LC has been extensively studied in many different dementia subtypes and has 
been shown to be highly affected by pathological protein deposits, there has not been a 
systematic study evaluating these changes and alterations to the ARAS as a whole, in 




and its constituent parts in the pathophysiological framework of cognitive fluctuations 
(Matar et al., 2019). Therefore, the aim of this present study was to investigate whether 
pathological changes in the LC are specific to the cases with cognitive fluctuations and that 
may contribute to the severity of the cognitive fluctuations.   
3.1.1 Aims 
It was hypothesised that the LC will display a pattern of pathological protein deposition that 
relates to the presence of cognitive fluctuations. Using post-mortem tissue sections 
containing the locus coeruleus from DLB and nLBD cases with fluctuations, nLBD and AD 
cases without cognitive fluctuations, and aged cognitively normal controls, this study aims 
to 
1. Quantify the burden of neuropathological protein lesions, utilising 
immunohistochemical techniques for Aβ, tau and α-synuclein 
2. Assess whether the neurodegenerative changes seen are related to the presence or 



















3.2.1 Study Cohort 
Five groups were included in the LC study with a total of 67 cases (table 2.1). 14 DLB cases 
that had been recorded to have experienced cognitive fluctuations during life; 13 nLBD 
cases who did not experience cognitive fluctuations during life, containing a mixture of 
mixed AD/DLB and DLB cases; 11 AD cases with no recorded experience of cognitive 
fluctuations during life; 12 nLBD cases who did experience cognitive fluctuations during life, 
mixed AD/DLB; and 17 aged matched controls with no history of cognitive impairment. 
Cases who during life were uncooperative with neuropsychiatric testing, were postulated to 
have cognitive fluctuations due to medicine regimes and contained brainstem infarcts were 
excluded from the study. Within the study cohort a number of those with a history of 
cognitive fluctuations had the severity of these measured via CAF (9 DLB and 9 nLBD with 
cognitive fluctuations) allowing associations with severity of fluctuations to be assessed. 
3.2.2 Tissue Acquisition 
The LC is located 1mm below the fourth ventricle and 3mm from the midline  (German et 
al., 1988; Fernandes et al., 2012). The LC is easily identifiable, even by the naked eye, due to 
the presence of neuromelanin within the noradrenergic neurons (figure 3.1). Sections for 
analysis were taken from the paraffin embedded formalin fixed tissue blocks containing the 
upper mid pons, as described in 2.4.5.  
3.2.3 Pathology 
Sections containing the LC underwent IHC staining, as described in 2.5, with antibodies 
against hyperphosphorylated tau (AT8), Aβ (4G8) and α-synuclein (KM51) (table 3.1). The 
three pathology antibodies were utilised as they have been widely validated and utilised for 
diagnostic within the NBTR. A large image, with an area of 10.1mm2, was created by 
capturing and stitching 25 adjacent, 5x5, single images at x100 magnification using NIS-
Elements AR3.2 software (Nikon, Surrey), a Nikon 90i microscope, with a fully motorised 
stage, and DsFi1 camera microscope coupled to a PC.  
Stitched images were analysed using a standardised red-green-blue threshold on NIS 
elements AR3.2 software. Thresholds were determined for AT8, 4G8 and KM51 separately 
to detect only immunopositive signals, without detection of non-specific background and 




included a size threshold to ensure intracellular APP was excluded from the analysis. 
 
 






1:4000 0.1M Citrate pH 6.0 
4G8, Aβ Covance, NJ, 
USA 
1:15000 Formic acid (1 hour) 
KM51, α-synuclein Leica 
Biosystems, UK 
1:200 Formic Acid (10 minutes), 1mM 
EDTA pH 8.0 
500µm 10mm 
Figure 3.1. Location and identification of the locus coeruleus.                                                                                                               
Neuromelanin containing noradrenergic neurons of the locus coeruleus located close to the fourth ventricle in the 
upper-mid pons in a fixed tissue control case section counterstained with haematoxylin. Scale bar = 500µm. Inset 
displays fixed tissue block with red arrow indicating the location of the locus coeruleus as can be seen with the naked 
eye. Inset scale bar = 10mm. IV-IV ventricle 
Table 3.1. Antibodies utilised in the locus coeruleus study.                                                                                                            





3.2.4 Statistical analysis 
Statistical analysis was conducted using SPSS v.26 (IBM). Variables were assessed for 
normality by the Shapiro-Wilk test and inspection of histograms and Q-Q plots. Pathology 
data was found to be non-normal leading to non-parametric tests being employed. To 
determine differences in pathological burden between the study groups Kruskal-Wallis and 
post-hoc Mann-Whitney were undertaken. To determine whether there was an association 
between pathological burden and severity of cognitive fluctuations as measured by CAF 
scores, Spearman’s rank correlations were conducted, firstly in both DLB and nLBD (mixed 
AD/DLB) with cognitive fluctuations together and then both groups separately. Corrections 
such as Bonferroni were not applied due to the fact that there is not a true null hypothesis 
because of the classification of neurogenerative diseases, for example AD will have higher 























No significant differences were observed in post-mortem delay, fixation duration, and age 
between the study groups. There was no significant difference observed in disease duration 
between the neurodegenerative disease groups. Between the groups, a significant 
difference was found in the proportion of males to females, with the DLB group having a 
significantly higher proportion of males compared to nLBD with fluctuations (χ(1)=3.869, 
p=0.049), nLBD without fluctuations (χ(1)=4.747, p=0.029), AD (χ(1)=4.588, p=0.032) and 
controls (χ(1)=6.419, p=0.011). 
CAF scores were available for 25/67 cases. 18/26 of the cases with cognitive fluctuations 
possessed at least one CAF score. No significant difference was observed between the last 
(p=0.927), maximal (p=1.000) or average (p=0.789) CAF score between the DLB with 
fluctuations or the nLBD with fluctuation groups. 
Final MMSE scores were available for 55/67 cases: 13 DLB cases with fluctuations, 12 nLBD 
with fluctuations, 11 nLBD without fluctuations, 10 AD and 9 Controls. No significant 
difference in the interval between the last MMSE and death was observed between the 
groups. Significantly lower last MMSE scores were observed between all disease groups and 
controls: DLB cases with fluctuations (z=-21.363, p=0.002), nLBD with fluctuations 
(z=28.722, p<0.001), nLBD without fluctuations (z=-26.510, p<0.001) and AD cases (z=-
27.156, p<0.001). No significant differences in last MMSE score were observed between the 
4 disease groups. 
3.3.2 Pathology 
Alpha-synuclein pathology was observed in all cases with cognitive fluctuations, DLB and 
nLBD, with a mixture of Lewy bodies and Lewy neurites observed in the majority of cases 
(figure 3.2A). A significant main effect of disease group on α-synuclein was observed in the 
LC (χ²=39.505, p<0.001) (figure 3.2B). Alpha-synuclein pathological burden was higher in DLB 
with fluctuations (z=32.315, p<0.001), nLBD with fluctuations (z=-30.363, p<0.001) and nLBD 
without fluctuations (z=30.376, p<0.001) than controls. Pathological burden of α-synuclein 
was significantly higher in DLB with fluctuations (z=29.604, p<0.001), nLBD with fluctuations 
(z=-27.652, p<0.001) and nLBD without fluctuations (z=27.664, p<0.001) than AD cases. No 




nLBD groups with and without fluctuations (p=0.999) or between the DLB with fluctuations 
group and the nLBD groups with (p=0.797) and without (p=0.794) fluctuations. No 
significant difference was also observed between AD and control cases.  
Tau pathological burden was observed in all cases, including control cases which typically 
possessed one or two small AT8 positive neuropil threads or neurites. The highest LC tau 
burdens were observed in the AD and nLBD groups, both with and without fluctuations, 
with cases containing neurofibrillary tangles, neuropil threads and neurites (figure 3.2C). A 
significant main effect of disease group on tau pathological burden was observed in the LC 
(χ²=34.079, p<0.001) (figure 3.2D). Tau pathological burden was higher in nLBD with 
fluctuations (z=-21.069, p=0.004), nLBD without fluctuations (z=29.312, p<0.001) and AD 
cases (z=32.963, p<0.001) than controls. Pathological burden for tau was significantly higher 
in nLBD with fluctuations (z=-19.333, p=0.012), nLBD without fluctuations (z=-27.577, 
p<0.001) and AD cases (z=-31.277, p<0.001) than DLB with fluctuations. No significant 
differences between the level of tau burden were observed between the nLBD groups with 
and without fluctuations (p=0.291) or between the AD group and the nLBD groups with 
(p=0.144) and without (p=0.647) fluctuations. No significant difference was also observed 
between DLB with fluctuations and control cases 
The percentage area stained for Aβ, as measure by 4G8 was the lowest of the three 
pathological protein observed, with variable pathological burden observed within the cases 
and disease groups (figure 3.2E). The majority of plaques were ill-defined aggregations of 
fine argentophilic processes, type 3 as previously described by (Iseki et al., 1989). A 
significant main effect of disease group on Aβ pathological burden was observed in the LC 
(χ²=30.216, p<0.001) (figure 3.2F). Aβ pathological burden was higher in nLBD with 
fluctuations (z=-27.995, p<0.001), nLBD without fluctuations (z=19.335, p=0.005) and AD 
cases (z=32.366, p<0.001) than controls. Pathological burden for Aβ was significantly higher 
in nLBD with fluctuations (z=-21.619, p=0.003) and AD cases (z=-25.990, p=0.001) than DLB 
with fluctuations. In the nLBD without fluctuations group a trend  
 
 Figure 3.2. Pathology in the locus coeruleus.                                                                                                                                             
Representative images of A-α-synuclein (KM51), C- tau (AT8), E-Aβ (4G8).  Pathological burden data for B- α-synuclein, 
D- tau and F- Aβ. Data is shown as median with interquartile range. ** p<0.01 ***p<0.001 compared to controls. Scale 
bar 500µm, inset 100µm. Abbreviations: AD- Alzheimer’s disease; DLB- dementia with Lewy bodies; nLBD- 



































































































































































































































towards a significantly higher Aβ burden was observed compared to the DLB with 
fluctuations (p=0.070) group and a trend towards a significantly lower Aβ burden was 
observed compared the AD cases (p=0.087). No significant differences were observed 
between DLB with fluctuations and control cases, between the nLBD groups with and 
without fluctuations (p=0.245) and between nLBD groups with fluctuations and AD cases 
(p=0.573). 
No associations were found between disease duration, across the disease groups, and α-
synuclein (p=0.903), tau (0=0.976) or Aβ (p=0.360) pathological burden.  
3.3.3 Relationship with cognitive fluctuations 
Within the groups that contained cases which during life had experienced cognitive 
fluctuations, both DLB and nLBD, a significant positive Spearman’s rank correlation was 
observed between tau pathology in the LC and last CAF score (rs=0.473, p=0.047) (figure 
3.3A) and average CAF score (rs=0.477, p=0.045) (figure 3.3B). No other associations were 
observed between pathological burden and severity of cognitive fluctuations in the 
combined DLB and nLBD with fluctuations group. 
When the combined cognitive fluctuation group was separated into DLB and nLBD, the 
previously observed association between cognitive fluctuation severity and LC tau burden 
was lost in the DLB only group, last CAF (rs=0.094, p=0.813) (figure 3.3E) and average CAF 
(rs=-0.017, p=0.982) (figure 3.3F). The positive association of cognitive fluctuation severity, 
as measured by last and average CAF score, and LC tau pathological burden was only 
observed within the nLBD with fluctuations group (rs=0.870, p=0.005; rs=0.798, p=0.014) 









Figure 3.3. Correlations between locus coeruleus tau pathology and cognitive fluctuation severity.                                                                                                                                                              
A and B- LC tau pathology against last CAF scores and average CAF scores respectively shown all cases whom experienced 
cognitive fluctuations during life and had at least one CAF score in both the DLB and nLBD groups. C and D- nLBD cases 
only for LC tau pathology against last and average CAF score respectively. E and F- DLB cases only for LC tau pathology 
against last and average CAF score respectively. Abbreviations: LC- locus coeruleus; CAF-clinical assessment of fluctuation; 











































































































































































The present study identified significant differences in LC pathological burden between the 
disease groups utilised. As expected, α-synuclein pathology was found to be the significantly 
higher in the groups that were pathologically classified as LBDs; with tau and Aβ pathology 
significantly higher in the groups that were pathologically classified as having high AD 
neuropathological change. Increased CAF score, suggestive of an increased severity of 
cognitive fluctuations, was observed to be positively associated with an increased tau 
burden in nLBD with cognitive fluctuations but not in DLB with cognitive fluctuations. No 
relationship was observed between α-synuclein pathological burden or Aβ and presence or 
severity of cognitive fluctuations. 
Cognitive fluctuations are one of the four core features of DLB; however, little is known 
about their pathophysiology. Clinical research into this phenomenon, has implicated both 
arousal and attention in cognitive fluctuations (Bliwise et al., 2014; McKeith et al., 2017; 
O'Dowd et al., 2019). The LC and its noradrenergic projections have been heavily implicated 
in the maintenance and control of arousal and attention, both directly and indirectly 
through the ARAS (Jones, 2005a; Samuels and Szabadi, 2008a), with a recent opinion paper 
theorising that the ARAS and its constituent parts could be involved in the neural 
underpinning of cognitive fluctuations (Matar et al., 2019). 
3.4.1 Pathology alone does not distinguish fluctuating from non-fluctuating groups 
This present study aimed to investigate the involvement of LC pathology, α-synuclein, tau 
and Aβ, on the presence and severity of cognitive fluctuations in DLB. Although, significant 
differences were identified between the groups within the study, these differences were 
related to the pathological diagnosis rather than the presence or absence of cognitive 
fluctuations.  
Within the current investigation there was no observed difference between the nLBD 
groups with and without fluctuations. The majority of cases within each of the nLBD groups 
are classified as mixed AD/DLB, meeting the pathological criteria for both AD and DLB. The 
segregation based on the clinical presence of cognitive fluctuations between the nLBD 
groups also leads to a division based upon clinical phenotype. For nLBD cases with cognitive 
fluctuations, ten out of the twelve cases assessed were clinically classed as DLB; whereas 




classified as AD. A previous study investigating the effect of clinical phenotype on the 
pathological burdens of mixed AD/DLB identified a significant difference in tau, but not α-
synuclein or Aβ, burden in the LC between the mixed AD/DLB cases that were clinically AD 
compared to clinically DLB (Walker et al., 2015). Within the previous study, tau pathological 
burden was found to be significantly higher in those that were classified as clinically AD 
compared to those that were clinically DLB, a finding that was not replicated within the 
current study.  
The LC has been shown to be affected at a very early stage of disease progression by tau 
and α-synuclein pathology, Braak stage 0 b and Braak 2 respectively (Braak et al., 2003; 
Braak et al., 2011). The difference observed between tau pathology burden in clinically AD 
and DLB by Walker et al. (2015) was hypothesised to be due to an earlier progression of tau 
in the clinically AD cases, in the current study classified as nLBD without fluctuations. The 
clinically AD cases were hypothesised to have originated as AD cases, which then developed 
Lewy body pathology further along the disease course. Conversely, the clinically DLB cases, 
in the current study nLBD cases with fluctuations, were hypothesised to start as DLB which 
later developed AD-type pathology. Pathology in earlier affected regions has been shown to 
increase with disease progression (Walker et al., 2017). Therefore, it could be expected that 
the nLBD cases with cognitive fluctuations, clinically DLB, would possess higher levels of α-
synuclein in the earliest affected regions, including the LC, than clinically AD nLBD cases. 
However, this was not found in the present study or the previous study by Walker et al 
(2015).  
There has been a debate among researchers as to whether the progression of α-synuclein 
pathology occurs in the same manner in all LBDs, with different initial clinical presentations 
suggestive of differing initially affected regions. In DLB the spread of pathology has been 
proposed to originate in the amygdala (Beach et al., 2009) and the olfactory bulb 
(Cersosimo, 2017). If α-synuclein pathology was to originate in non-brainstem structures in 
DLB, and progress in an anterograde manner (Henderson et al., 2019), it would explain why 
α-synuclein pathological burdens in the LC do not differ between clinically AD and clinically 
DLB nLBD cases. Studies examining the SN in PD have identified an association between the 
number of Lewy bodies within the region and the number of dopaminergic neurons 




present. The LC, similarly to the SN, is subject to neuronal loss in neurodegenerative 
diseases. Therefore, a further hypothesis as to why α-synuclein pathological burdens in the 
LC did not differ between clinically AD and clinically DLB nLBD is due to loss of the neurons 
bearing Lewy bodies. The current study did not investigate neuronal loss in the LC; thus, it is 
not possible to control for the level of neuronal loss in the α-synuclein burden analysis. 
Previous studies have shown that it is pre-synaptic accumulations of α-synuclein and not 
Lewy bodies that leads to neuronal death and possible cellular dysfunction in DLB (Kramer 
and Schulz-Schaeffer, 2007). The presence of disease-relevant α-synuclein pathology in the 
presynaptic compartments of noradrenergic neurons could elicit neuronal dysfunction 
without detectable pathology present in the cell bodies in the LC. These presynaptic 
alterations could explain why, although alterations to the LC have been implicated in the 
pathophysiology of cognitive fluctuations, no specific pathological alterations within the 
soma of LC neurons were attributed to the presence of cognitive fluctuations. 
3.4.2 Tau burden was associated with CAF score 
The present study identified a positive association, when both DLB and nLBD with 
fluctuations groups were combined, but only in the nLBD group when analysed individually, 
between LC tau burden and CAF score. The association between tau and last CAF score was 
lost in the DLB group, when analysed separately from the nLBD with fluctuation group.  
Stimulation of the LC increases awareness and attention, with lesions leading to an increase 
in REM and SWS (Jones, 2005a; Jones, 2005b). The LC most densely innervates frontal 
regions, most specifically the PFC, where the noradrenergic projections have been 
implicated in behavioural flexibility and attentional systems (Borodovitsyna et al., 2017). 
Although tau pathology has been identified within the nucleus at a very early stage of 
disease progression, the presence and severity of tau specifically has been found not to 
relate to the level of neuronal loss observed within the nucleus both in AD and in DLB 
(Brunnstrom et al., 2011; Weinshenker, 2018). The lack of association between tau 
pathological burden and neuronal loss suggests that the presence of the pathology may not 
be the direct cause for the loss of neurons within the LC. However, tau could be a marker of 
dysfunction within the neuron and possibly the noradrenergic system as a whole, with 
alterations to the remaining LC neuronal morphology, synapses and dendrites having been 




was the frontal region that was affected first (Iba et al., 2015), and further studies have 
identified a distinct noradrenergic pathway from the LC to frontal regions (Chandler et al., 
2014). Together, this suggests how tau in the LC could lead to dysfunction within the 
noradrenergic system and its terminal regions. However, it does not explain how it could be 
specifically related to cognitive fluctuations, as although a relationship between tau and 
severity was observed in the nLBD group, there was no difference in the LC tau burden 
between the nLBD groups with and without fluctuations.  
Although an association was observed when both fluctuation groups were analysed 
together, when the two groups were analysed individually the association between tau and 
CAF score only remained in the nLBD group. The burden of tau in the nucleus could be 
representative of more severe degeneration within the LC or more severe tau deposition 
globally within the brain or general disease progression, that could lead to more severe 
cognitive fluctuations being present. However, as the association was only identified in the 
nLBD and not the DLB group when analysed individually, the relationship could be spurious 
with no meaningful biological effect. Due to the relatively small cohort sizes within the 
current study it is not possible to make firm conclusions. Any conclusions or hypotheses 
drawn from the present study, should be treated with caution until further experiments 
with additional cases can be undertaken, to assess if the results can be confirmed.  
3.4.3 Limitations 
A major caveat of the current study was that the LC was not sampled at a consistent level in 
all cases. Although all sections analysed came from within the same tissue block, containing 
the upper mid pons. Previous studies have identified that noradrenergic neurons in 
different LC regions preferentially innervate different cortical and sub-cortical regions (Ward 
and Gunn, 1976), and neuronal loss varies along the extent of the LC in AD (German et al., 
1992), although in PD this loss is more uniform in nature (Chan-Palay and Asan, 1989a). The 
variability within the level sampled could have affected made it harder to find relevant real 
changes if present. If regions that are known to highly innervate the frontal region had been 
consistently sampled it would have strengthened the ability to test the generated by the 
hypotheses.  
Another limiting factor of the study was the sample size, although 67 cases were utilised 




was retrospective, the sample size was further limited, as not all cases utilised had been 
assessed for cognitive fluctuations. This limited the number of cases that could be utilised to 
test associations with severity of cognitive fluctuations using CAF score. Although the 
pathological analysis that was undertaken was quantitative, rather than qualitative, in 
nature a large cohort would be required to attain more meaningful results. Therefore, the 
conclusions from this study should be validated with a larger cohort before meaningful 
results can be inferred. Pathological correlations with cognitive fluctuation measure were 
not corrected for multiple comparisons within this study. Although corrections such as 
Bonferroni adjustment can reduce type I error it is considered too conservative to be 
utilised in certain situations where it can increase the likelihood of type II errors (Armstrong, 
2014). Further investigations with a larger cohort, specifically a larger number of cases who 
have had their cognitive fluctuations assessed would be required to determine if the 
associations within the current study could withstand robust statistical testing.  
The current study only investigated the pathological burden of protein aggregates. 
However, limited relationships were observed between pathological protein burdens and 
clinical data. It could be possible that investigations into markers of cellular stress, neuronal 
loss or specific species of protein aggregates may have been more informative. Therefore, 
future investigations should focus on more specific changes to noradrenergic neurons.  
3.4.4 Conclusions 
This study aimed to investigate the pathological differences in the LC between cases that 
clinically presented with cognitive fluctuations and those that did not, along with 
investigating whether there was an association between pathological burden and cognitive 
fluctuation severity.  
The data showed pathological differences related to the pathological diagnosis of the cases, 
with no changes related specifically to the presence or absence of cognitive fluctuations. An 
association was observed between CAF score and tau pathological burden, only in the nLBD 
with fluctuation group. This association could reflect dysfunction in the noradrenergic 
system; however, it is difficult to assess whether the association is suggestive of a 
meaningful biological effect from the data obtained in the current study. It is likely that 
cognitive fluctuations are related to a global system failure rather than one specific change, 




with alterations to other neurotransmitter systems could lead to the presence of cognitive 
fluctuations. Investigations into cortical regions which receive noradrenergic projections and 






Chapter 4: Pathological studies in the pedunculopontine nucleus  
4.1 Introduction 
The PPN has been thought of as the main driver and critical cell group for waking and REM 
sleep in the ARAS (Garcia-Rill and Simon, 2015); and is highly interconnected with all of the 
major neurotransmitter systems involved in the ARAS (Benarroch, 2013; Beck and Garcia-
Rill, 2015; Yates and Garcia-Rill, 2015). Lesions to the PPN have been shown to alter or 
eliminate REM sleep (Shouse and Siegel, 1992; Deurveilher and Hennevin, 2001) and 
stimulation increasing waking like EEG activity (Steriade et al., 1991; Datta and Siwek, 1997). 
Alterations to the PPN have been observed in pathologies of wakefulness, such as 
narcolepsy, either directly though dysfunction to PPN neurons or indirectly via the inputs 
into the PPN (Yates and Garcia-Rill, 2015). Dysfunctional PPN output, directly or indirectly, 
could result in alterations to arousal and awareness through a changes to cortical 
stimulation (Yates and Garcia-Rill, 2015). 
Pathologically the PPN is affected by Lewy body pathology at an early stage of disease 
progression, Braak stage 3 (Braak et al., 2003; Grinberg et al., 2011). The PPN has been 
extensively examined in PD, in relation to a number of different clinical phenotypes, though 
there has been less focus on the nuclei in DLB. Loss of cholinergic PPN neurons is observed 
in PD, where studies have reported a 50% reduction (Pahapill and Lozano, 2000), as well as a 
reduction in neuronal size compared with controls, (Rinne et al., 2008b; Jenkinson et al., 
2009). The neuronal loss observed in PD was shown to correlate with the degree of 
dopaminergic loss (Di Giovanni et al., 2019). Loss of cholinergic neurons in the PPN leads to 
a subsequent loss of cholinergic innervation to the thalamus (Francis and Perry, 2007). 
The PPN is also known to play a role in locomotion and muscle tone through its ascending 
connections with the SN and globus pallidus internus and descending connections with the 
spinal cord (Shute and Lewis, 1967; Benarroch, 2013; Garcia-Rill and Simon, 2015). The role 
of the PPN regarding locomotion and muscle tone has led to researchers investigating its 
contribution to the postural instability gait difficulty (PIGD) parkinsonian phenotype 
(Hamani et al., 2016). The tremor dominant (TD) phenotype has mainly been ascribed to 
dopaminergic deficits, as the phenotype typically responds to dopaminergic treatments 
(Hughes et al., 1992; Thenganatt and Jankovic, 2014). To support this hypothesis 




severity of parkinsonian symptoms in PD (Zweig et al., 1989; Rinne et al., 2008a); and 
targeting the nucleus for DBS improved gait disturbances (Ferraye et al., 2010; Moro et al., 
2010).  
Although the PPN is one of the more well-studied nuclei in the context of arousal and motor 
control, there is a lack of research into the role of the PPN in DLB, and research has mainly 
having focused on cholinergic pathways rather than the nucleus. Stimulation of the PPN has 
been shown to have improved measures of executive function and working memory 
(Alessandro et al., 2010; Tykocki et al., 2011; Stefani et al., 2013) and lead to beneficial 
changes in sleep architecture (Stefani et al., 2007) in PD. Therefore, the improvement to 
sleep architecture and executive function through stimulation of the PPN, could suggest 
that there are salvageable neuronal projections that could be targeted in a less invasive 
manner to help improve the cognitive dysfunction in PD and possibly other Lewy body type 
diseases. Hence, the present study aimed to assess neuropathological changes to the PPN 
that could relate to, the presence and severity cognitive fluctuations and, the phenotype 
and severity parkinsonian features.  
4.1.1 Aims 
Using post-mortem tissue sections containing the PPN from DLB cases with fluctuations, 
compared to nLBD cases, both with and without cognitive fluctuations, AD cases without 
cognitive fluctuations, to control for the high levels of AD-type pathology in the nLBD cases, 
and aged cognitively normal controls, this study aims to: 
3. Quantify the burden of neuropathological protein lesions, utilising 
immunohistochemical techniques for Aβ, tau and α-synuclein 
4. Assess whether the neurodegenerative changes seen are related to the presence or 
severity of cognitive fluctuations, utilising neuropsychiatric data obtain intra vitam 
5. Assess whether the neurodegenerative changes seen are related to the different 
parkinsonian subtypes and the severity of parkinsonian symptoms. 
6. Evaluate whether levels of pathology in the PPN relate to levels of the pathology 






4.2.1 Study Cohort 
Five groups were included in the PPN study with a total of 52 cases (table 2.1): 11 DLB cases 
that had been recorded to experience cognitive fluctuations during life; 11 nLBD cases 
whom did not experience cognitive fluctuations during life, containing a mixture of mixed 
AD/DLB and DLB cases; 9 AD cases with no recorded experience of cognitive fluctuations 
during life; 11 nLBD cases whom did experience cognitive fluctuations during life, mixed 
AD/DLB; and 10 aged matched controls with no history of cognitive impairment. Cases that 
were uncooperative with neuropsychiatric testing or postulated to have cognitive 
fluctuations due to medicine regimes were excluded from the study. A subset of cases in the 
present study had cognitive fluctuation severity measured via CAF, 7 DLB with cognitive 
fluctuations and 8 nLBD with cognitive fluctuations. A further subset of 11 cases had their 
parkinsonian symptoms classified into either the PIGD or TD subtype.  
4.2.2 Tissue Acquisition 
The PPN is a large nucleus extending through the upper pons and midbrain (Hamani et al., 
2016). Sections for analysis were taken from the paraffin embedded formalin fixed tissue 
blocks containing the lower midbrain, as described in 2.4.4 and 2.4.5.  
4.2.2.1 Pedunculopontine nucleus localisation 
The PPN was identified within the sections by first assessing an LFB/H&E section from the 
lower midbrain to identify neuronal structures to ascertain the brainstem level in the 
brainstem atlas (Paxinos and Huang, 2013). If the section assessed by LFB/H&E contained 
structures known to be present at the same level as the PPN a sequential section underwent 
ChAT IHC. Three ChAT antibodies were utilised to locate the PPN for analysis (table 4.1). The 
rationale for the three ChAT antibodies being utilised was that the different epitopes of the 
antibodies enabled the identification of the PPN in more cases, as described below. The 
cases that were identified more preferentially by one antibody over another did not relate 
to the diagnosis of the case and it is currently unknown why some PPN regions were more 
immunopositive than others. 
Sections first underwent staining the goat-polyclonal ChAT antibody. With the antibody 
being raised in goat the normal IHC protocol, following antigen retrieval could not be 




0.9% H2O2 in 0.01M PBS with 0.1% triton (Sigma-Aldrich, Dorset, UK) for 30 minutes. 
Sections were then washed in PBS, prior to blocking in normal rabbit serum (Vector 
Laboratories, Burlingame, CA, USA), diluted 1:60 in PBS for 30 minutes. Block was washed 
off before immediate incubation in ChAT primary antibody serum for 1 hour at room 
temperature. Sections were then washed in PBS, prior to incubation in secondary 
biotinylated anti-goat antibody (Vector Laboratories, Burlingame, CA, USA) diluted 1:200 in 
1:60 normal rabbit serum in PBS for 30 minutes. Sections were then washed in PBS prior to 
incubation in ABC solution for 30 minutes at room temperature. Sections were washed in 
PBS and then acetate buffer, 100mM sodium acetate trihydrate (VWR, Lutterworth, UK) 
solution in H2O adjusted to pH 6.0 with acetic acid. Sections were then incubated for 10 
minutes at room temperature in DAB/Nickel solution: 233mM DAB, 7.5mM ammonium 
chloride, 11mM β-D+ glucose and 0.01% glucose oxidase, added to an 87mM diammonium 
nickel sulphate solution in acetate buffer. Sections were subsequently washed in acetate 
buffer prior to counterstaining and rehydration and mounting as described in 2.5. Upon 
examination of the slides stained using the goat-polyclonal ChAT antibody it was noted that 
although cholinergic structures within the sections were recognised (figure 4.1A), there was 
a high level of non-specific staining with non-cholinergic structures being immunopositive 
for ChAT staining. A number of cases at this stage, however, where identified as being too 
rostral to contain the PPN due to the presence of the oculomotor nucleus. Furthermore, the 
Table 4.1. Antibodies utilised in the pedunculopontine nucleus study.                                                                               





levels stated by the brainstem atlas were observed to be misleading, as the fixed tissue 
utilised was dissected at a different angle. Assessment of cases, for the PPN, at this stage 
was aided by the help of Dr. Chris Morris, an expert in brain anatomy. 
Sections thought to contain the PPN were then stained with mouse monoclonal ChAT 
antibody (figure 4.1B) following the protocol outlined in 2.5. Although, staining was intense 
when optimised in the striatum (figure 4.1D) when IHC was undertaken in the midbrain 
staining was much weaker. Utilising the mouse monoclonal ChAT, a number of cases were 
positively identified as containing the PPN, allowing for delineation of the region. Cases 
which were thought to contain the PPN but were immunonegative with the mouse 
monoclonal ChAT antibody underwent staining with a rabbit polyclonal ChAT antibody 
(figure 4.1C). Following assessment with the third ChAT antibody the PPN was identified in a 
total of 52/67 cases within the PhD cohort. 
A B 
C D 
Figure 4.1. Representative choline acetyltransferase staining in the midbrain and striatum.                                                                                                       
Choline acetyltransferase (ChAT) positive staining in the midbrain (A-C) and striatum (D). Representative images of A-
goat polyclonal ChAT, B- mouse monoclonal ChAT, C- rabbit polyclonal ChAT and D- mouse monoclonal ChAT in the 





Following identification of the PPN, consecutive sections underwent IHC staining, as 
described in 2.5, with antibodies against hyperphosphorylated tau (AT8), Aβ (4G8) and α-
synuclein (KM51) (table 4.1).  
A large image, with an area of 41.5mm2, was created by capturing and stitching 100 
adjacent, 10x10, single images at x100 magnification using NIS-Elements AR3.2 software 
(Nikon, Surrey), a Nikon 90i microscope, with a fully motorised stage, and DsFi1 camera 
microscope coupled to a PC.  
Stitched images were analysed using a standardised red-green-blue threshold on NIS 
elements AR3.2 software. Thresholds were determined for AT8, 4G8 and KM51 separately 
to detect only immunopositive signals, without detection of non-specific background. The 
PPN was delineated on the pathology sections by comparison to the ChAT section prior to 
application of the threshold (figure 2.6). 
4.2.3.1 LC pathology 
All cases within the current study also had the pathological burdens for 
hyperphosphorylated tau, Aβ and α-synuclein assessed and analysed in the LC, as described 
in 3.2.3.  
4.2.4 Statistical analysis 
Statistical analysis was conducted using SPSS v.26 (IBM). Variables were assessed for 
normality by the Shapiro-Wilk test and inspection of histograms and Q-Q plots. Pathology 
data was found to be non-normal, therefore, non-parametric tests were employed. To 
determine differences in pathological burden between the study groups Kruskal-Wallis and 
post-hoc Mann-Whitney were undertaken. To determine whether there was an association 
between pathological burden and severity of cognitive fluctuations as measured by CAF 
scores, Spearman’s rank correlations were conducted, firstly in both DLB and nLBD (mixed 
AD/DLB) with cognitive fluctuations together and then both groups separately. Corrections 
such as Bonferroni were not applied due to the fact that there is not a true null hypothesis 
because of the classification of neurogenerative diseases, for example AD will have higher 








No significant differences were observed in post-mortem delay, fixation duration, and age 
between the study groups. There was no significant difference observed in disease duration 
between the neurodegenerative disease groups. Between the groups a significant difference 
was found in the proportion of males to females, with the DLB group have a significantly 
higher proportion of males compared to nLBD with fluctuations (χ(1)=7.071, p=0.008), AD 
(χ(1)= 5.089, p=0.024) and controls (χ(1)=8.240, p=0.004). A trend to a significantly higher 
proportion of males in DLB compared to nLBD without fluctuations (χ(1)=3.667, p=0.056) 
was seen. 
CAF scores were available for 20/52 cases, and 15 cases with cognitive fluctuations 
possessed at least one CAF score. No significant difference was observed between the last 
(p=0.668), maximal (p=0.684) or average (p=0.536) CAF score between the DLB with 
fluctuations or the nLBD with fluctuations groups. 
Final MMSE scores were available for 44/52 cases: 10 DLB cases with fluctuations, 11 nLBD 
with fluctuations, 10 nLBD without fluctuations, 8 AD and 5 Controls. No significant 
difference in the interval between the last MMSE and death was observed between the 
groups. Significantly lower last MMSE scores were observed between: DLB cases with 
fluctuations (z=-16.050, p=0.021), nLBD with fluctuations (z=2.027, p=0.001), nLBD without 
fluctuations (z=-19.600, p=0.005) and AD cases (z=-20.330, p=0.005) and controls. No 
significant differences in last MMSE score were observed between the four disease groups. 
A number of cases were classified as either having the tremor predominant (n=3) or 
postural instability gait difficulty (n=8) parkinsonian symptom subtype.  
4.3.2 Pathology 
α-synuclein pathology was observed in all DLB cases with cognitive fluctuations, and the 
majority of nLBD cases with cognitive fluctuations, most frequently as Lewy bodies (figure 
4.2A). A significant main effect of disease group on α-synuclein was observed in the PPN 
(χ²=27.470, p<0.001) (figure 4.3A). α-synuclein pathological burden was higher in DLB with 
fluctuations (z=23.495, p=0.001), nLBD with fluctuations (z=-16.041, p=0.015) and nLBD 
without fluctuations (z=15.495, p=0.019) than controls. Pathological burden of α-synuclein 




(z=-22.924, p=0.001) and nLBD without fluctuations (z=22.379, p=0.001) than AD cases. No 
significant differences between the level of α-synuclein burden were observed between the 
nLBD groups with and without fluctuations (p=0.933) or between the DLB with fluctuations 
group and the nLBD groups with (p=0.248) and without (p=0.215) fluctuations. No 
significant difference was observed between AD and control cases.  
Tau pathological burden was observed in the majority of cases. The highest PPN tau burdens 
were observed in the AD and nLBD groups both with and without fluctuations, with cases 
containing neurofibrillary tangles, neuropil threads and neurites (figure 4.2B). A significant 
main effect of disease group on tau pathological burden was observed in the PPN 
(χ²=27.621, p<0.001) (figure 4.3B). Tau pathological burden was higher in nLBD with 
fluctuations (z=-26.400, p<0.001), nLBD without fluctuations (z=25.400, p<0.001) and AD 
cases (z=22.178, p=0.001) than controls. Pathological burden of tau was significantly higher 
in nLBD with fluctuations (z=-21.182, p=0.001), nLBD without fluctuations (z=-20.182, 
p=0.002) and AD cases (z=-16.960, p=0.013) than DLB with fluctuations. No significant 
differences between the level of tau burden were observed between the nLBD groups with 
and without fluctuations (p=0.877) or between the AD group and the nLBD groups with 
(p=0.535) and without (p=0.636) fluctuations. No significant difference was observed 
between DLB with fluctuations and control cases. 
Aβ pathology was observed in 70% of cases analysed, with 6 DLB and 9 control cases 
possessing no positive 4G8 staining (figure 4.2C). In the majority of cases Aβ pathology was 
higher in neighbouring regions rather than the PPN itself. A significant main effect of disease 
group on Aβ pathological burden was observed in the PPN (χ²=24.569, p<0.001) (figure 
4.3C). Aβ pathological burden was higher in nLBD with fluctuations (z=-28.186, p<0.001), 
nLBD without fluctuations (z=19.050, p=0.003) and AD cases (z=23.994, p<0.001) than 
controls. Pathological burden of Aβ was significantly higher in nLBD with fluctuations (z=-
19.182, p=0.002) and AD cases (z=-14.990, p=0.025) than DLB with fluctuations; DLB with 
fluctuations and nLBD without fluctuations did not have a significantly different Aβ burdens 
(p=0.112). No significant differences between the level of Aβ burden were observed 
between the nLBD groups with and without fluctuations (p=0.149) or between the AD group 
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Figure 4.2. Representative pathology in the pedunculopontine nucleus.                                                                                                                                                                                                    




difference was also observed between DLB with fluctuations or control cases. No other 
significant differences were observed between the disease groups. 
No associations were found for disease duration, across the disease groups, with α-






































































































































































































Figure 4.3. Pathology in the pedunculopontine nucleus.                                                                                                
Pathological burden data for A- α-synuclein, B- tau and C- Aβ in the pedunculopontine nucleus. Data is shown as 
median with interquartile range. ** p<0.01 ***p<0.001 compared to controls. Abbreviations: AD- Alzheimer’s 














4.3.3 Relationship to locus coeruleus pathology 
All cases that had pathological burden assessed for the PPN, also had the pathological 
burden assessed within the LC.  
In the whole cohort, excluding the control group, Spearman’s rank correlations revealed 
associations between pathological burden of α-synuclein, tau and Aβ in the LC and the 
pathological burdens in the PPN (table 4.2). PPN α-synuclein pathology was associated with 
LC pathological burden of α-synuclein positively (rs=0.641, p<0.001), tau negatively (rs=-
0.530, p<0.001) and Aβ negatively (rs=-0.432, p=0.004). PPN Aβ burden was associated with 
LC pathological burden of tau positively (rs=0.321, p=0.038) and Aβ burden positively 
(rs=0.386, p=0.012). PPN tau pathological burden was positively associated with the LC 
pathological burden of tau (rs=0.445, p=0.003). No other associations between PPN 
pathological burden and LC pathological burden were associated (table 4.2). 
When the fluctuation groups were assessed independently from each other no associations 
were observed between PPN pathological burden and LC pathological burden in the DLB, 
nLBD with cognitive fluctuations and AD cases (table 4.2). Within the nLBD without cognitive 
fluctuations group a negative association was observed between PPN α-synuclein pathology 
and LC Aβ pathology (rs=-0.618, p=0.043), no other associations between PPN and LC 
pathological burdens were observed within the fluctuation group (table 4.2). 
4.3.4 Relationship to cognitive fluctuations 
No association was observed between α-synuclein, tau or Aβ pathological burden and 
severity of cognitive fluctuations as measured by CAF score, in all cases that during life 
possessed cognitive fluctuations (table 4.3). When fluctuation groups were separated into 
DLB and nLBD with fluctuations no associations were observed between PPN pathological 






Table 4.4. Associations between pedunculopontine nucleus and locus coeruleus pathological burdens.                                                                                                                                                        
Data shown for the Spearman’s rank correlation between PPN pathology and LC pathological burden for α-synuclein, tau 
and Aβ. Correlations shown for:  All-whole cohort minus the control cases), DLB with cognitive fluctuations, nLBD with 
cognitive fluctuations, nLBD without cognitive fluctuations and AD cases. An Asterix indicates a significant result: * p<0.05 
** p<0.01 ***p<0.001. Abbreviations: AD- Alzheimer’s disease; DLB- dementia with Lewy bodies; LC- locus coeruleus 

























nLBD and DLB with 
cognitive fluctuations 
α-synuclein   rs=0.244, p=0.380 
 Tau rs=0.233, p=0.403 
 Aβ rs=-0.095, p=0.737 
 
DLB with cognitive 
fluctuations 
α-synuclein   rs=0.037, p=0.937 
 Tau rs=-0.206, p=0.658 
 Aβ rs=-0.208, p=0.655 
 
nLBD with cognitive 
fluctuations 
α-synuclein   rs=0.421, p=0.298 
 Tau rs=0.511, p=0.196 
 Aβ rs=-0.243, p=0.563 
    
Average CAF 
nLBD and DLB with 
cognitive fluctuations 
α-synuclein   rs=0.384, p=0.157 
 Tau rs=0.289, p=0.296 
 Aβ rs=0.016, p=0.954 
 
DLB with cognitive 
fluctuations 
α-synuclein   rs=0.180, p=0.699 
 Tau rs=0.072, p=0.878 
 Aβ rs=0.055, p=0.908 
 
nLBD with cognitive 
fluctuations 
α-synuclein   rs=0.551, p=0.157 
 Tau rs=0.359, p=0.382 
 Aβ rs=-0.192, p=0.649 
    
Maximum CAF 
nLBD and DLB with 
cognitive fluctuations 
α-synuclein   rs=0.225, p=0.420 
 Tau rs=0.284, p=0.305 
 Aβ rs=0.167, p=0.553 
 DLB with cognitive 
fluctuations 
α-synuclein   rs=-0.279, p=0.545 
 Tau rs=0.378, p=0.402 
 Aβ rs=0.563, p=0.188 
 nLBD with cognitive 
fluctuations 
α-synuclein   rs=0.332, p=0.422 
 Tau rs=0.485, p=0.223 
 Aβ rs=-0.013, p=0.976 
Table 4.7. Associations between cognitive fluctuation severity and pedunculopontine pathology.                                                                                                                                   
Spearman’s rank correlations between pedunculopontine pathology and severity of cognitive fluctuations as measure 
by last, average and maximum CAF score. Associations were undertaken in dementia with Lewy bodies and 
neocortical/limbic Lewy body disease both combined and individually. Abbreviations: CAF- clinical assessment of 
fluctuation: DLB- dementia with Lewy bodies; nLBD- neocortical/limbic pathologically Lewy body disease; rs- 
spearman’s rank coefficient. 
 
 
Table 4.8. Associations between cognitive fluctuation severity and pedunculopontine pathology.                                                                                                                                   
Spearman’  rank correlations between pedunculopontine pathology and severity of cognitive fluctuatio s as measure 
by last, average and maximum CAF score. Associations were undertaken in dementia with Lewy bodies and 
neocortical/limbic Lewy body disease both combined and individually. Abbreviations: CAF- clinical assessment of 
fluctuation: DLB- dementia with Lewy bodies; nLBD- neocortical/limbic pathologically Lewy body disease; rs- 





4.3.5 Relationship to parkinsonian subtype  
In the cases that had been classified as being either tremor predominant or postural 
instability gait difficulty parkinsonian subtype, there was no difference in the level of PPN α-
synuclein (p=0.376), tau (p=0.194) or Aβ (p=0.376) pathological burden observed between 













































































Figure 4.4. Pedunculopontine nucleus pathology in parkinsonian subtypes.                                                                                                                                                                                  
Pathological burden for A- α-synuclein, B- tau and C- Aβ between the PIGD and TD parkinsonian subtypes. 





The present study identified no relationship between pathological burden of α-synuclein, 
tau and Aβ, and the presence of cognitive fluctuations. Similarly, no association was found 
between pathological burden and the severity of cognitive fluctuations as measured by CAF 
scores in either the combined or separate DLB and nLBD with cognitive fluctuation groups. 
However, associations were found between that pathological burdens in PPN and those in 
the LC within the whole cohort, excluding controls. Although, the majority of these 
associations were lost when the cohort was split into individual fluctuation groups. 
Furthermore, the study identified no difference in the PPN pathological burden between 
those classified as having a PIGD or TD parkinsonian subtype.  
4.4.1 Pathology in the PPN does not relate to the presence or severity of cognitive 
fluctuations 
Previous studies have investigated the vulnerability of the PPN to accumulation of 
pathological proteins and neuronal loss in a number of neurodegenerative diseases, 
including AD and LBD (Rinne et al., 2008b; Dugger et al., 2012; Seidel et al., 2015). The 
results from the current study are in agreement with previous findings that the PPN is 
vulnerable to α-synuclein and AD-type pathology. However, the present study extends the 
current findings to include the pathological vulnerability of the region in those diagnosed 
with mixed AD/DLB, with data showing that the region is vulnerable to all three pathological 
proteins investigated in these cases. 
The PPN has been described as a key centre in the ARAS, and is most active during waking 
and REM sleep (Jenkinson et al., 2009; Benarroch, 2013). Alterations to the PPN have been 
implicated in a number of clinical phenotypes including cognitive fluctuations, PIGD subtype 
and RBD; with an MRI study identifying an association with volumetric changes in the PPN 
and visual hallucinations in PD and PDD (Janzen et al., 2012). A previous retrospective study 
undertaken by Dugger et al. (2012) examined the role of α-synuclein and tau pathology in 
the PPN and LC in regards to RBD. The study identified no differences in the pathological 
burden between LBD cases with and without RBD, similar to the results from our study 
where no difference was observed in pathological burden between cases with and without 
cognitive fluctuations. As suggested by Dugger et al. (2012), although the PPN is a key 




high frequency EEG required for arousal, it could be possible that the clinical phenotype of 
RBD, or in this case cognitive fluctuations could be a product of a network dysfunction. 
Dysfunction to the PPN could be a factor but not a key role within the dysfunctional network 
suggesting why no associations were observed between pathological burdens and the 
presence of cognitive fluctuations.   
Rodent models have also identified that lesions of the PPN can elicit fluctuations in 
consciousness (Cyr et al., 2015). However, these lesions were acute in nature and do not 
represent the chronic and progressive nature of changes seen in neurodegenerative 
diseases. Whereas, other studies have identified that lesions to the PPN do not have the 
effect on wakefulness as would be expected, due to there being compensation from other 
regions, with lesions affecting REM and SWS but not affecting the ability of the PPN to 
maintain high frequency EEG activity which is required for the maintenance of arousal and 
waking (Mahaffey and Garcia-Rill, 2015). The lesions are also not known to affect higher 
cognitive functions (Mahaffey and Garcia-Rill, 2015). These studies further suggest that 
single lesions may not be the sole underpinning factors for complex clinical phenotypes and 
that network disturbances may be the main factor.  
The PPN is a highly interconnected nucleus (Mahaffey and Garcia-Rill, 2015). The midlatency 
auditory P50 potential is functionally related to arousal state and has been postulated to be 
a proxy measure of PPN activity (Hyde and Garcia-Rill, 2015). Dysfunction to PPN activity has 
been identified in PD patients, as studies have identified increases to the amplitude and 
decreased habituation of the P50 potential that suggest overactivation of the PPN (Teo et 
al., 1997). A further study has demonstrated the P50 potential returned to normal levels 
immediately after a bilateral pallidotomy, which could indicate that the increased PPN 
output was reinhibited and restored to normal levels (Teo et al., 1998). With no pathological 
findings within the PPN having been found to relate to the presence of cognitive 
fluctuations it could be that dysfunction to the PPN is in part caused by dysfunction to its 
inputs including the LC, which synapses with both the cholinergic and non-cholinergic 
neurons in order to control activity levels in the PPN. The main output centre for the PPN 
arousal-mediating neurons is the thalamus. A number of different studies have identified 
molecular alterations, including increased thalamic dopamine D2 receptor levels in DLB with 




patients with more severe fluctuations related to greater connectivity to the left thalamus 
and decreases connectivity for the right thalamus (Chabran et al., 2020), to the thalamus in 
DLB. Studies have observed alterations to the cholinergic system in the thalamus relating to 
cognitive fluctuations; including preservation of thalamic nicotinic receptors in those with 
fluctuations compared to those without (Pimlott et al., 2006) and increased levels of 
acetylcholine precursors which were closely related to the presence and severity of 
fluctuations (Delli Pizzi et al., 2015). Studies have also noted that loss of cholinergic neurons 
in the PPN leads to a decrease in cholinergic innervation to the thalamus (Francis and Perry, 
2007). From these studies it could be suggested that neurodegenerative and molecular 
alterations occur to PPN cholinergic neurons both within the PPN and its synaptic regions 
that relate to the presence and severity of cognitive fluctuations. However, these changes 
may be independent from the pathological protein accumulation within the region. 
Quantification of cholinergic neuronal number was not undertaken within the current study 
and thus neuronal counts would be required to assess whether pathological burden was 
related to loss of neurons within the region. 
4.4.2 PPN pathology relates to LC pathology in the whole cohort but not in individual groups 
When the whole cohort, excluding the controls, was analysed a number of relationships 
between the level of pathological proteins in the PPN and LC were identified. However, 
upon examination of the fluctuation groups individually the majority of these relationships 
were lost, with only an association between PPN α-synuclein and LC tau in the nLBD without 
cognitive fluctuations group remaining. The likely cause of the associations observed in the 
whole cohort are group effects due construction of the cohort, with pathologically AD cases 
having higher AD-type pathology in both the LC and PPN compared to DLB cases. These 
group differences would drive an apparent association which was then lost upon 
examination of the groups separately. The association observed within the individual nLBD 
without cognitive fluctuations group could again be driven by the fact that the group is 
formed by both mixed AD/DLB and DLB cases who did not possess cognitive fluctuations 
clinically. As DLB and mixed AD/DLB, within the current study had been shown to have 
significantly different levels of PPN and also LC pathology (Chapter 3) this could have driven 




pathological mixed AD/DLB and DLB would identify whether this association is driven by 
group factors. 
The LC is highly interconnected with the PPN, with the PPN receiving both excitatory and 
inhibitory projections from the PPN in order to control PPN neuronal firing (Mahaffey and 
Garcia-Rill, 2015). With the PPN and LC thought to be vulnerable to α-synuclein at an early 
stage of disease progression it is surprising that pathology within the two nuclei does not 
progress at a similar rate. With neuronal loss known to occur in both the PPN and LC in a 
number of neurodegenerative dementias (Dugger et al., 2012), neurons bearing α-synuclein 
pathology could have died leading to a loss of relationship between the pathological burden 
in the two nuclei in pathologically DLB cases. 
4.4.3 PPN pathology does not distinguish parkinsonian subtypes 
Loss of cholinergic neurons within the PPN has been previously described to associated with 
gait and postural parkinsonian symptoms (Karachi et al., 2010); with gait and postural 
symptoms resistant to levodopa treatment unlike tremor symptoms which have been 
proposed to be due to nigrostriatal dopaminergic denervation (Grabli et al., 2012). The 
results from the current study identified no difference in the pathological burden of α-
synuclein, tau or Aβ in the PPN between those classified as either having the PIGD or TD 
subtype.  
The underlying differences between the TD and PIGD subtypes has been a focus for PD-
related research for a number of years. However, the classification of the symptoms into 
two subgroups has not been without controversy. A number of studies have investigated 
the progression and pathological differences between the two subgroups with varying 
results. Studies have reported that patients with a TD subtype have a better prognosis and 
mild progression rate compared to those with a PIGD subtype (Lee et al., 2019), which could 
suggest a more ‘pure’ dopaminergic pathology in those classified as TD. However, studies 
investigating the pathologies have identified differing and conflicting results about 
dopaminergic dysfunction between the two subtypes, with more dopaminergic dysfunction 
observed via imaging in PIGD groups than TD at baseline (Lee et al., 2019). Together the 
data from Lee et al. (2019) could suggest that differences between the two subtypes may 
not be as clear cut as dopaminergic vs cholinergic dysfunction, which could explain why no 




study. Alterations to DaTSCAN ligand binding have been shown to reflect changes to 
neuronal number and not pathological burden in the SN (Colloby et al., 2012), with further 
studies observing no relationship between imaging findings and Braak stage (Burke et al., 
2008; Lee et al., 2019) and no associations between α-synuclein pathology and motor 
dysfunction (Parkkinen et al., 2005). From these studies it could be suggested that loss of 
PPN cholinergic neurons, which have previously been shown to relate to gait impairments 
(Rinne et al., 2008b), could differ between the two subtypes, irrespective of the level of 
pathological burden. However, due to the group numbers utilised and lack of neuronal 
counting, a follow-up study with large cohort numbers and assessment of cholinergic 
neuronal numbers in the TD and PIGD groups are needed to validate this result. It could also 
be suggested that it is the balance between dopaminergic and cholinergic deficits that 
underlie the PIGD and TD subtypes and thus further studies investigating the ratio between 
SN and PPN neurodegenerative changes are required. 
4.4.4 Limitations 
The most influential caveat of this study was the relatively small cohort, 56 cases across five 
groups. Although quantitative neuropathological assessment provides an accurate 
representation of the pathological burden, large cohorts are required to obtain significant 
statistical results. Therefore, the results should be confirmed utilising a larger cohort. 
Correlations within the current study were not corrected for multiple comparisons. 
Although corrections such as Bonferroni adjustment can reduce type I error, it is considered 
too conservative to be utilised in certain cases where it can increase the likelihood of type II 
errors (Armstrong, 2014). In the current study corrections would have been too 
conservative, previous studies have inferred relationships between pathology in the PPN 
and LC due to their close proximity and inter connectivity, along with previously described 
patterns of spread for pathological proteins (Braak et al., 2003; Braak et al., 2006; Braak et 
al., 2011).  
A limitation to a retrospective anatomical study was that stereological analysis of the entire 
region was not possible. The PPN is known to be heterogeneous structure and different 
locations within the PPN project to different anatomical locations and have differing 
cognitive and motor effects. This has been exemplified by the fact PPN DBS does not have 




2016). Although the pathological findings are in agreement with previous studies (Dugger et 
al., 2012), the lack of a consistent level analysed within the region could explain why no 
relationship was observed with cognitive fluctuations. Lack of neuronal count data also 
limited the study’s ability to relate neuropathological findings to changes in neuronal 
number and clinical data which would have further strengthened the study. Future studies 
should aim to utilise a single ChAT antibody using a stereological method to assess neuronal 
levels within cases that have experienced cognitive fluctuations. 
The cohort utilised within this study was limited as it required tissue samples that had 
information relating to cognitive fluctuations status obtained during life. With the 
structuring of the cohort related to cognitive fluctuations as well as it being a retrospective 
study not all cases had additional clinical data including parkinsonian subtype. This led to a 
smaller subset of cases being utilised for investigation into parkinsonian phenotypes.  
Secondly due to the remit of the study, the pathological burden within the SN was not 
investigated which would have strengthened the study in relation to the role of the 
cholinergic system in the PIGD subtype, with the possible calculation of the relative 
dopaminergic to cholinergic dysfunction. Although a limiting factor to further examine this 
by increasing the number of TD cases is that pathways involved in cognitive impairment are 
thought to overlap with those impaired in the PIGD subtype, meaning DLB or mixed AD/DLB 
cases are more likely to be classified as PIGD (Zuo et al., 2017), with TD cases slower to 
progress to dementia (B. Tilley 2020, personal communication, 22nd May 2020).  
4.4.5 Conclusions 
The study aimed to investigate the pathological difference in the PPN between cases that 
clinically presented with cognitive fluctuations and those that did not. Along with 
investigating the difference in pathological burden in the PPN between TD and PIGD 
parkinsonian subtypes. 
The data showed pathological differences in the PPN related to the pathological diagnosis of 
the cases, with no changes specifically related to the presence or absence of cognitive 
fluctuations. This could suggest that cognitive fluctuations could be the result of more 
widespread changes within the brain or changes that are ‘upstream’ of the PPN that are 
independent from PPN pathological burden, with changes having already been observed to 




also showed that there were no pathological differences in the PPN between those 





Chapter 5: Pathological studies in the raphe nucleus 
5.1 Introduction 
The rostral raphe, including the DR and MnR subnuclei, has been proposed to play an 
important role in the maintenance of sleep and wake states (Monti, 2011), and forms part 
of the ventral ARAS pathway (Zeman, 2001). Serotonergic neurons in the DR are thought to 
fire maximally during waking and cease during REM sleep (Trulson and Jacobs, 1979; 
Mahaffey and Garcia-Rill, 2015), indicating that the nucleus promotes wakefulness. 
However, studies have identified lesions of the raphe can elicit states of permeant 
wakefulness (Jouvet, 1968), with depletion of cortical serotonin having a sedative effect 
(Brodie et al., 1955), suggestive that the raphe plays a complex role in the maintenance of 
arousal states. Alterations to sleep-wake states, including insomnia, increase in proportion 
of REM sleep and reduction in slow-wave sleep duration, have been observed in 
serotonergic system disturbances, including depression (Murphy and Peterson, 2015); with 
antidepressant drugs, including selective serotonin reuptake inhibitors, altering the levels of 
arousal, sleeping efficiency (Dorsey et al., 1996) and exacerbating (Gagnon et al., 2006) or 
inducing RBD symptoms (Schenck et al., 1992).  
In DLB, clinical features, including the presence of depression and anxiety, would imply 
serotonergic dysfunction, including RBD, depression and alterations to arousal levels, are 
suggestive of serotonergic dysfunction (McKeith et al., 2017). Pathologically the raphe is 
affected by Lewy body pathology at Braak stage 2, the same timepoint as the LC (Braak et 
al., 2003), with detectable alterations to the neurotransmitters thought to be present at this 
stage (Boeve, 2013). Degeneration of both DR and MnR neurons have been reported in DLB, 
although this loss was not related to any clinical features, including depression (Benarroch 
et al., 2007). Alterations to regions that the serotonergic system innervates, including 
atrophy of the basal forebrain (Grothe et al., 2014) and volumetric reductions in the 
hypothalamus associated with changes to arousal (Whitwell et al., 2007), have been 
identified in DLB. Despite the link between the raphe, serotonergic system and arousal, no 
neuropathological studies have investigated the role of the raphe in cognitive fluctuations in 
DLB. Therefore, the present study aimed to assess neuropathological changes to the raphe 





Using post-mortem tissue sections containing the raphe from DLB cases with fluctuations; 
nLBD cases, both with and without cognitive fluctuations; AD cases without cognitive 
fluctuations; PDD cases and aged cognitively normal controls, this study aims to: 
1. Quantify the burden of neuropathological protein lesions, utilising 
immunohistochemical techniques for Aβ, tau and α-synuclein 
2. Quantify the expression levels of TPH2, utilising immunofluorescence techniques  
3. Assess whether the neurodegenerative changes seen are related to the presence or 






5.2.1 Study Cohort 
5.2.1.1 Raphe pathology and immunofluorescence cohort 
Five groups were included in the raphe pathology study and the immunofluorescent analysis 
with a total of 65/47 cases respectively (table 2.1): 13/10 DLB cases with cognitive 
fluctuations; 13/10 nLBD cases without cognitive fluctuations; 10/7 AD cases without 
cognitive fluctuations; 12/10 nLBD with cognitive fluctuations; and 17/10 aged matched 
controls with no history of cognitive impairment. One DLB case with a history of cognitive 
fluctuations underwent immunofluorescence analysis but did not undergo pathological 
analysis in the raphe.  
Within the study cohort a number of those with a history of cognitive fluctuations had the 
severity of these measured via CAF. For the raphe pathology analysis, 8 DLB with cognitive 
fluctuations and 9 nLBD with cognitive fluctuations; within the raphe immunofluorescence 
subset CAF scores were available for 9 DLB with cognitive fluctuations and 9 nLBD with 
cognitive fluctuations, allowing associations with severity of the fluctuations to be assessed. 
Within the cases that had a history of cognitive fluctuations, in both the main cohort and 
subset utilised for immunofluorescence, 16 cases had neuropsychiatric scores relating to 
depression severity. 9 DLB and 7 nLBD with fluctuations had at least one Geriatric 
depression scale (GDS) score available. The average GDS score was calculated for each case. 
Average GDS score was utilised due to the large variation in time from last GDS score till 
death, as well as taking into account any fluctuations in depression severity if multiple 
scores were recorded.   
 5.2.2 Tissue Acquisition 
The raphe nuclei is a collection of sub-nuclei located along the entire rostro-caudal aspect of 
the brainstem (Hornung, 2003). Sections for analysis were taken from paraffin embedded 




5.2.2.1 Raphe localisation 
The raphe nuclei, DR and MnR, were identified within sections by immunostaining against 
the serotonin synthesis enzyme tryptophan hydroxylase, as outline in 2.5. Sections were 
stained with antibodies against tryptophan hydroxylase 1 and TPH2 (figure 5.1), to assess 
which marker would best identify the serotonergic neurons of the raphe. TPH2 was 
identified as the best marker for the raphe, consistent with the fact TPH2 is the more 
abundant isoform expressed in the brain (Hasegawa and Nakamura, 2010). Following the 
validation of TPH2 all sections underwent TPH2 IHC to identify the raphe. The raphe nuclei, 






Figure 5.1. Representative tryptophan hydroxylase 1 and 2 positive staining.                                                       
Representative images of A- tryptophan hydroxylase 1 and B- tryptophan hydroxylase2 in the upper pons. Scale bar 











Consecutive sections, following the section assessed with TPH2 identifying the raphe, 
underwent IHC staining, as described in 2.5, with antibodies against hyperphosphorylated 
tau (AT8), Aβ (4G8) and α-synuclein (KM51) (table 5.1). A large image, with an area of 
46.1mm2, was created by capturing and stitching 112 adjacent, 8x14, single images at x100 
magnification using NIS-Elements AR3.2 software (Nikon, Surrey), a Nikon 90i microscope, 
with a fully motorised stage, and DsFi1 camera microscope coupled to a PC.  
Stitched images were analysed using a standardised red-green-blue threshold on NIS 
elements AR3.2 software. Thresholds were determined for AT8, 4G8 and KM51 separately 
to detect only immunopositive signals, without detection of non-specific background. The 
threshold for 4G8 also included a size threshold to ensure intracellular Aβ, APP, was 
excluded from the analysis. The raphe was delineated on the pathology sections by 
comparison to the TPH2 section prior to application of the threshold (figure 2.6). The DR 
and MnR were delineated and analysed as a single unit. A further threshold was determined 
for TPH2 to detect immunopositive signals, to assess the percentage area stained for the 
serotonin synthesis enzyme.  
 
Antibody Manufacturer Dilution Antigen Retrieval 
AT8, hyperphosphorylated 
tau 
Autogen, MA, USA 1:4000 0.1M Citrate pH 6.0 
4G8, Aβ Covance, NJ, USA 1:15000 Formic acid (1 hour) 
KM51, α-synuclein Leica Biosystems, 
UK 
1:200 Formic Acid (10 














0.1M Citrate pH 6.0 
pS129, α-synuclein 
phosphorylated at Serine 
129 
Abcam, UK 1:200 0.1M Citrate pH 6.0 
Table 5.1. Antibodies utilised in the raphe study.                                                                                                                         
Optimised dilutions and antigen retrieval protocols for the antibodies utilised in the raphe study. Abbreviations: IF-
immunofluorescence; IHC- immunohistochemistry. 
 
Table 5.2. Antibodies utilised in the raphe study.                                                                                                                         
Optimised dilutions and antigen retrieval protocols for the antibodies utilised in the raphe study. Abbreviations: IF-




5.2.3.1 LC and PPN pathology 
All cases within the raphe pathology study also had the pathological burdens for 
hyperphosphorylated tau, Aβ and α-synuclein assessed and analysed in the LC, as described 
in 3.2.3. 50/65 cases also had neuropathology evaluated in the PPN: 10 DLB with cognitive 
fluctuations, 11 nLBD without fluctuations, 11 nLBD with fluctuations, 8 AD and 10 controls, 
as described in 4.2.3. 
5.2.4 Immunofluorescence 
A consecutive section to those that were assessed for pathological staining underwent 
double immunofluorescent labelling, as described in 2.7, for TPH2 and α-synuclein (pS129) 
(table 5.1). 
Sections were manually imaged at x100 magnification, captured using a Nikon 90i 
microscope with a fully motorised stage, and DsQi1Mc camera microscope coupled to a PC. 
Images obtained covered the whole raphe, including the DR and MnR. Sections were imaged 
twice, firstly to obtain a TPH2 (FITC/green channel) only image for analysis of TPH2 intensity. 
Secondly the section was captured to obtain a merged (FITC, TRITC and DAPI channels) 
image to identify TPH2-positive neurons that contained Lewy bodies. The multiple adjacent 
images, both single channel and merged, were then manually stitched together based upon 
overlapping landmarks to create a large single image of the region of interest (figure 2.8).  
5.2.4.1 Intensity analysis of immunofluorescence 
Individual TPH2-positive neuron intensity was assessed within the raphe as outlined in 
2.8.2.1. Individual TPH2-positive neurons were delineated with the area integrated intensity 
and mean grey value measured. The number of TPH2-positive neurons delineated per case 
ranged from 16-688, with a mean of 192. Background measurements from 30-40 areas 
within the raphe were taken to provide an average background measurement for the region 
of interest. The corrected total cell fluorescence for each individual TPH2-positive neuron 




The corrected TPH2 intensity was adjusted for area to account for atrophic neurons. The 
median corrected TPH2 intensity for all assessed TPH2-positive neurons was calculated for 




 z-scores were calculated to assess variability within the corrected TPH2 intensity values 
across all the disease groups and controls. As the corrected TPH2 intensity data was not 
normally distributed the data was log transformed to a natural logarithm (log10). The mean 
and standard deviation for the log transformed corrected TPH2 intensity data for all control 
cases that underwent immunofluorescent analysis was calculated. The individual z-scores 
were then calculated using the following formula, where the mean and standard deviation 




A z-score was calculated for each TPH2-positive neuron analysed. The proportion of neurons 
in each case that had a z-score less than -1 and less than -2 was then calculated. 
5.4.4.2 Analysis of colocalization 
Utilising the merged image, the total number of TPH2-positive within the section were 
counted and the percentage bearing α-synuclein calculated (figure 2.9). Through 
comparison of the merged image to the green, TPH2, only, corrected TPH2 intensity 
adjusted for area was calculated for the TPH2-positive neurons containing Lewy bodies. The 
cytoplasm of the Lewy body containing neurons was also delineated, to calculate the 
corrected TPH2 intensity adjusted for area of the cytoplasm of TPH2-positive neurons 
bearing Lewy bodies, (figure 5.2). 
A ratio was calculated to calculate the magnitude of difference in the median corrected 
TPH2 intensity value for the TPH2-postive neurons without Lewy bodies and the median 
corrected TPH2 intensity value for the TPH2-postive neurons with Lewy bodies. A further 
ratio was calculated between the median corrected TPH2 intensity value for the TPH2-
postive neurons without Lewy bodies and the median corrected TPH2 intensity value for the 
part of the neuron that the Lewy body did not occupy in Lewy body bearing TPH2-postive 
neurons. For the two ratios calculated a value of 1 would suggest that the corrected TPH2 
intensity values are the same for the TPH2-positive neurons without Lewy bodies and those 
with Lewy bodies, including or excluding the Lewy body respectively. A ratio value >1 would 
suggest the corrected TPH2 intensity value is higher in the TPH2-positive neurons with Lewy 
bodies. A ratio value <1 would suggest the corrected TPH2 intensity value is higher in TPH2- 




5.2.6 Statistical analysis 
Statistical analysis was conducted using SPSS v.26 (IBM). Variables were assessed for 
normality by the Shapiro-Wilk test and inspection of histograms and Q-Q plots. A normal 
distribution could be assumed for the two ratios and the proportion of TPH2-positive 
neurons that contain Lewy bodies. Therefore, on the normally distributed data ANOVA was 
conducted with Tukey’s HSD as the post-hoc test. However, pathology data, corrected TPH2 
intensity data, and the z-scores were found to be non-normal leading to non-parametric 
tests being employed. To determine differences in the non-normally distributed data 
Kruskal-Wallis and post-hoc Mann-Whitney were undertaken. A one-sample Wilcoxon 
signed rank test was utilised to determine whether the corrected TPH2 intensity ratios 
calculated deviated from a median of 1. 
To determine whether there was an association between any pathology measures or 
immunofluorescence intensity and neuropsychological data obtained intra vitam 
Spearman’s rank correlations were conducted. Corrections such as Bonferroni were not 
A B C 
D E 
Figure 5.2. Analysis of α-synuclein and tryptophan hydroxylase 2 colocalization.                                                                                                                             
A- ps129 only, B- TPH2 only, C- merge all channels: DAPI, pS129 and TPH2, D- delineation of the Lewy body containing 
TPH2-positive neuron, E- delineation of the cytoplasm of TPH2- positive neuron bearing a Lewy body. Scale bar 10µm. 




applied due to the fact that there is not a true null hypothesis because of the classification 
of neurogenerative diseases, for example AD will have higher levels of AD-type pathology 





5.3.1 Raphe pathology 
5.3.1.1 Demographics 
No significant differences were observed in post-mortem delay, fixation duration, and age 
between the study groups. There was no significant difference in disease duration between 
the neurodegenerative disease groups. Between the groups a significant difference was 
found in the proportion of males to females, with the DLB group have a significantly higher 
proportion of males compared to nLBD without fluctuations (χ(1)=4.248, p=0.039 and 
controls (χ(1)=5.792, p=0.016). No further differences in the proportion of males to females 
were observed. 
CAF scores were available for 24/65 cases. 17/25 of the cases with cognitive fluctuations 
possessing at least one CAF score. No significant difference was observed between the last 
(p=0.728), maximal (p=0.592) or average (p=0.837) CAF score between the DLB with 
fluctuations or the nLBD with fluctuations groups. 
Final MMSE scores were available for 53/65 cases: 12 DLB cases with fluctuations, 12 nLBD 
with fluctuations, 12 nLBD without fluctuations, 9 AD and 9 Controls. No significant 
difference in the interval between the last MMSE and death was observed between the 
groups. Significantly lower last MMSE scores were observed between all disease groups and 
controls: DLB cases with fluctuations (z=-20.889, p=0.002), nLBD with fluctuations 
(z=27.222, p<0.001), nLBD without fluctuations (z=-25.237, p<0.001) and AD cases (z=-
26.056, p<0.001). No significant differences in last MMSE score were observed between the 
four disease groups. 
At least one GDS score was available for 29/65 cases: 9 DLB cases with fluctuations, 7 nLBD 
with fluctuations, 3 nLBD without fluctuations, 3 AD and 7 Controls. No significant 
difference in average GDS score was observed across the groups within the study. 
5.3.1.2 Pathology 
α-synuclein pathology was observed in all DLB cases with cognitive fluctuations, most 
frequently as Lewy bodies (figure 5.3B). A significant main effect of disease group was 
observed on α-synuclein burden in the raphe (χ²=34.538, p<0.001) (figure 5.4A). α-synuclein 







Figure 5.3. Representative pathology in the raphe.                                                                                                                                                                                                                                            
Representative images of A- tryptophan hydroxylase 2 (TPH2) B- α-synuclein (KM51), C- tau (AT8), D-Aβ (4G8).  Scale bar 1000µm, inset 100µm. IV- IV ventricle  
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Figure 5.4. Pathology and tryptophan hydroxylase 2 in the raphe.                                                                                   
Pathological burden data for A- α-synuclein, B- tau and C- Aβ. D- immunopositivity for tryptophan hydroxylase 2. Data 
is shown as median with interquartile range. *p<0.05 ** p<0.01 ***p<0.001 compared to controls. Abbreviations: AD- 




























































































































































































































































































with fluctuations (z=-19.662, p=0.005) and nLBD without fluctuations (z=18.566, p=0.007) 
than controls. Pathological burden of α-synuclein was significantly higher in DLB with 
fluctuations (z=36.715, p<0.001), nLBD with fluctuations (z=-21.850, p=0.006) and nLBD 
without fluctuations (z=20.754 p=0.008) than AD cases. DLB with fluctuations had a 
significantly higher pathological burden in the raphe compared to nLBD with cognitive 
fluctuations (z=15.962, p=0.030) and nLBD without cognitive fluctuations (z=14.865, 
p=0.047). No differences in pathological burden were observed between controls and AD 
cases (p=0.769) or nLBD with and without cognitive fluctuations (p=0.884). 
Tau pathological was observed in the all DLB and nLBD cases. The highest raphe tau burdens 
were observed in the AD and nLBD groups both with and without fluctuations, with cases 
containing neurofibrillary tangles, neuropil threads and neurites (figure 5.3C). A significant 
main effect of disease group on tau pathological burden was observed in the raphe 
(χ²=39.952, p<0.001) (figure 5.4B). Tau pathological burden was higher in nLBD with 
fluctuations (z=-29.108, p<0.001), nLBD without fluctuations (z=33.557, p<0.001), AD cases 
(z=39.241, p=0.001) and DLB with fluctuations (z=14.095, p=0.043) than controls. 
Pathological burden for tau was significantly higher in AD cases (z=-16.862, p=0.012), nLBD 
with fluctuations (z=-15.013, p=0.047) and nLBD without fluctuations (z=-19.462, p=0.009) 
than DLB with fluctuations. No significant differences between the level of tau burden were 
observed between the nLBD groups with and without fluctuations (p=0.557) or between the 
AD group and the nLBD groups with (p=0.211) and without (p=0.475) fluctuations.  
Aβ pathology was observed in all AD and nLBD with fluctuation cases, with a number of DLB 
and control cases possessing no positive 4G8 staining (figure 5.3D). A significant main effect 
of disease group on Aβ pathological burden was observed in the raphe (χ²=17.549, p=0.002) 
(figure 5.4C). Aβ pathological burden was higher in nLBD with fluctuations (z=-16.750, 
p=0.005), nLBD without fluctuations (z=15.000, p=0.011) and AD cases (z=23.400, p<0.001) 
than controls. Pathological burden for Aβ was significantly higher in AD cases (z=-14.990, 
p=0.025) than DLB with fluctuations. No significant differences between the level of tau 
burden were observed between the nLBD groups with and without fluctuations (p=0.784) or 
between the AD group and the nLBD groups with (p=0.330) and without (p=0.210) 




the nLBD with (p=0.110) or without fluctuations groups (p=0.176) or control cases 
(p=0.266). 
No associations were found between disease duration, across the disease groups, and α-
synuclein (p=0.230), tau (p=0.622) or Aβ (p=0.194) raphe pathological burden.  
5.3.1.3 TPH2 Immunopositivity 
TPH2 immunopositivity was measured utilising IHC, data measured represented TPH2 levels 
in both neuronal soma and in surrounding neuronal fibres (figure 5.3A). A significant main 
effect of disease group on TPH2 immunopositivity was observed in the raphe (χ²=10.476, 
p=0.033) (figure 5.4D). A significantly higher TPH2 percentage area stained was observed in 
the control group compared to those in the nLBD with fluctuations (z=22.623, p=0.002). A 
trend towards a higher TPH2 immunopositivity in the control group was observed with the 
nLBD without fluctuations group (p=0.060). No significant difference was observed between 
the DLB with fluctuation groups and the nLBD with (p=0.104) and without (p=0.709) 
fluctuation groups. No further significant differences in TPH2 immunopositivity were 
observed between the disease groups.  
TPH2 immunopositivity did not relate to the raphe pathological burden of α-synuclein 
(p=0.579), tau (p=0.405) and Aβ (p=0.521) or disease duration (p=0.275).  
5.3.1.4 Relationship to PPN and LC pathology 
Cases that had pathological burden assessed for the raphe, also had the pathological burden 
examined in other ARAS regions, the LC (65/65) and PPN (50/65).  
In the whole cohort, excluding the control group, Spearman’s rank correlations revealed 
associations between pathological burden of α-synuclein, tau and Aβ in the LC and the 
pathological burdens in the raphe (table 5.2). Raphe α-synuclein pathology was associated 
with LC pathological burden of α-synuclein, positively (rs=0.707, p<0.001), tau, negatively 
(rs=-0.422, p=0.003) and Aβ, negatively (rs=-0.392, p=0.006). Raphe tau pathological burden 
was associated with the LC pathological burden of α-synuclein, negatively (rs=-0.367, 
p=0.010), tau, positively (rs=0.684, p<0.001) and Aβ, positively (rs=0.510, p<0.001). Raphe 
Aβ pathological burden was associated with the LC pathological burden of α-synuclein, 
negatively (rs=-0.286, p=0.049), tau, positively (rs=0.409, p=0.004) and Aβ, positively 




  Table 5.3. Associations between raphe and locus coeruleus pathological burdens.                                                                       
Data shown for the Spearman’s rank correlation between raphe pathology and LC pathological burden for α-synuclein, 
tau and Aβ. Correlations shown for:  All-whole cohort minus the control cases, DLB with cognitive fluctuations, nLBD 
with cognitive fluctuations, nLBD without cognitive fluctuations and AD cases. An Asterix indicates a significant result: * 
p<0.05 ** p<0.01 ***p<0.001. Abbreviations: AD- Alzheimer’s disease; DLB- dementia with Lewy bodies; LC- locus 




When the disease groups were assessed independently, a number of associations observed 
between raphe pathological burden and LC pathological burden in the whole cohort were 
lost (table 5.2). Within the DLB with cognitive fluctuations groups a positive association was 
observed between raphe and LC α-synuclein pathological burdens (rs=0.720 p=0.006). 
Within the nLBD without cognitive fluctuations a positive relationship was observed with LC 
Aβ immunopositivity with raphe tau (rs=0.774, p=0.002) and Aβ (rs=0.612, p=0.026) 
pathological burden. No relationships were observed between LC and raphe pathology in 
the nLBD with and the AD without fluctuations groups (table 5.2). 
In the whole cohort, excluding the control group, Spearman’s rank correlations revealed 
associations between pathological burden of α-synuclein, tau and Aβ in the PPN and the 
pathological burdens in the raphe (table 5.3). Raphe α-synuclein pathology was positively 
associated with PPN α-synuclein (rs=0.702, p<0.001). Raphe tau pathological burden was 
negatively associated with the PPN pathological burden of α-synuclein (rs=-0.497, p=0.001) 
and positively associated with PPN tau burden (rs=0.430, p=0.006). Aβ burden in the raphe 
was negatively associated with PPN pathological burden of alpha-synuclein (rs=-0.369, 
p=0.019) and positively associated with Aβ burden (rs=0.490, p=0.001).  
When the disease groups were assessed independently from each a number of associations 
observed between raphe pathological burden and LC pathological burden in the whole 
cohort were lost (table 5.3). Within the DLB with cognitive fluctuations groups a positive 
association was observed between raphe and PPN α-synuclein pathological burdens 
(rs=0.648 p=0.043).  
A negative association was identified in the nLBD group with fluctuations between raphe Aβ 
and PPN α-synuclein (rs=-0.658, p=0.028). A negative relationship was observed with PPN 
tau immunopositivity and raphe α-synuclein pathological burden within the nLBD without 
cognitive fluctuations (rs=-0.738, p=0.037) and AD without cognitive fluctuation (rs=-0.748, 
p=0.033) groups. No further relationships were observed between PPN and raphe pathology 










Table 5.6. Associations between raphe and pedunculopontine nucleus pathological burdens.                                               
Data shown for the Spearman’s rank correlation between raphe pathology and PPN pathological burden for α-synuclein, 
tau and Aβ. Correlations shown for:  All-whole cohort minus the control cases, DLB with cognitive fluctuations, nLBD with 
cognitive fluctuations, nLBD without cognitive fluctuations and AD cases. An Asterix indicates a significant result: * p<0.05 
** p<0.01 ***p<0.001. Abbreviations: AD- Alzheimer’s disease; DLB- dementia with Lewy bodies; nLBD- neocortical/limbic 





5.3.1.5 Relationship to cognitive fluctuations 
No association was observed between α-synuclein, tau or Aβ raphe pathological burden or 
TPH2 immunoreactivity with the severity of cognitive fluctuations as measured by CAF 
score, in all cases that during life possessed cognitive fluctuations (table 5.4). When 
fluctuation groups were separated into DLB and nLBD with fluctuations, a positive 
association was observed between last CAF and raphe Aβ immunopositivity in the DLB 
group (rs=0.833, p=0.010). No further associations were observed between raphe 
pathological burden and any of the measures of cognitive fluctuation severity in the 
separated groups (table 5.4). 
Table 5.9. Associations between cognitive fluctuation severity and raphe pathology.                                                      
Spearman’s rank correlations between raphe pathology and severity of cognitive fluctuations as measure by last, average 
and maximum CAF score. Associations were undertaken in DLB and nLBD both combined and individually. Abbreviations: 
CAF- clinical assessment of fluctuation: DLB- dementia with Lewy bodies; nLBD- neocortical/limbic pathologically Lewy 




5.3.1.6 Relationship to depression 
In the cases that were pathologically classified as LBD, nLBD or DLB groups, which had GDS, 
no associations were observed between the average GDS score and raphe pathological 




No significant differences were observed in post-mortem delay, fixation duration, and age 
between the study groups. There was no significant difference observed in disease duration 
between the neurodegenerative disease groups. Between the groups a significant difference 
was found in the proportion of males to females, with the DLB group having a significantly 
higher proportion of males compared to AD without fluctuations (χ(1)=4.408, p=0.036) and 
nLBD with fluctuations (χ(1)=5.495, p=0.019). 
CAF scores were available for 22/47 cases. 18/20 of the cases with cognitive fluctuations 
possessing at least one CAF score. No significant difference was observed between the last 
(p=0.927), maximal (p=1.000) or average (p=0.789) CAF score between the DLB with 
fluctuations or the nLBD with fluctuations groups. 
Final MMSE scores were available for 40/47 cases: 10 DLB cases with fluctuations, 10 nLBD 
with fluctuations, 8 nLBD without fluctuations, 7 AD and 5 Controls. No significant 
difference in the interval between the last MMSE and death was observed between the 
groups. Significantly lower last MMSE scores were observed between all disease groups and 
controls: DLB cases with fluctuations (z=-14.900, p=0.017), nLBD with fluctuations 
(z=20.950, p=0.001), nLBD without fluctuations (z=-19.412, p=0.003) and AD cases (z=-
18.600, p=0.005). No significant differences in last MMSE score were observed between the 
4 disease groups. 
At least one GDS score was available for 25/47 cases: 9 DLB cases with fluctuations, 7 nLBD 
with fluctuations, 1 nLBD without fluctuations, 3 AD and 5 Controls. No significant 




5.3.2.2 Number of TPH2 neurons assessed 
The number of TPH2 neurons that were assessed for corrected TPH2 intensity ranged from 
16-688. No significant effect of disease fluctuations groups was observed on the number of 
TPH2 neurons assessed (χ²=5.575, p=0.233). 
5.3.2.3 Corrected TPH2 intensity 
No significant effect of disease group was observed on TPH2 corrected TPH2 intensity 
adjusted for area (χ²=1.014, p=0.908) (figure 5.5). The level of raphe pathological burden of 
α-synuclein (p=0.270), tau (p=0.676), Aβ (p=0.379) or TPH2 immunopositivity (p=0.348) was 
not found to relate to the TPH2 corrected TPH2 intensity adjusted for area values.  
Corrected TPH2 intensity values were calculated for TPH2-positive neurons both with and 
without Lewy bodies, for those that bore Lewy bodies the corrected TPH2 intensity value 
was additionally calculated for the cytoplasmic part of the neuron. A ratio was calculated to 
measure the magnitude of difference in median corrected TPH2 intensity value for the 
TPH2-postive neurons without Lewy bodies and TPH2-postive neurons with Lewy bodies; as 
well as a further ratio between the median corrected TPH2 intensity value for the TPH2-
Figure 5.5. Corrected tryptophan hydroxylase 2 intensity in the raphe.                                                                                                          
Corrected tryptophan hydroxylase 2 (TPH2)-intensity data. Data is shown as median with interquartile range. 
Abbreviations: AD- Alzheimer’s disease; DLB- dementia with Lewy bodies; nLBD- neocortical/limbic pathologically 





















































postive neurons without Lewy bodies and the median corrected TPH2 intensity value for the 
cytoplasmic portion in Lewy body bearing TPH2-postive neurons. A one-sample Wilcoxon 
signed rank test was undertaken to assess whether the observed median for the two 
deviated from a hypothetical median of 1. A hypothetical median of 1 represents the value 
at which there would be no difference between the corrected TPH2 intensity value in the 
TPH2-postive neurons without Lewy bodies and those with Lewy bodies. A ratio value of >1 
would be suggestive that the corrected TPH2 intensity was higher in the TPH2 neurons 
without Lewy bodies and a ratio <1 suggestive that the corrected TPH2 intensity was higher 
in the TPH2 neurons with Lewy bodies. All cases which had ratios calculated in DLB and 
nLBD groups were analysed collectively. No significant deviation from a median of 1 was 
observed for the magnitude of difference between TPH2 neurons with Lewy bodies and 
those without, median 0.88, (z=39.000, p=0.650) (figure 5.6A). A significant deviation from a 
hypothesised median of 1 was observed for the magnitude of difference in corrected TPH2 
intensity between the cytoplasmic portion of Lewy body bearing neurons and those without 
Lewy bodies, median 0.73, (z=3.000, p=0.005) (figure 5.6B). No significant effect of disease 



































Figure 5.6. Ratios for corrected tryptophan hydroxylase 2 intensity in tryptophan hydroxylase 2-positive neurons with and 
without Lewy bodies.                                                                                                                                                                                                          
Ratios for corrected tryptophan hydroxylase 2 (TPH2) intensity in TPH2 positive neurons without Lewy bodies (LBneg) with 
corrected TPH2 intensity in TPH2 positive neurons containing Lewy bodies (LBpos) (A) and the corrected TPH2 intensity 
value for the part of the neuron that the Lewy body did not occupy in Lewy body bearing TPH2-postive neurons (LBexc) (B). 





neurons without Lewy bodies and those with Lewy bodies, inclusive of the Lewy body 
(χ²=0.440, p=0.803) or only the cytoplasmic portion (χ²=1.186, p=0.553). 
5.3.2.4 Location of pathology 
The percentage of TPH2-postive neurons bearing Lewy bodies was calculated for 6 DLB with 
fluctuations, 4 nLBD with fluctuations and 3 nLBD without fluctuation cases. A significant 
effect of disease group was observed on the percentage of TPH2-positive neurons bearing 
Lewy bodies (χ²=6.242, p=0.044) (figure 5.7). DLB with fluctuation cases were observed to 
have a significantly higher proportion of Lewy body bearing TPH2-positive neurons than 
nLBD without cognitive fluctuation cases (z=6.667, p=0.015). No significant difference in 
proportion of Lewy body bearing neurons was observed between the nLBD with cognitive 
fluctuation group and the DLB with (p=0.145) and nLBD without (p=0.313) fluctuations 
groups.  
5.3.2.5 Variability in TPH2 corrected TPH2 intensity 
z-scores were calculated to assess variability within the corrected TPH2 intensity values 
across all the disease groups. The proportion of neurons for each case that had a z-score 
less than -1 and less than -2 was calculated. No significant effect of disease group was 
observed in the proportion of neurons with a z-score less than -1 (χ²=1.554, p=0.817) or a z-
































































Figure 5.7. Proportion of tryptophan hydroxylase 2-positive neurons bearing Lewy bodies.                                                                                                                                              
Proportion of tryptophan hydroxylase 2 (TPH2)-positive neurons bearing Lewy bodies. Data is shown as median with 
interquartile range. * p<0.05 shown to nLBD without fluctuations. Abbreviations: DLB- dementia with Lewy bodies; 











5.3.2.6 Relationship to cognitive fluctuations 
No association was observed between the proportion of TPH2-postive neurons bearing 
Lewy bodies and the severity of cognitive fluctuations as measured by CAF score, in all cases 
that during life possessed cognitive fluctuations (table 5.5). However, a trend towards 
significance was observed between average CAF score and the proportion of TPH2-neurons 
bearing Lewy bodies. When the fluctuation groups were separated into DLB and nLBD with 
Figure 5.8. Variability of corrected tryptophan hydroxylase 2-intensity.                                                                            
Proportion of tryptophan hydroxylase 2 (TPH2)-positive neurons with a z-score of less than -1 (A) or less than -2 (B). 

































































































































Table 5.11. Associations between cognitive fluctuation severity and the proportion of tryptophan hydroxylase 2 positive 
neurons bearing Lewy bodies.                                                                                                                                                       
Spearman’s rank correlations between tryptophan hydroxylase 2 positive neurons bearing Lewy bodies and severity of 
cognitive fluctuations as measure by last, average and maximum CAF score. Associations were undertaken in DLB and 
nLBD both combined and individually. Abbreviations: CAF- clinical assessment of fluctuation: DLB- dementia with Lewy 





fluctuations, a negative association was observed between average CAF score and the 
proportion of TPH2-neurons bearing Lewy bodies in the DLB with fluctuations group (rs=-
0.899, p=0.015). No further associations were observed between the proportion of TPH2-
neurons bearing Lewy bodies and any of the measures of cognitive fluctuation severity 
(table 5.5).  
The two ratios generated described the magnitude of difference in the corrected TPH2 
intensity between neurons without Lewy bodies and either the cytoplasmic portion or the 
whole neuron of those that do contain Lewy bodies. A value <1 suggests that the corrected 
TPH2 intensity is higher in the neurons without Lewy bodies and a value >1 that it is created 
in the neurons with Lewy bodies. A positive association was observed between the 
magnitude of difference in corrected TPH2 intensity between neurons with and without 
Lewy bodies and the severity of cognitive fluctuations as measured by last (rs=0.792, 
Table 5.14. Associations between the ratio of corrected tryptophan hydroxylase 2-intensity in tryptophan hydroxylase 2-
positive neurons with and without Lewy bodies.                                                                                                                                     
Spearman’s rank correlations between corrected  tryptophan hydroxylase 2 (TPH2)-intensity in TPH2 positive neurons 
without Lewy bodies (LBneg) with corrected TPH2 intensity in TPH2 positive neurons containing Lewy bodies (LBpos) and 
for the part of the neuron that the Lewy body did not occupy in Lewy body bearing TPH2-postive neurons (LBexc) and 
severity of cognitive fluctuations as measure by last, average and maximum CAF score. Associations were undertaken in 
DLB and nLBD both combined and individually. Abbreviations: CAF- clinical assessment of fluctuation: DLB- dementia 




p=0.006) and average (rs=0.684, p=0.029) CAF score, in all cases that during life possessed 
cognitive fluctuations (table 5.6). A positive association between the magnitude of 
difference in corrected TPH2 intensity between the cytoplasmic portion of neurons with and 
without Lewy bodies and severity of cognitive fluctuations as measured by last CAF score 
was observed (rs=0.697, p=0.025), in all cases that during life possessed cognitive 
fluctuations. When the fluctuation groups were separated into DLB and nLBD with 
fluctuations no associations were observed between two ratios calculated and any of the 
measures of cognitive fluctuation severity (table 5.6). 
5.3.2.7 Relationship to depression 
No associations were observed between the average GDS score and TPH2 corrected TPH2 





The raphe has been implicated in the maintenance of arousal states (Monti, 2011). 
Alterations to the raphe and its serotonergic projections have been identified in a number 
of neurodegenerative diseases, including AD and DLB (Chen et al., 2000; Kovacs et al., 2003; 
Benarroch et al., 2007; Grinberg et al., 2009). The role of the raphe and the serotonergic 
system in depression within dementia has been examined (Hendricksen et al., 2004; 
Michelsen et al., 2008), however, the role of any changes in relation to cognitive 
fluctuations has yet to be investigated. 
5.4.1 Relationship between raphe pathology and cognitive fluctuations 
The present study identified α-synuclein pathological burden was the highest in the DLB 
with fluctuations group. However, no specific pattern was observed between raphe 
pathological burden, α-synuclein, tau and Aβ, on the presence of cognitive fluctuations. No 
associations were found between pathological burden and severity of cognitive fluctuations, 
in the combined with fluctuation group. Although, a positive association was observed with 
Aβ pathological burden and severity of cognitive fluctuation was observed when the DLB 
with fluctuations group was analysed separately. The study also identified associations 
between pathological burdens in raphe and those in the LC and PPN within the whole 
cohort, excluding controls. However, the majority of these associations were lost when the 
cohort was split into individual disease groups, with no associations present in both groups 
with cognitive fluctuations. 
5.4.1.1 Pathology alone in the raphe does not distinguish fluctuating from non-fluctuating 
groups 
The present study aimed to investigate the involvement of raphe pathology, α-synuclein, 
tau and Aβ, on the presence and severity of cognitive fluctuations in DLB. Previous studies 
have investigated the vulnerability of the raphe to accumulation of pathological proteins 
and neuronal loss in a number of neurodegenerative diseases, including DLB, AD and PD 
(Braak et al., 2003; Kovacs et al., 2003; Benarroch et al., 2007; Grinberg et al., 2009; Seidel 
et al., 2015). The results from the current study are in agreement with previous findings that 
the raphe is vulnerable to α-synuclein and AD-type pathology; along with α-synuclein being 




study no differences in the pathological burdens were related to the presence or absence of 
cognitive fluctuations.  
The raphe and serotonergic system have been strongly implicated to play a role in idiopathic 
depression and anxiety (Hale and Lowry, 2011). Clinically, depression and anxiety are 
supportive features of DLB and they are more persistent than those observed in AD (Fritze 
et al., 2011). Therefore, the presence of depression in DLB and other neurodegenerative 
dementia disorders may suggest impairment to the serotonergic system. The majority of 
studies examining the raphe nucleus and the serotonergic system in dementia have centred 
on the examination of the possible relationship to depressive symptoms, with a studies 
primarily investigating changes in AD (Chen et al., 2000; Ballard et al., 2002a; Hendricksen et 
al., 2004; Thomas et al., 2006; Vermeiren et al., 2015). Studies have investigated the raphe 
and serotonergic system in relation to clinical features of DLB, including visual hallucinations 
(Perry et al., 1990a; Perry et al., 1993). However, the majority of studies in DLB have been in 
relation to general alterations of the serotonergic system (Azmitia and Nixon, 2008; Mace et 
al., 2016) and comparison of pathological burdens to other neurodegenerative diseases 
(Benarroch et al., 2007). The present study is the first to my knowledge that has 
investigated the involvement of the raphe in relation to cognitive fluctuations. 
The raphe has been implicated to play a complex role in the maintenance of arousal states 
through its widespread serotonergic projections to regions within the ARAS, including the 
PPN, LC and hypothalamus, as well as cortical regions (Vertes, 1991; Jones, 2005b; 
Michelsen et al., 2007). DR neurons have been identified to fire maximally during waking 
(Trulson and Jacobs, 1979; Mahaffey and Garcia-Rill, 2015), however, lesioning of the 
nucleus in cats can lead to permanent states of wakefulness (Jouvet, 1968). The raphe’s role 
in the maintenance of arousal systems is believed to occur through a complex network of 
projections and receptor expression patterns (Mihailescu et al., 2002; Jones, 2003; McDevitt 
and Neumaier, 2011; Mahaffey and Garcia-Rill, 2015). However, the present study identified 
no differences in pathological burden specific to those with cognitive fluctuations, with 
similar lack of associations having been identified with raphe pathology and depression in 
AD (Chen et al., 2000). Studies have identified alterations to serotonergic system in DLB, 
including alterations to serotonergic fibre morphology and reductions in serotonin levels in 




not explored in relationship to clinical features. Furthermore, reductions to cortical levels of 
serotonin have been further identified in DLB cases with depression (Vermeiren et al., 
2015). With the raphe’s control of arousal likely through a complex system of projection and 
receptor expression patterns it is likely that a complex set of alterations to the raphe and 
serotonergic system would relate to the clinical manifestations of arousal disturbances, and 
these changes may be independent of the pathological protein accumulation within the 
raphe. Analysis of serotonergic receptor population levels and integrity of serotonergic 
projections were not undertaken within the current study and thus further experiments 
investigating these changes would be required to explore the role of the raphe and 
serotonergic system in cognitive fluctuations. 
5.4.1.2 Relationship of raphe pathology to pathology in the LC and PPN 
When the whole cohort, excluding the controls, was analysed a number of relationships 
between the level of pathological proteins in the raphe and those in the PPN and LC were 
identified. However, upon examination of the disease groups individually the majority of 
these relationships were lost. The likely cause of the associations observed in the whole 
cohort are group effects due construction of the cohort, with pathologically AD cases having 
higher AD-type pathology in both the LC and PPN compared to DLB cases. These group 
differences would drive an apparent association which was then lost upon examination of 
the groups separately. Although associations were observed between raphe pathology and 
pathological burden in the LC and raphe when the fluctuations groups were analysed 
individually, no associations were observed in both the DLB and nLBD groups with 
fluctuations.  
The ARAS is a diffuse complex system comprising of a number of nuclei and 
neurotransmitter systems, with studies having identified a degree of redundancy with the 
system (Kovalzon, 2016b). Due to the level of redundancy within the ARAS it is possible to 
suggest all three key brainstem structures would need to be affected or that one region or 
neurotransmitter system is severely affected and the parts of the ARAS are not able 
consistently undertake the role of the affected region, in order to elicit fluctuations in 
consciousness. If all three key brainstem regions were to be affected creating a vulnerability 
towards fluctuating cognition, it could be that regions contain a specific pattern of 




of associations between the pathological burdens of the three ARAS nuclei, specific to the 
groups with cognitive fluctuations. The lack of conserved associations in the fluctuation 
groups suggests that there is no topographical pattern of pathological burden that is specific 
for the presence of cognitive fluctuations. 
5.4.2 Corrected TPH2 intensity 
The present study identified no relationship between the intensity of TPH2 and the 
presence or severity of cognitive fluctuations. Pathological burden in the raphe was also 
found not to relate to TPH2 intensity, across the whole cohort including controls. DLB cases 
were also observed to have a higher proportion of TPH2-positive neurons that contained 
Lewy bodies compared to the nLBD group without cognitive fluctuations, with a negative 
association observed between the proportion and fluctuation severity. In the pathologically 
LBD cases, a difference in TPH2 intensity was observed between the TPH2-positive neurons 
that do not bear Lewy bodies and the cytoplasm of TPH2-positive neurons that do contain 
Lewy bodies. Within the fluctuating cognition groups, the magnitude of difference in the 
corrected TPH2 intensity between neurons without Lewy bodies and either the cytoplasmic 
portion or the whole neuron of those that do contain Lewy bodies were found to have a 
positive association with the severity of cognitive fluctuations, however, no association was 
observed when the fluctuating cognition groups were split into DLB and nLBD.  
5.4.2.1 Alterations to the serotonergic system relate to the severity of cognitive fluctuations 
The current study identified changes to the serotonergic system which could play a role in 
the serotonergic dysfunction in LBDs. A limited number of previous studies have 
investigated the levels of rate-limiting catalytic enzymes in transmitter systems known to be 
dysfunctional in LBDs, with the main focus being on tyrosine hydroxylase (Whitehouse et al., 
1983; Nakashima and Ikuta, 1984; Mori et al., 2006) and none to my knowledge 
investigating TPH2. The observed difference in TPH2 level between neurons without Lewy 
bodies and the cytosolic part of those bearing Lewy bodies is in agreement with a study by 
Dugger et al. (2010) who identified a reduction in cytoplasmic levels of ChAT and tyrosine 
hydroxylase in neurons bearing Lewy bodies compared to neurons without. The observed 
reduction in cytoplasmic ChAT and tyrosine hydroxylase levels were thought to be due to 
sequestration of the enzymes into the Lewy body present within the neurons, with the 




and Dickson, 2010). The current study identified no difference between the magnitude of 
difference in the corrected TPH2 intensity between neurons without Lewy bodies and the 
whole neuron of those that do contain Lewy bodies and a hypothesised median of 1; 
whereas a difference was observed for the magnitude of difference in the corrected TPH2 
intensity between neurons without Lewy bodies and the cytoplasmic portion of those that 
do contain Lewy bodies, which could suggest that TPH2 is sequestered into Lewy bodies in 
TPH2-positive neurons, although further investigations are required to validate this. The 
sequestration of enzyme into the Lewy body could lead to a reduction in catalytic enzyme 
available to synthesis the neurotransmitter, leading to a reduction in serotonergic 
transmission. However, neither the current study, nor the study by Dugger et al. (2010), 
investigated neurotransmitter levels, so were unable to verify whether the sequestration of 
catalytic enzyme into Lewy bodies led to a reduction in transmitter level. Although 
investigations of neurotransmitter levels would verify whether sequestration of catalytic 
enzymes reduced their levels, at present there is no available method to do so in human 
post-mortem tissues.  
Dysfunction to the serotonergic system has been implicated to play a role in a number of 
clinical features of DLB, including depression (Vermeiren et al., 2015) and visual 
hallucinations (Perry et al., 1990a). In the current study no difference was observed for 
TPH2-intensity in relation to the presence of cognitive fluctuations; although utilising IHC 
TPH2-levels in the raphe both in neuronal soma and fibres was trending towards a 
significant reduction compared to controls. However, a number of associations were 
observed with the between the severity of cognitive fluctuations and the proportion of 
TPH2-positive neurons containing Lewy bodies, and the magnitude of difference in the 
corrected TPH2 intensity between neurons without Lewy bodies and either the cytoplasmic 
portion or the whole neuron of those that do contain Lewy bodies.  
Cognitive fluctuations are a transient clinical phenomenon, suggestive of a flexible 
underlying mechanism, rather than a permanent change (O'Dowd et al., 2019). Permanent 
changes such as the loss of serotonergic neurons or the presence of pathology, measured 
through antibodies as in the current study, are likely not to underly the more flexible 
changes required to elicit a transient clinical feature. In the current study a positive 




corrected TPH2 intensity between neurons without Lewy bodies and the cytoplasmic 
portion of those that do contain Lewy bodies, as well as the magnitude of difference in the 
corrected TPH2 intensity between neurons without Lewy bodies and the whole neuron of 
those that do contain Lewy bodies. The positive association shows that when the difference 
for the corrected TPH2 levels in the whole neuron and cytoplasmic fraction of those with 
Lewy bodies compared to those without Lewy bodies is smaller, closer to 1, more severe 
cognitive fluctuations are present. A further positive association observed with average CAF 
score and the magnitude of difference in the corrected TPH2 intensity between neurons 
without Lewy bodies and the whole neuron of those that do contain Lewy bodies when the 
fluctuation groups were analysed together. As the ratio values increase this suggests that 
the TPH2-positive neurons with Lewy bodies have the TPH2-intensity value similar if not 
higher than the TPH2-positive neurons without. The results obtained from the current study 
are in support of the hypothesis, with the associations indicating that a more intact, 
although not necessarily fully functional, serotonergic system is associated with more 
severe cognitive fluctuations. To verify this, studies would be required to ascertain whether 
the levels of serotonergic neurotransmitter are altered between neurons with and without 
Lewy bodies, however currently no technique is capable of doing this in human post-
mortem tissue. The data from the current study could suggest that to counteract 
dysfunction to the system the neurons upregulate serotonergic markers in the neuronal 
soma to try and normalise serotonergic transmission levels. A study examining the 
serotonergic system in regard to depression in DLB identified the preservation of SERT sites 
in the parietal neocortex of DLB patients with depression compared to non-affected cases, 
suggesting a reduction in synaptic plasticity of the serotonergic neurons rather than cell loss 
within the raphe, which could lead to a more dynamic dysfunction rather than a permanent 
one (Ballard et al., 2002a).  
Although a positive relationship was observed between the magnitude of difference in TPH2 
intensity between neurons without and either the cytoplasmic or whole neuron of those 
bearing Lewy bodies and severity of cognitive fluctuations when the fluctuation groups were 
combined, a negative association was observed between the proportion of TPH2-positive 
neurons bearing Lewy bodies and the severity of cognitive fluctuations in the DLB-only 




not possess Lewy bodies the more severe the cognitive fluctuations experienced. This data 
combined suggests that there may be alterations to the non-Lewy body bearing TPH2-
positive neurons that were not measure within the current study that relate to the 
vulnerability towards cognitive fluctuations. Further studies are required to ascertain what 
pathological changes are related to the severity of cognitive fluctuation, including whether 
the changes could relate to forms of α-synuclein not measured within the current study, 
such as α-synuclein levels within the synaptic compartments. In the current study 
colocalization between small TPH2-positive punctate staining and α-synuclein was observed. 
Although not analysed, α-synuclein in these structures could be more pathogenic to 
serotonergic dysfunction. Previous studies in dopaminergic neurons have identified 
disruption to mitochondrial function (Sarafian et al., 2019) and synaptic vesicles (Plotegher 
et al., 2017) due to interactions between dopaminergic catabolites and α-synuclein; recent 
studies have identified similar interactions with a serotonergic catabolite (Falsone et al., 
2011; Jinsmaa et al., 2015). Disruption to synaptic compartments could alter synaptic 
plasticity and lead to a more dynamic dysfunction of the system which could underly a 
variable clinical feature such as cognitive fluctuations. Further research into α-synuclein in 
serotonergic synaptic compartments is required to understand how this could affect 
serotonergic transmission. 
5.4.4 Limitations 
The most influential limiting factor of this study was the small number of cases that 
underwent analysis for the colocalization of α-synuclein and TPH2, only 6 DLB with 
fluctuations, 4 nLBD with fluctuations and 3 nLBD without fluctuation cases. All cases in the 
immunofluorescent cohort underwent dual labelling with pS129, however due to a global 
pandemic, priority was given to collection of the TPH2 data. Therefore, the small group 
numbers that meant that the correlations undertaken on the cognitive fluctuation groups, 
specifically when analysed separately, are likely to be under powered due to the low group 
numbers and thus any conclusion should be treated with caution until further cases can be 
added.  
The study did not measure the levels α-synuclein present in the TPH2-positive synapses or 
the degree of neuronal loss within the nucleus. Further clarification of these are required to 




The raphe is known to be a heterogeneous structure with different subnuclei, including the 
DR and MnR known to project to different anatomical locations (Hornung, 2003). Within the 
current study there was a lack of consistent level analysed and the DR and MnR were 
analysed together. The variability within the level sampled and combination of the DR and 
MnR could have affected the relationships observed.  
5.4.4 Conclusions 
The study aimed to investigate the neuropathological differences in the raphe between 
cases that clinically presented with cognitive fluctuations and those that did not, along with 
investigating whether there was an association between neuropathological changes and 
cognitive fluctuation severity. 
The study identified pathological differences in the raphe related to the pathological 
diagnosis of the cases, with no changes specifically related to the presence or absence of 
cognitive fluctuations. However, alterations to the level of the serotonin catalytic enzyme, 
TPH2, in neurons with Lewy bodies did relate to the severity of cognitive fluctuations. This 
data suggests that cognitive fluctuations could be the result of dynamic serotonergic 






Chapter 6: Biochemical studies in the medial prefrontal cortex  
6.1 Introduction 
The ARAS projects from various brainstem nuclei, including the LC, raphe and PPN, to the 
cortex, thalamus and basal forebrain to mediate wakefulness and arousal through cortical 
activation, suppression of slow rhythms in EEG and synchronisation of faster frequency 
rhythms (Sarter, 2006; Edlow et al., 2012; Kovalzon, 2016a). The mPFC is one of the cortical 
regions to which the nuclei of the ARAS project, both directly and indirectly (Paus, 2000; 
Jones, 2003). Projections from the LC (Chandler et al., 2014) and raphe (Martín-Ruiz et al., 
2001) are known to innervate the mPFC both directly and indirectly via the cholinergic 
neurons of the basal forebrain (Bloem et al., 2014); with the PPN sending indirect 
projections via the thalamus (Jang et al., 2020). The mPFC has also been shown to be 
reciprocally connected with ARAS nuclei, including the raphe (Celada et al., 2001) and PPN 
(Clark et al., 2018), in order to maintain control cortical states. From the previous studies in 
the brainstem, it was discovered that pathological protein burden in the ARAS nuclei do not 
relate to the presence or absence of cognitive fluctuations. Therefore, examination of a 
cortical ARAS region that the ARAS brainstem nuclei project to, both directly and indirectly 
would enable the further investigation into whether the projections from the brainstem 
regions are still innervating the cortical region, as well as whether cortical changes to the 
ARAS are involved in the underlying pathophysiology of cognitive fluctuations.  
The mPFC is a cortical region that integrates information from numerous cortical and 
subcortical areas (Xu et al., 2019). Dysfunction of the mPFC has been identified in various 
neurodegenerative disorders, including AD (Xu et al., 2019) and DLB (Chabran et al., 2020). 
Studies have implicated the mPFC in arousal (Zhang et al., 2014) and attention (Riga et al., 
2014), with alterations having been identified in cognitive fluctuations in DLB (Bliwise et al., 
2014), as well as the region forming part of the default mode network (Li et al., 2014). In 
DLB, MRI studies have identified alterations to connectivity within attentional networks, 
including the default mode network involving the mPFC suggesting that these pathways 
could be altered (Galvin et al., 2011; Franciotti et al., 2013; Peraza et al., 2014). 
Furthermore, atrophy has been observed in the basal forebrain which sends cholinergic 
projections to the mPFC (Grothe et al., 2014; Schumacher et al., 2020). Severity of the loss 




levels and maintenance (Kasanuki et al., 2018). Studies have investigated the role of the 
mPFC in disorders of consciousness, including alterations to consciousness post-stroke (Liu 
et al., 2017), as well as where alterations to the default mode network has been suggested. 
Furthermore, studies of post-stroke alterations to consciousness, have identified an 
increase in thalamocortical activity to the mPFC, after the initial stroke, was associated with 
recovery from a vegetative state to a normal conscious state (Jang et al., 2020). Therefore, 
the present study aimed to determine whether cognitive fluctuations are associated with 
local pathological protein deposits and/or synaptosomal changes, as a proxy of innervation 
to the mPFC.  
6.1.1 Aims 
Using frozen post-mortem tissue containing the mPFC from DLB cases with fluctuations, 
nLBD cases, both with and without cognitive fluctuations, AD cases without cognitive 
fluctuations and aged cognitively normal controls, this study aims to: 
1. Evaluate synaptosomes as a proxy of innervation of mPFC from the ARAS, utilising 
immunoblots 
2. Quantify the burden and identify the neuronal localisation of neuropathological 
protein lesions, utilising immunoblots 
3. Assess whether the neurodegenerative changes seen are related to the presence or 






6.2.1 Study Cohort 
Five groups were included in the mPFC study with a total of 49 cases (table 2.1). 10 DLB 
cases that had been recorded to have experienced cognitive fluctuations during life; 10 
nLBD cases whom did not experience cognitive fluctuations during life, mixed AD/DLB cases; 
9 AD cases with no recorded experience of cognitive fluctuations during life; 10 nLBD cases 
whom did experience cognitive fluctuations during life, mixed AD/DLB; and 10 aged 
matched controls with no history of cognitive impairment. Cases which during life were 
uncooperative with neuropsychiatric testing, were postulated to have cognitive fluctuations 
due to medicine regimes and those who had brainstem infarcts were excluded from the 
study. Within the study cohort a number of those with a history of cognitive fluctuations 
had the severity of these measured via CAF, 9 DLB with cognitive fluctuations and 9 nLBD 
with cognitive fluctuations, allowing associations with severity of fluctuations to be 
assessed. 
6.2.2 Tissue Acquisition 
Frozen tissue was acquired from the mPFC, BA12 (figure 6.1). BA12 was selected for frozen 
tissue analysis due to a study by Jang et al (2020) which identified the mPFC as a region 
involved in post-stroke recovery of consciousness, with the study stating the mPFC to be 
comprised of BA12 and BA32. However, the literature surrounding the region which BA32 is 
functionally part of is divided between the anterior cingulate cortex and the mPFC, due to 
this disparity between functional grouping, only BA12 was selected for the present study. 
Figure 6.1. Newcastle Brain Tissue Resource frozen tissue dissection protocol.                                                                      




Approximately 250mg of tissue was dounce homogenised in cold lysis buffer, as described in 
2.9.1, before undergoing synaptosomal fragmentation. 
6.2.3 Synaptosomal fragmentation 
Homogenised aliquots underwent synaptosomal fragmentation by sequential centrifugation 
(figure 6.2) as described in 2.9.2, previously described by Wirths (2017), immediately after 
tissue homogenisation. Sequential fragmentation produced: P1- nuclei, S2-microsomes and 
soluble enzymes, P2-crude synaptosomal and mitochondrial fraction. All fractions were 
stored at -80°C until further use. 
 
6.2.4 SDS-PAGE and Western blotting 
The three fractions obtained from the sequential fractionation underwent western blotting, 
as described in 2.9.2.1, to assess the levels of nuclear (H3), mitochondrial (VDAC1) and 
synaptic markers (SNAP25) in the three fractions. The three fractions were assessed for 
their respective levels of H3, VDAC1 and SNAP25 in order to validate the fractionation 
procedure. The three markers assessed were expressed relative to GAPDH, a house-keeping 
Tissue Homogenate 
 




Pellet 1: nuclei 
 
12,000g 20 minutes 
 
Supernatant 2: microsomes 
and soluble enzymes 
Pellet 2: crude synaptosomal 
and mitochondrial fraction 
Figure 6.2. Synaptosomal fragmentation protocol.                                                                                                                             




protein that has a stable and ubiquitous expression, to control for variation in protein 
loading. Briefly, total protein concentration for each fraction was determined using a 
Bradford assay, as described in 2.9.2.1. 10µg of 0.5µg/µl total protein was loaded into each 
well of a NuPAGE 4-12% Bis-Tris gel (Invitrogen, Waltham, MA, USA). The samples were 
separated using SDS-PAGE. Proteins were transferred to a nitrocellulose membrane and 
probed with primary and secondary antibodies (table 6.1). Size and intensity of the protein 
bands on the blots was quantified using FIJI (Schindelin et al., 2012) with the target protein 










Dot blots were undertaken to assess the levels of a number of different proteins within the 
P2 and S2 fractions, as described in 2.9.3. Briefly, total protein concentration for each 
fraction was determined using a Bradford assay, as described in 2.9.2.1. Samples were 
adjusted to 1µg/µl with distilled water and directly dotted in duplicate onto a 0.2µm 
nitrocellulose membrane (10µl per sample, 10µg per dot). Two blots were run in parallel for 
all antibodies: AD, DLB with fluctuations and controls, and nLBD with and without 
fluctuations and controls. Two blots were utilised to ensure the groups which needed to be 
directly compared AD and DLB, and nLBD with and without fluctuations could be done 
directly without pooling across blots as well as to ensure minimal variability across the 
samples loaded onto the blot which would occur if a larger blot had been used. All 10 
control cases were run on each blot to reduce variation in analysis. One antibody, NDUFB8, 
required sample pre-treatment, incubation at 100oC for 5 minutes, before being dotted 
onto the blot (table 6.2). Noradrenaline reuptake transporter (NET) antibody underwent a 
Antibody Manufacturer Dilution Species 
H3, Histone H3 Cell Signalling, UK 1:5000 Mouse 
SNAP25, Synaptosome 





anion-selective channel 1 
Abcam, UK 1:1000 Mouse 
GAPDH, Glyceraldehyde 3-
phosphate dehydrogenase 
Cell Signalling, UK 1:5000 Rabbit 
Table 6.1. Antibodies utilised to validate the synaptosomal fractional protocol.                                                            
Optimised dilutions and species of the antibodies utilised for the synaptosomal fractionation validation via SDS-PAGE 
and Western blotting.  
 
 
Table 6.2. Antibodies utilised in the medial prefrontal cortex study.                                                                                           
Optimised dilutions, species and sample pre-treatment protocols for the antibodies utilised for the immunoblots in the 
medial prefrontal ortex study. *various pre-treatments utilised are outlined in 6.3.4. ** three phosphorylated tau 
antibodies, PHF-1, AT8 and CP-13 were utilised together creating a phospho-tau ‘cocktail’. Abbreviations: Aβ- Aβ; Ser-
Serine; Thr-Threonine.Table 6.3. Antibodies utilised to validate the synaptosomal fractional protocol.                                                            
Optimised diluti ns and species of the antibodies utilised for the synaptosomal fractionation validation via SDS-PAGE 





series of different pre-treatment steps, including addition of various SDS concentrations, 
incubation at 100oC and 70oC and addition of a reducing agent, in order to try and optimise 
an experimental protocol (figure 6.5). Blots were blocked in 10% milk powder before being 
incubated in primary antibody (table 6.2) overnight at 4°C. Blots were then incubated with 
an appropriate, goat anti-mouse or goat anti-rabbit horseradish peroxidase conjugated 
secondary antibody. Immunoblots were visualised with enhanced chemiluminescence, total 
protein was measured utilising ponceau. Images were captured using a Fuji LAS 4000 with 
imaging software (Fuji LAS Image, Raytek, Sheffield, UK).  
To ensure specificity of the detected signal, appropriate non-primary antibody control dot 
blots were undertaken. For heat treated and soluble enzyme fraction immunoblots a small 
detectable immunoreactive signal was observed, following an exposure time comparable to 
the primary treated immunoblot. Non-specific immunoreactive signal was subtracted from 
the signal detected on the primary incubated immunoblot. No other immunoblots 
possessed a detectable non-specific immunoreactive signal at an exposure time comparable 
to the primary incubated blot. 
6.2.6 Blot analysis 
Immunoreactivity was quantified from 16-bit digitised images utilising FIJI (Schindelin et al., 
2012) based on area under curve measurements normalised to total protein load 
established via area under the curve for ponceau processed blots, as previously described 
by Koss et al (2016). Immunoblot intensity data were normalised within blot using total 
protein adjusted values and expressed relative to the control cases, prior to being pooled 
across blots. 
Ratios were generated between the levels of 5G4 and pS129 in the P2 and S2 fractions; with 
values over 1 suggestive that the levels of the α-synuclein species are higher in the P2 
fraction, and values under 1 suggestive that the levels of the α-synuclein species are higher 
the S2 fraction. A ratio was also generated between the level of NDUFB8, a mitochondrial 
complex I subunit, and TOM20, an outer mitochondrial membrane transporter, 
(NDUFB8:TOM20). NDUFB8:TOM20 allows examination of differences in Complex I 
expression relative to the total number of mitochondria, therefore reducing the possibility 






6.2.7 Statistical analysis 
Statistical analysis was conducted using SPSS v.26 (IBM). Variables were assessed for 
normality by the Shapiro-Wilk test and inspection of histograms and Q-Q plots. All 
immunoblot data, analysed with values expressed relative to control cases within blot, was 
found to be non-normal leading to non-parametric tests being employed. To determine 
differences in the non-normally distributed data Kruskal-Wallis and post-hoc Mann-Whitney 
Antibody Manufacturer Dilution Species 
Sample              
pre-treatment 





1:1000 Mouse NA 
VMAT2, vesicular monoamine 
transporter 2 
Abcam, UK 1:500 Rabbit NA 












1:500 Rabbit NA 
pS129, α-synuclein 
phosphorylated at Ser129 
Abcam, UK 1:1000 Rabbit NA 
5G4, aggregated α-synuclein Analytik Jena, 
Germany 
1:2500 Mouse NA 
**PHF-1, tau phosphorylated 
at Ser396 and 404 
Peter Davies Lab 1:1000 Mouse NA 
**AT8, tau phosphorylated at 
Ser199 and 202, and Thr404 
Autogen, MA, USA 1:1000 Mouse NA 
**CP-13, tau phosphorylate 
at Ser202 
Peter Davies Lab 1:1000 Mouse NA 
MOAB, Aβ peptide 40/42 Biosensis, SA, 
Australia 
1:1000 Mouse NA 
NDUFB8, Mitochondrial 
complex I subunit (NDUFB8) 
Mitosciences, 
Abcam, UK 
1:1000 Mouse 5 minutes at 
100°C 





1:1000 Rabbit NA 
Table 6.4. Antibodies utilised in the medial prefrontal cortex study.                                                                                           
Optimised dilutions, species and sample pre-treatment protocols for the antibodies utilised for the immunoblots in the 
medial prefrontal cortex study. *various pre-treatments utilised are outlined in 6.3.4. ** three phosphorylated tau 





were undertaken. Blots were analysed within blot when the disease groups were compared 
to controls: AD and DLB with fluctuations with controls, and nLBD with and without 
fluctuations with controls. As all control cases were used on both blots, two values for each 
control cases were produced, which precluded the analysis of control cases when analysing 
across blots. A one-sample Wilcoxon signed rank test was utilised to determine whether the 
ratios between α-synuclein levels in the P2 and S2 fractions calculated deviated from a 
median of 1. 
To determine whether there was an association between any immunoblot measures and 
neuropsychological data obtained intra vitam, Spearman’s rank correlations were 
conducted. Corrections such as Bonferroni were not applied due to the fact that there is not 
a true null hypothesis because of the classification of neurogenerative diseases, for example 








No significant differences were observed in post-mortem delay, fixation duration, and age 
between the study groups. There was no significant difference observed in disease duration 
between the neurodegenerative disease groups. Between the groups, no difference was 
found in the proportion of males to females. 
CAF scores were available for 22/49 cases. 17/20 of the cases with cognitive fluctuations 
had at least one CAF score. No significant difference was observed between the last 
(p=0.842), maximal (p=0.815) or average (p=0.884) CAF score between the DLB with 
fluctuations or the nLBD with fluctuation groups. 
Final MMSE scores were available for 40/49 cases: 10 DLB cases with fluctuations, 10 nLBD 
with fluctuations, 8 nLBD without fluctuations, 8 AD and 4 Controls. No significant 
difference in the interval between the last MMSE and death was observed between the 
groups. In comparison to controls, significantly lower last MMSE scores were observed in 
DLB cases with fluctuations (z=-18.250, p=0.014), nLBD with fluctuations (z=19.150, 
p=0.005), nLBD without fluctuations (z=-20.625, p=0.003) and AD cases (z=-18.250, 
p=0.009). No significant differences in last MMSE score were observed between the disease 
groups. 
6.3.2 Fractionation Validation 
Western blot analysis of synaptosomal fractions, undertaken in a control case, validated the 
fractionation with P2 enriched for SNAP25 (figure 6.3). A single band at approximately 15 
kDa was demonstrated for Histone H3, in the P1 fraction only. A band for SNAP25, at 
approximately 23 kDa was observed in all fractions. Two bands were observed for VDAC, at 
approximately 31 kDa, in the P1 and P2 fractions. When protein levels were expressed 
relative to GAPDH, fraction P2 was found to be have a two-fold higher relative level of 





6.3.3 Transporter Blots 
Native state dot blots of transporter proteins showed that in the synaptosomal fraction, P2, 
the disease groups did not differ in comparison to controls. For SERT no difference in SERT 
level across the blot was observed for AD and DLB (p=0.777) or nLBD with and without 
fluctuations (p=0.860), no differences were observed between the disease groups (figure 
6.4A). For the vesicular monoamine transporter 2 (VMAT2) no difference was observed for 
AD and DLB (p=0.785) or nLBD with and without fluctuations (p=0.492) and controls, no 
differences were observed between the disease groups (figure 6.4B). A trend towards a 
relationship was observed between the synaptosomal level of SERT and the level of VMAT2 
(rs=0.305, p=0.059) in the disease groups. 
Figure 6.3. Fractionation validations by western blotting.                                                                                                                  
The three fractions, P1, S2 and P2 were western blotted for nuclear (H3), synaptic (SNAP25) and mitochondrial (VDAC1) 
markers, with levels of these proteins were expressed relative to GAPDH, a ubiquitous housekeeping protein. Blotting 
identified that the fragmentation process has produced a crude synaptosomal fragment (P2), however, this fragment 
did not contain all the synaptosomes from the original tissue fraction due to the presence of SNAP25, albeit at a lower 
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Figure 6.4. Serotonin reuptake transporter and vesicular monoamine transporter 2 levels.                                                                                                                                                                              
Dot blots for A- serotonin reuptake transporter (SERT) and B- vesicular monoaminergic transporter 2 (VMAT2). i representative dots from both blots. The two left columns are dots from the 
AD and DLB blot; the right two columns are dots from the nLBD with (+CF) and without (-CF) fluctuations blot. Dots representing the minimum, median and maximum are shown for the 
four fluctuation groups. Control (Con1 and Con2) show the cases with minimum (left) and maximum level (right) for the two blots, the dots representing the minimum and maximum are 
the same case for both blots. Analyses ii (AD, DLB and control) and iii (nLBD with and without fluctuations and controls) within blot iv fluctuation groups across blots. Data from both within 
and across blots  shows no difference between the synaptosomal levels of SERT or VMAT2 across any of the groups. Data is shown relative to controls with median and interquartile range. 




No associations were found between disease duration across the disease groups and 
synaptosomal SERT (p=0.304) or VMAT2 (p=0.946). 
6.3.4 NET optimisation 
Noradrenergic projections from the LC are known to project to the mPFC (Samuels and 
Szabadi, 2008a) and are speculated to play a key role in attentional and cognitive functions 
Figure 6.5. Optimisation of noradrenergic transporter dot blot.                                                                                                      
Images represent the progression of optimisation experiments for the noradrenergic transporter (NET) antibody. A- 
native state blot NET 1:1000 i pons control (PC) ii synaptosomal fraction from a control case (P2). B- 2% SDS, NET 1:1000 
i PC ii P2. C- 2% SDS with 5 minutes at 100oC, NET 1:1000 i PC ii P2. D- 5 minutes at 100oC, NET 1:1000 i PC ii P2. E- native 
state blot NET 1:500 i PC ii P2. F- 2% SDS, NET 1:500 i PC ii P2. G- 2% SDS with 5 minutes at 100oC, NET 1:500 i PC ii P2. H- 
5 minutes at 100oC, NET 1:500 i PC ii P2. I- Native state NET 1:1000 i PC ii P2, no primary iii PC iv P2. J- 5 minutes at 70oC 
NET 1:1000 i PC ii P2, no primary iii PC iv P2. K-0.05% SDS with 5 minutes at 70oC, NET 1:500 i PC ii P2 no primary iii PC iv 
P2. L- 0.05% SDS, NET 1:500 i PC ii P2 no primary iii PC iv. M- 0.1% SDS with 5 minutes at 70oC, NET 1:500 i PC ii P2 no 
primary iii PC iv P2. N- 0.1% SDS with 5 minutes at 70oC, NET 1:500 i PC ii P2 no primary iii PC iv P2. O- 0.1% SDS, 5 
minutes heat at 70oC, Reducing agent 1:10, NET 1:500 i PC ii P2 no primary iii PC iv P2. P- 0.05% SDS, 5 minutes heat at 
70oC, Reducing agent 1:10, NET 1:500 i PC ii P2 no primary iii PC iv P2. Q- 0.1% SDS, 10 minutes heat at 70oC, NET 1:500 i 
PC ii P2 no primary iii PC iv P2. R- 0.05% SDS, 10 minutes heat at 70oC, NET 1:500 i PC ii P2 no primary iii PC iv P2. S-0.1% 
SDS, 10 minutes heat at 70oC, Reducing agent 1:10, NET 1:500 i PC ii P2 no primary iii PC iv P2. T- 0.05% SDS, 10 minutes 
heat at 70oC, Reducing agent 1:10, NET 1:500 i PC ii P2 no primary iii PC iv P2. U- 10 minutes heat at 70oC, NET 1:500 i P2 
ii soluble enzyme fraction from the same case as P2 (S2) no primary iii P2 iv S2. V- native state blot with a 4-fold increase 
in protein loaded (40µg), NET 1:500, i P2 ii S2 no primary iii P2 iv S2. W- reducing agent 1:10, 10 minutes at 70oC, NET 
1:500 i P2 ii S2 no primary iii P2 iv S2. X- NET immunohistochemical staining 1:50, section is from the fixed hemisphere 




(Samuels and Szabadi, 2008b). To assess noradrenergic innervation in the mPFC in the 
present study dot it was aimed to look at the levels of NET via dot blot. The experimental 
protocol for the NET dot blot underwent a series of optimisations (figure 6.5).  
Briefly, the antibody was tested in various conditions on a number of fractions from both 
the mPFC and the pons. The fractions utilised were from the same control case. mPFC P2 
and S2 fractions were examined, the S2 fraction was examined to determine that NET was 
not present in another fraction. A further S1 fraction, only undergoing the first 
centrifugation, from the pons containing the LC was also utilised. Conditions included 
preheating the sample, addition of SDS, in order to denature and linearize the protein, and 
altering the dilution of NET antibody. However, although the antibody used has been 
previously validated on human cingulate cortex via immunoblotting (Lina Pattinson, 
personal communication, 2020), a working experimental protocol could not be established 
for mPFC tissue. Upon further examination of the antibody in fixed pons tissue containing 
the LC, where a working dilution of 1:5000 had been previously shown, a dilution of 1:50 
was required to obtain positive staining. 
6.3.5 ChAT Blots 
Native state dot blots of ChAT showed that in the synaptosomal fraction, P2, the disease 
groups did not differ in comparison to controls. No significant difference was observed for 
AD and DLB with fluctuations (p=0.959) or nLBD with and without fluctuations (p=0.618) 
with controls, no differences were observed between the disease groups (p=0.799) (figure 
6.6).  
No association was found for disease duration across the disease groups for synaptosomal 
ChAT (p=0.585). 
6.3.5.1 Relationship of ChAT with VMAT2 and SERT levels 
A positive relationship was observed between synaptosomal ChAT levels and VMAT2 levels 
(rs=0.809, p<0.001) (figure 6.7), when the disease groups were analysed together. When 
analysed individually synaptosomal ChAT and VMAT2 levels were identified to be positively 
associated in the DLB with fluctuations (rs=0.903, p<0.001), nLBD without fluctuations 
(rs=0.806, p=0.005) and AD (rs=0.783, p=0.013) groups. A trend towards an association was 
observed between ChAT and VMAT2, synaptosomal fraction levels in the nLBD with 




























































































































Figure 6.7. Choline acetyltransferase levels.                                                                                                                                                                                                                                                                             
Dot blot for choline acetyltransferase (ChAT). A- representative dots from both blots. The two left columns are dots from the AD and DLB blot; the right two columns are dots from the nLBD 
with (+CF) and without (-CF) fluctuations blot. Dots representing the minimum, median and maximum are shown for the four fluctuation groups. Control (Con1 and Con2) show the cases 
with minimum (left) and maximum level (right) for the two blots, the dots representing the minimum and maximum are the same case for both blots. Analyses B and C within blot; D 
fluctuation groups across blots. Data is shown relative to controls with median and interquartile range. Abbreviations: AD- Alzheimer’s disease; CF- cognitive fluctuations; DLB- dementia 
with Lewy bodies; nLBD- neocortical/limbic pathologically Lewy body disease. 
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Figure 6.6. Correlation between choline acetyltransferase and vesicular monoamine 
transporter 2 levels.                                                                                                                  
Scatterplot illustrating the significant correlation between choline acetyltransferase (ChAT) 
and vesicular monoamine transporter 2 (VMAT2) levels in all cases apart from controls. Data 






No relationship was observed for ChAT and SERT levels (p=0.147), when the disease groups 
were jointly analysed. Synaptosomal fraction ChAT levels were not associated with SERT 
levels in the disease groups when analysed individually. 
6.3.6 mPFC α-synuclein Pathology  
α-synuclein pathology was measured utilising two antibodies 5G4, (figure 6.8) which 
recognises aggregated α-synuclein, and pS129 (figure 6.9) recognising α-synuclein 
phosphorylated at serine 129, within the synaptosomal, P2, and the soluble enzyme, S2, 
fractions. 5G4 recognises a conformation that is believed to be pathogenic and pS129 
recognises a post-translationally modified form which is upregulated in disease states 
No significant effect of disease group was observed between AD and DLB compared to 
control for 5G4 in the P2 fraction (p=0.276) (figure 6.8A). No effect of disease group was 
identified for nLBD with and without fluctuations compared to controls for 5G4 in the P2 
fraction (p=0.178) (figure 6.8A). When 5G4 levels were analysed across blots a significant 
effect of disease group was observed in the P2 fraction (χ²=8.073, p=0.045) (figure 6.8A); AD 
had a significantly lower level of 5G4 than nLBD with fluctuations (z=-12.056, p=0.021) and 
nLBD without fluctuations (z=13.656, p=0.009). No differences were observed between the 
nLBD with and without fluctuation groups (p=0.754) or between the DLB with fluctuations 
and the nLBD with (p=0.388) or without fluctuations (p=0.239). No further differences were 
identified.  
In the S2 fraction a trend towards a significant effect of disease group on the level of 5G4 
was observed between AD and DLB compared to controls (p=0.078) (figure 6.8B). A 
significant effect of disease group for nLBD with and without fluctuations compared to 
controls was observed for 5G4 in the S2 fraction (χ²=11.585, p=0.003) (figure 6.8B). In the S2 
fraction controls had a significantly lower level of 5G4 than nLBD with fluctuations (z=-
12.200, p=0.002) and nLBD without fluctuations (z=10.900, p=0.006), no difference was 
observed between the nLBD groups (p=0.741). No effect of disease group was observed 
when analysed across blots within the S2 fraction (p=0.283) (figure 6.8B). 
A significant effect of disease group was observed for AD and DLB with control for pS129 in 
the P2 fraction (χ²=13.880, p=0.001) (figure 6.9A). DLB with fluctuations had a significantly 
higher level of pS129 in the P2 fraction than AD (z=13.556, p<0.001) and controls (z=9.778, 




controls was observed for pS129 in the P2 fraction (χ²=14.532, p=0.001) (figure 6.9A). 
Controls had a significantly lower level of pS129 in the P2 fraction in comparison to nLBD 
with fluctuations (z=-14.278, p<0.001) and nLBD without fluctuations (z=11.178, p=0.004); 
no difference was observed between the nLBD groups with and without fluctuations 
(p=0.416). When analysed across blots a significant effect of disease group was observed for 
pS129 P2 levels (χ²=19.432, p<0.001) (figure 6.9A). Within the P2 fraction, pS129 levels were 
significantly higher in DLB with fluctuations (z=15.711, p=0.003), nLBD with fluctuations (z=-
21.811, p<0.001) and nLBD without fluctuations (z=17.511, p=0.001) in comparison to AD. 
No difference in P2 pS129 levels were observed between the DLB with fluctuation and nLBD 
with (p=0.232) or without fluctuation groups (p=0.724). No further differences were 
observed.  
Within the S2 fraction a significant effect of disease group was observed for AD and DLB 
with control for pS129 (χ²=14.678, p=0.001) (figure 6.9B). DLB with fluctuations had a 
significantly higher level of pS129 in the S2 fraction than AD (z=11.033, p=0.005) and 
controls (z=13.850, p<0.001). In the S2 fraction a significant effect of disease group for nLBD 
with and without fluctuations with controls was observed for pS129 (χ²=18.715, p<0.001) 
(figure 6.9B). Control cases had a significantly lower S2 pS129 level than nLBD with 
fluctuations (z=-15.400, p<0.001) and nLBD without fluctuations (z=14.000, p<0.001); no 
difference was observed between the two nLBD groups (p=0.722). pS129 levels in the S2 
fraction when analysed across blots identified a significant effect of disease group 
(χ²=15.305, p=0.002) (figure 6.9B). Within the S2 fraction, pS129 levels were significantly 
higher in DLB with fluctuations (z=15.389, p=0.003), nLBD with fluctuations (z=-18.389, 
p<0.001) and nLBD without fluctuations (z=16.489, p=0.002) in comparison to AD. No 
difference in S2 pS129 levels were observed between the DLB with fluctuations and nLBD 
with (p=0.556) or without fluctuations groups (p=0.829). No further significant differences 
between the level of pS129 in the S2 fraction were identified.  
In summary, 5G4 was higher in the nLBD with and without fluctuations groups compared to 
AD, in the P2 fraction and compared to controls in the S2 fraction. pS129 was higher in the 
DLB with fluctuations, nLBD with and without fluctuations groups in comparison to both AD 






Figure 6.8. α-synuclein -5G4 pathology.                                                                                                                                                                                                                                                                            
Dot blots for A- Synaptosomal fraction, P2, and B- Soluble enzyme fraction, S2, 5G4. i representative dots from both blots. The two left columns are dots from the AD and DLB blot; the right 
two columns are dots from the nLBD with (+CF) and without (-CF) fluctuations blot. Dots representing the minimum, median and maximum are shown for the four fluctuation groups. Control 
(Con1 and Con2) show the cases with minimum (left) and maximum level (right) for the two blots, the dots representing the minimum and maximum are the same case for both blots. Analyses 
ii and iii within blot iv fluctuation groups across blots. Data is shown relative to controls with median and interquartile range *p<0.05 **p<0.01. Abbreviations: AD- Alzheimer’s disease; CF- 
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Figure 6.9. α-synuclein -pS129 pathology.                                                                                                                                                                                                                                                                             
Dot blots for A- Synaptosomal fraction, P2, and B- Soluble enzyme fraction, S2, pS129. i representative dots from both blots. The two left columns are dots from the AD and DLB blot; the right 
two columns are dots from the nLBD with (+CF) and without (-CF) fluctuations blot. Dots representing the minimum, median and maximum are shown for the four fluctuation groups. Control 
(Con1 and Con2) show the cases with minimum (left) and maximum level (right) for the two blots, the dots representing the minimum and maximum are the same case for both blots. Analyses ii 
and iii within blot iv fluctuation groups across blots. Data is shown relative to controls with median and interquartile range *p<0.05 **p<0.01 ***p<0.001. Abbreviations: AD- Alzheimer’s disease; 
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6.3.6.1 Relationship between α-synuclein in different cellular locations 
A positive association was observed between 5G4 levels in the P2 and S2 fractions, when 
analysed across the disease groups (rs=0.417, p=0.008). When analysed separately based 
upon disease group a positive association was only observed between 5G4 P2 and S2 levels 
in the nLBD without fluctuations group (rs=0.673, p=0.033). The level of pS129 was found to 
have a positive association, when analysed across all disease groups, between the P2 and S2 
fraction (rs=0.869, p<0.001). When the disease groups were analysed individually positive 
relationships between the pS129 level in the P2 and S2 fraction were observed in the DLB 
with fluctuations (rs=0.685, p=0.029), nLBD with fluctuations (rs=0.891, p=0.001) and the 
nLBD without fluctuations groups (rs=0.842, p=0.002). 
pS129 and 5G4 are markers of species of α-synuclein, both forms of α-synuclein are thought 
to be important in LBD. When the disease groups were analysed together no association 
was observed between the synaptosomal level of 5G4 with the P2 fraction (p=0.252) or S2 
fraction (p=0.222) level of pS129. No relationships between the level of 5G4 in the P2 
fraction and the level of pS129 in the P2 or S2 fraction were observed when the disease 
groups were analysed individually. The soluble enzyme, S2 fraction level of 5G4 was not 
associated with the P2 fraction (p=0.341) or S2 fraction (p=0.098) level of pS129. No 
relationships between the level of 5G4 in the S2 fraction and the level of pS129 in the P2 or 
S2 fraction were observed when the disease groups were analysed individually. 
6.3.6.2 Cellular location of α-synuclein species 
Different species of α-synuclein have been speculated to be preferentially located in 
different subcellular compartments, for example, the synaptic cleft and the neuronal soma 
(Miraglia et al., 2018). Ratios were generated between the levels of 5G4 and pS129 in the P2 
and S2 fractions; with values over 1 suggestive that the levels of the α-synuclein species are 
higher in the P2 fraction and those under 1 the S2 fraction.  
A one-sample Wilcoxon signed rank test was undertaken to assess whether the observed 
median for the ratios between P2 and S2 fractions deviated from a hypothetical median of 
1, indicative that the species were equally present in both fractions. A significant deviation 
from the hypothetical median of 1 was observed, in all disease groups combined, for 5G4 
levels, actual median 0.53 (z=74.000, p<0.001) (figure 6.10A). When the disease groups 




observed in nLBD with fluctuations, actual median 0.58 (z=3.000, p=0.013) nLBD without 
fluctuations, actual median 0.53 (z=5.000, p=0.022) and AD, actual median 0.47 (z=0.000, 
p=0.008) groups for the ratio of 5G4 levels between the P2 and S2 fractions (figure 6.10B). 
No deviation for the 5G4 ratio was observed for the DLB group, actual median 0.62 
(p=0.139). The pS129 ratio between levels in the P2 and S2 fraction did not deviate from the 
hypothetical median, actual median 0.86 (p=0.446) (figure 6.10A). When the disease groups 
were analysed individually only the AD group had a pS129 ratio that significantly deviated 
from 1, actual median 0.49 (z=4.000, p=0.050). The pS129 ratios in the DLB with 
fluctuations, actual median 0.80 (p=0.386), nLBD with fluctuations, actual median 1.13 
(p=0.285) and nLBD without fluctuations, actual median 0.84 (p=0.799) did not deviate from 
the hypothetical median (figure 6.10C). 
To summarise, the data suggests that 5G4 is observed preferentially in the S2 in comparison 
to the P2 fraction, however when analysed individually based upon disease group DLB with 
fluctuation cases were not seen to have 5G4 preferentially in either fraction. In comparison, 
pS129 was observed not to be preferentially located in either fraction, although when 
analysed individually based upon disease group AD cases were found to have pS129 
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Figure 6.10. Ratios for level of 5G4 and pS129 between the synaptosomal and soluble enzyme fractions.                                                                                                                                       
Ratios for level of 5G4 and pS129 between the synaptosomal, P2, and soluble enzyme, S2 fractions.  A- all fluctuation 
groups, median: 5G4-0.53, pS129-0.86; B- individual fluctuation groups for 5G4 ratio, median: DLB with fluctuations- 
0.62, nLBD with fluctuations-0.58, nLBD without fluctuations- 0.53, AD- 0.47 ; C- individual fluctuation groups for pS129 
ratio, median, DLB with fluctuations- 0.80, nLBD with fluctuations-1.13, nLBD without fluctuations- 0.84, AD- 0.49. 
Dotted line represents the hypothetical median of 1. *p<0.05 **p<0.01 ***p<0.001. Abbreviations: AD- Alzheimer’s 





6.3.6.3 Relationship with cognitive fluctuations 
No association was observed between the level of pS129 or 5G4 in the P2 or S2 fraction and 
the severity of cognitive fluctuations as measured by CAF score, when the DLB and nLBD 
with fluctuations groups were analysed together (table 6.3). When the fluctuation groups 
Table 6.5. Associations between cognitive fluctuation severity and α-synuclein pathology.                                               
Spearman’s rank correlations between α-synuclein, 5G4 and pS129, in the synaptosomal, P2, and soluble enzyme, S2, 
fractions, and severity of cognitive fluctuations as measured by last, average and maximum CAF score. Associations were 
undertaken in DLB and nLBD both combined and individually. *p<0.05 Abbreviations: CAF- clinical assessment of 
fluctuation: DLB- dementia with Lewy bodies; nLBD- neocortical/limbic pathologically Lewy body disease; rs- spearman’s 





were analysed separately a negative association was observed with the level of pS129 in the 
P2 fraction and the severity of cognitive fluctuations as measured by the maximal CAF score 
(rs=-0.789, p=0.011) in the DLB with fluctuation group. No further associations were 
observed between the level of pS129 and 5G4 in the P2 or S2 fraction with the severity of 
cognitive fluctuations as measured by CAF score in the DLB and nLBD with fluctuations 
groups when analysed individually (table 6.3).    
6.3.7 mPFC Phosphorylated tau Pathology 
Tau pathology was measured utilising a ‘cocktail’ of three antibodies which recognise 
different phosphorylated forms of tau: PHF-1, recognises tau phosphorylated at serine 396 
and serine 404; AT8, recognises tau phosphorylated at serine 199 and 202, and threonine 
205; CP-13 recognises tau phosphorylated at serine 202 only. Phosphorylated tau levels 
were measured in the soluble enzyme, S2 (figure 6.11B) and synaptosomal, P2 (figure 6.11A) 
fractions. 
In the P2 fraction, a significant effect of disease group was observed between AD and DLB 
compared to control with phosphorylated tau (χ²=18.237, p<0.001) (figure 6.11A). The level 
of phosphorylated tau was significantly higher in the AD group in comparison to DLB with 
fluctuations (z=-12.700, p=0.001) and control (z=15.444, p<0.001). No difference was 
observed between the level of phosphorylated tau between the DLB with fluctuation group 
and the control cases (p=0.468). A significant main effect of disease group on the level of 
phosphorylated tau for nLBD with and without fluctuations in comparison to controls 
(χ²=17.906, p<0.001) (figure 6.11A). Phosphorylated tau levels were significantly lower in 
controls compared with nLBD with fluctuations (z=-13.289, p=0.001) and nLBD without 
fluctuations (z=15.389, p<0.001). No difference in phosphorylated tau in the P2 fraction was 
observed between both nLBD fluctuation groups (p=0.581). When analysed across blots 
there was a significant main effect of disease group on the level of phosphorylated tau in 
the P2 fraction (χ²=20.885, p<0.001) (figure 6.11A). P2 fraction phosphorylated tau levels 
were lower in DLB with fluctuations compared to nLBD with fluctuations (z=-15.000, 
p=0.003), nLBD without fluctuations (z=-18.300, p<0.001) and AD (z=-21.933, p<0.001). No 
differences were observed in the level of phosphorylated tau in the P2 fraction between 
both nLBD fluctuation groups and between the AD cases and the nLBD with (p=0.186) and 









































































































































































































































































Figure 6.11. Phosphorylated tau pathology.                                                                                                                                                                                                                                                                  
Dot blots for A- Synaptosomal fraction, P2, and B- Soluble enzyme fraction, S2, phosphorylated tau (ptau). i representative dots from both blots. The two left columns are dots from the AD 
and DLB blot; the right two columns are dots from the nLBD with (+CF) and without (-CF) fluctuations blot. Dots representing the minimum, median and maximum are shown for the four 
fluctuation groups. Control (Con1 and Con2) show the cases with minimum (left) and maximum level (right) for the two blots, the dots representing the minimum and maximum are the same 
case for both blots. Analyses ii and iii within blot iv fluctuation groups across blots. Data is shown relative to controls with median and interquartile range *p<0.05 **p<0.01 ***p<0.001. 


























Within the S2 fraction a significant effect of disease group on phosphorylated tau level was 
observed for AD and DLB in comparison to controls (χ²=18.797, p<0.001) (figure 6.11B). The 
level of phosphorylated tau was significantly higher in the AD group in comparison to DLB 
with fluctuations (z=-12.800, p=0.001) and control (z=16.200, p<0.001). No difference was 
observed between the level of phosphorylated tau between the DLB with fluctuations group 
and the control cases (p=0.372). A significant main effect of disease group on level of 
phosphorylated tau was observed nLBD with and without fluctuations (χ²=18.209, p<0.001) 
in comparison to controls, in the S2 fraction (figure 6.11B). Phosphorylated tau levels were 
significantly lower in controls compared with nLBD with fluctuations (z=-13.200, p=0.001) 
and nLBD without fluctuations (z=15.600, p<0.001). No difference in phosphorylated tau in 
the S2 fraction was observed between both nLBD fluctuation groups (p=0.542). When 
analysed across blots there was a significant main effect of disease group on the level of 
phosphorylated tau in the S2 fraction (χ²=22.547, p<0.001) (figure 6.11B). S2 fraction 
phosphorylated tau levels were lower in DLB with fluctuations compared to nLBD with 
fluctuations (z=-14.100, p=0.006), nLBD without fluctuations (z=-18.300, p<0.001) and AD 
(z=-23.367, p<0.001). No differences were observed in the level of phosphorylated tau in 
the S2 fraction between both nLBD fluctuation groups and between the AD cases and the 
nLBD without (p=0.333) fluctuations group, although a trend towards a significant 
difference was observed between AD and nLBD with fluctuations (p=0.077). 
In summary, phosphorylated tau was higher in the AD and nLBD with and without 
fluctuations groups compared to controls and DLB in both the P2 and S2 fractions. No 
further differences were observed. 
6.3.7.1 Relationship between neuronal sublocations 
A positive association was observed between phosphorylated tau levels in the P2 and S2 
fractions, when analysed across the disease groups (rs=0.964, p<0.001). When the disease 
groups were analysed individually, positive relationships between the phosphorylated tau 
level in the P2 and S2 fractions were observed in all the groups: DLB with fluctuations 
(rs=0.648, p=0.043), nLBD with fluctuations (rs=0.988, p<0.001), nLBD without fluctuations 




6.3.7.2 Relationship with α-synuclein species 
Phosphorylated tau levels in the synaptosomal, P2 fraction, when analysed across all disease 
groups were found not to be associated with the P2 (p=0.883) or S2 (p=0.717) level of 5G4 
and the P2 (p=0.407) or S2 (p=0.137) level of pS129. When the disease groups were 
analysed individually a positive relationship was observed between the level of 
phosphorylated tau in the P2 fraction and the level of pS129 in the P2 fraction within the 
DLB with fluctuations group (rs=0.661, p=0.038). No further associations were observed for 
the level of phosphorylated tau in the P2 fraction and the level of 5G4 and pS129 in the P2 
and S2 fractions in the individual disease groups. 
In the soluble enzyme, S2 fraction, the level of phosphorylated tau was identified to not 
associated with the level of 5G4 in the P2 (p=0.169) or S2 (p=0.488) fraction and the level of 
pS129 in the P2 (p=0.487) or S2 (p=0.359) fraction, when the disease groups were jointly 
analysed. When the disease groups were analysed individually a positive relationship was 
observed between the level of phosphorylated tau in the S2 fraction and the level of pS129 
in the P2 fraction within the DLB with fluctuations group (rs=0.806, p=0.005). No further 
associations were observed for the level of phosphorylated tau in the S2 fraction and the 
level of 5G4 and pS129 in the P2 and S2 fractions in the individual disease groups. 
6.3.7.3 Relationship with cognitive fluctuations 
No association was observed between the level of phosphorylated tau in the P2 or S2 
fraction with the severity of cognitive fluctuations as measured by CAF score, when the DLB 
and nLBD with fluctuations groups were analysed together (table 6.4). When the fluctuation 
groups were analysed separately a negative association was observed with the level of 
phosphorylated tau in the S2 fraction and the severity of cognitive fluctuations as measured 
by the last CAF score (rs=-0.778, p=0.014) in the DLB with fluctuation group. No further 
associations were observed between the level of phosphorylated tau in the P2 or S2 fraction 
with the severity of cognitive fluctuations as measured by CAF score in the DLB and nLBD 










6.3.8 mPFC Aβ pathology 
Aβ pathology was measured utilising an antibody that recognises unaggregated, oligomeric 
and fibrillar forms of Aß42, and unaggregated Aß40 and not APP. Aβ levels were measured 
in the soluble enzyme, S2 (figure 6.12B), and synaptosomal, P2 (figure 6.12A), fractions. 
In the P2 fraction, a significant effect of disease group was observed for AD and DLB 
compared to controls with the level of Aβ (χ²=6.808, p=0.033) (figure 6.12A). A significantly 
higher level of Aβ was observed in the AD group compared to controls (z=10.111, p=0.009). 
No difference was observed between the DLB with fluctuation group and control (p=0.209) 
or AD groups (p=0.156). A significant effect of disease group on Aβ level was observed nLBD 
with and without fluctuations (χ²=6.806, p=0.033) in comparison to controls, in the P2  
Table 6.7. Associations between cognitive fluctuation severity and phosphorylated tau.                                                                                                                                                                                    
Spearman’s rank correlations between phosphorylated tau (ptau), in the synaptosomal, P2, and soluble enzyme, S2, 
fractions, and severity of cognitive fluctuations as measured by last, average and maximum CAF score. Associations 
were undertaken in DLB and nLBD both combined and individually. *p<0.05 Abbreviations: CAF- clinical assessment of 
fluctuation: DLB- dementia with Lewy bodies; nLBD- neocortical/limbic pathologically Lewy body disease; rs- spearman’s 









































































































































































































































































A i ii iii iv 
B i ii iii iv 
Figure 6.12. Aβ pathology.                                                                                                                                                                                                                                                                                               
Dot blots for A- Synaptosomal fraction, P2, and B- Soluble enzyme fraction, S2, Aβ (MoAB). i representative dots from both blots. The two left columns are dots from the AD and DLB blot; 
the right two columns are dots from the nLBD with (+CF) and without (-CF) fluctuations blot. Dots representing the minimum, median and maximum are shown for the four fluctuation 
groups. Control (Con1 and Con2) show the cases with minimum (left) and maximum level (right) for the two blots, the dots representing the minimum and maximum are the same case for 
both blots. Analyses ii and iii within blot iv fluctuation groups across blots. Data is shown relative to controls with median and interquartile range *p<0.05 **p<0.01. Abbreviations: AD- 





fraction (figure 6.12A). P2 fraction Aβ levels were significantly higher in the nLBD with 
fluctuation group (z=-8.311, p=0.034) and nLBD without fluctuation (z=9.411, p=0.016) 
groups compared to control cases. No difference was observed in P2 fraction Aβ levels 
between both nLBD fluctuation groups (p=0.773). When analysed across blots no effect of 
disease group was observed on the level of Aβ in the P2 fraction (p=0.322) (figure 6.12A). 
In the S2 fraction, a trend towards a significant effect of disease group was observed for AD 
and DLB with control for the level of Aβ (p=0.051) (figure 6.12B). A significant effect of 
disease group was observed for Aβ level was observed nLBD with and without fluctuations 
(χ²=8.954, p=0.011) in comparison to controls, in the S2 fraction (figure 6.12B). S2 fraction 
Aβ levels were significantly higher in the nLBD with fluctuation group (z=-10.100, p=0.010) 
and nLBD without fluctuation (z=10.300, p=0.009) groups compared to control cases. No 
difference was observed in S2 fraction Aβ levels between both nLBD fluctuation groups 
(p=0.959). When analysed across blots no effect of disease group was observed on the level 
of Aβ in the S2 fraction (p=0.222) (figure 6.12B). 
In summary, Aβ was higher in the AD and nLBD with and without fluctuations groups 
compared to controls in the P2 fraction and in the S2 fraction Aβ was higher in the nLBD 
with and without fluctuations groups compared to controls. No further differences were 
observed. 
6.3.8.1 Relationship between neuronal sublocations 
A positive association was observed between Aβ levels in the P2 and S2 fractions, when 
analysed across the fluctuation groups (rs=0.905, p<0.001). When the fluctuation groups 
were analysed individually, positive relationships between the Aβ level in the P2 and S2 
fractions were observed in all the groups: DLB with fluctuations (rs=0.927, p<0.001), nLBD 
with fluctuations (rs=0.952, p<0.001), nLBD without fluctuations (rs=0.733, p=0.016) and AD 
(rs=0.917, p=0.001). 
6.3.8.2 Relationship with α-synuclein species 
Aβ in the synaptosomal, P2 fraction, when analysed across all disease groups was not 
associated with the P2 (p=0.572) or S2 (p=0.449) level of 5G4 and the P2 (p=0.928) or S2 
(p=0.457) level of pS129. When the disease groups were analysed individually no 
associations were observed for the level of Aβ in the P2 fraction and the level of 5G4 and 




In the soluble enzyme, S2 fraction, the level of Aβ was not associated with the level of 5G4 
in the P2 (p=0.772) or S2 (p=0.644) fraction and the level of pS129 in the P2 (p=0.580) or S2 
(p=0.395) fraction, when the disease groups were jointly analysed. When the disease groups 
were analysed individually no relationships were observed between the level of Aβ in the S2 
fraction and the level of 5G4 and pS129 in the P2 and S2 fractions. 
6.3.8.3 Relationship with phosphorylated tau levels 
The level of Aβ in the synaptosomal fraction was not associated with the level of 
phosphorylated tau in the P2 (p=0.438) and S2 (p=0.628) fractions, when analysed across all 
disease groups. When the disease groups were analysed individually a negative relationship 
was observed between the level of Aβ in the P2 fraction and the level of phosphorylated tau 
in the S2 fraction in the nLBD with fluctuations group (rs=-0.648, p=0.043). No further 
associations were observed between the level of Aβ in the P2 fraction and the P2 or S2 
fraction level of phosphorylated tau in the individual disease groups. 
Aβ in the S2 fraction, when analysed across all disease groups, was not associated with the 
level of phosphorylated tau in the P2 (p=0.325) or S2 (p=0.436) fractions. When the disease 
groups were analysed individually, the level of Aβ in the S2 fraction, and the level of 
phosphorylated tau in the S2 fraction in the nLBD with fluctuations group negatively 
associated (rs=-0.697, p=0.025), and the level of phosphorylate tau in the P2 fraction in the 
DLB with fluctuations group positively associated (rs=0.733, p=0.016). No further 
associations were observed between the level of Aβ in the S2 fraction and the P2 or S2 
fraction level of phosphorylated tau in the individual disease groups. 
6.3.8.4 Relationship with cognitive fluctuations 
No association was observed between the level of Aβ in the P2 or S2 fraction with the 
severity of cognitive fluctuations as measured by CAF score, when the DLB and nLBD with 
fluctuations groups were analysed together (table 6.5). When the fluctuation groups were 
analysed separately no associations were observed between the level of Aβ in the P2 or S2 
fraction with the severity of cognitive fluctuations as measured by CAF score in the DLB and 




6.3.9 Mitochondrial Blots 
The P2 fraction, as well as being enriched for synaptosomes, is enriched for mitochondria. 
The levels of NDUFB8, a subunit of complex I in the electron transport chain (figure 6.13B), 
and TOM20, an outer mitochondrial membrane transporter protein (figure 6.13A), were 
examined in the P2 fraction. The level of TOM20 is representative of the number of 
mitochondria present within the fraction, with the NDUFB8:TOM20 representative of the 
level of complex I relative to the level of mitochondria.   
No effect of disease group was identified on TOM20 for AD and DLB (χ²=1.117, p=0.572) or 
nLBD with and without fluctuations (χ²=0.101, p=0.951) with controls (figure 6.13A). When 
analysed across blots no effect of disease group was observed for TOM20 (χ²=2.336, 
p=0.506) (figure 6.13A). No effect of disease group on NDFUB8:TOM20 was observed for AD 
and DLB (χ²=0.727, p=0.695) or nLBD with and without fluctuations (χ²=2.476, p=0.290) with 
Table 6.9. Associations between cognitive fluctuation severity and Aβ.                                                                            
Spearman’s rank correlations between Aβ (MoAB), in the synaptosomal, P2, and soluble enzyme, S2, fractions, and 
severity of cognitive fluctuations as measured by last, average and maximum CAF score. Associations were undertaken in 
DLB and nLBD both combined and individually. Abbreviations: CAF- clinical assessment of fluctuation: DLB- dementia with 




controls (figure 6.13B). When analysed across blots no effect of disease group was observed 


















































































































































































































Figure 6.13. Mitochondria blots.                                                                                                                                                                                                                                                                                             
Dot blots for synaptosomal, P2 fraction A- TOM20 and B- NDUFB8:TOM20. i representative dots from A-B-TOM20 and NDUFB8 blots. The two left columns are dots from the AD and DLB blot; 
the right two columns are dots from the nLBD with (+CF) and without (-CF) fluctuations blot. Dots representing the minimum, median and maximum are shown for the four fluctuation groups. 
Control (Con1 and Con2) show the cases with minimum (left) and maximum level (right) for the two blots, the dots representing the minimum and maximum are the same case for both blots. 
Analyses ii and iii within blot iv fluctuation groups across blots. Data is shown relative to controls with median and interquartile range. Abbreviations: AD- Alzheimer’s disease; CF- cognitive 
fluctuations; DLB- dementia with Lewy bodies; nLBD- neocortical/limbic pathologically Lewy body disease. 
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The present study aimed to examine synaptosomes in a cortical target region of the ARAS, 
in order to assess the integrity of the projections from the nuclei investigated in the 
previous chapters, in addition to whether changes to the cortical regions could play a role in 
the presence or severity of cognitive fluctuations in DLB. Previous studies have identified 
changes to mPFC and its innervation in neurodegenerative dementias (Galvin et al., 2011; 
Chabran et al., 2020), with changes to input from the thalamus having been shown to play a 
role in the recovery from a vegetative state (Jang et al., 2020). The present study identified 
that in a synaptosomal-enriched fraction neurotransmitter marker levels did not differ from 
control levels and were not related to the presence of cognitive fluctuations or the level of 
pathological burden in their source nuclei. Pathological analysis also identified that the 
burden of pathological lesions in the mPFC were not to related with the presence or severity 
of cognitive fluctuations. However, differences in the neuronal sublocation of different α-
synuclein species was observed. Furthermore, the present study identified that in the 
synaptosomally enriched fraction there were no differences in the level of mitochondria or 
the level of complex I.   
6.4.1 Neurotransmitter markers do not differ from controls in the synaptosomal fraction 
The present study aimed to examine the integrity of the projections both directly and 
indirectly, via the basal forebrain, from the brainstem nuclei of the ARAS. Analysis of VMAT2 
and SERT, markers of direct projections, and ChAT, indirect projections via the basal 
forebrain, in the synaptosomal fraction identified no difference in neurotransmitter marker 
levels in the disease groups compared to the control cases.  
SERT is located on the presynaptic terminals of serotonergic neurons originating from the 
raphe nucleus. Alterations to the serotonin system have been observed in a number of 
neurodegenerative dementias including AD and DLB (Chen et al., 2000; Azmitia and Nixon, 
2008; Roselli et al., 2010). In AD a previous study identified a reduction in SERT density 
compared to controls utilising whole tissue analysis in the prefrontal cortex (Thomas et al., 
2006). A similar finding of reduced SERT level has been observed in DLB compared to 
controls in the parietal cortex (Ballard et al., 2002a; Francis, 2009). The current study, in 
comparison to previous studies, examined the level of SERT in a synaptosomal fraction 




specifically measure the levels of functional transporters, those at the synapse, compared to 
those that were stored in other neuronal compartments. The differences observed between 
the current study and those previously could be a reflection of the synaptosomal 
methodology used. The tissue fractionation was undertaken to select for the ‘functional’ 
transporters and receptors, those present at the synapse. If the crude synaptosomal 
fraction represented the levels of ‘functional’ SERT, our results, in combination with 
previous studies that have identified a loss of SERT in whole tissue analysis, could suggest 
that there is a loss of non-synaptically located SERT. This non-synaptically located SERT 
could represent reserve pool levels of the transporter, located outside of the synaptic 
compartment. A loss of non-synaptically localised SERT could impact upon dynamics in the 
serotonergic system, meaning that it is less able to cope with any changes; studies 
investigating the dopamine transporter have identified alterations to neuronal plasticity 
when the transporter wans inactivated or reduced (Jones et al., 1998). A serotonergic 
system that is less dynamic could lead to alterations in arousal levels due to subsequent 
changes to cortical activation and feedback to the raphe nucleus, which could clinically 
manifest as cognitive fluctuations. Alterations to levels in non-synaptically located SERT, 
which were not measured in the current study, may explain why no relationships were 
observed with severity of cognitive fluctuations.  
ChAT is the synthesis enzyme for acetylcholine, where it is the sole mechanism for the 
generation of acetylcholine in cholinergic neurons. In the mPFC the main cholinergic input 
originates from the basal forebrain (Bloem et al., 2014), which is the main relay for the 
monoaminergic nuclei of the ARAS (Mahaffey and Garcia-Rill, 2015). Cortical reductions in 
ChAT level and cholinergic degeneration in basal forebrain have been widely reported in 
both AD and DLB (Tiraboschi et al., 2000; Grothe et al., 2014; Taylor et al., 2017). 
Dysfunction of the cholinergic system has been implicated in visual hallucinations and 
cognitive fluctuations in DLB (Marra et al., 2012; Chabran et al., 2020). As with the previous 
studies investigating SERT, the studies investigating levels of ChAT within the brain have 
examined whole tissue fractions, compared to the fractionated analysis undertaken in the 
current study. The conflicting data obtained from the current study could be a reflection on 
level of synaptosomes within the crude synaptosomal fraction. It could be possible that 




same level of total protein as that in the control fractions. Therefore, although the same 
level of total protein was loaded onto the blots, a higher number of synaptosomes were 
loaded in the disease groups, which could lead to the appearance of similar ChAT levels in 
the synaptosomal fraction. As the immunoblots were not normalized to SNAP25, and 
validation of the synaptosomal fractionation validation was only examined in a control case 
it was not possible to assess either the number of synaptosomes present in the crude 
synaptosomal fraction in the disease groups or, express the levels of ChAT relative to the 
level of synaptosomes present. 
Both a hypothetical loss of the reserve pool of the transporter and/or a difference in the 
number of synaptosomes within the synaptosomal fraction would need to be validated by 
examining the levels of SERT, ChAT and SNAP25 within all the fractions, as well as 
examination of a whole tissue fraction. Furthermore, analysing the levels of SNAP25 present 
within the crude synaptosomal fraction could allow for the levels of SERT and ChAT to be 
expressed relative to the synaptosomal number, similar to the NDUFB8:TOM20.  
6.4.2 Pathology alone does not distinguish fluctuating from non-fluctuating groups 
The present study aimed to investigate the involvement of neuropathological changes in the 
mPFC, including the burden of α-synuclein, tau and Aβ, on the presence and severity of 
cognitive fluctuations in DLB. Previous studies have identified neuropathological changes to 
the mPFC, including neuronal cell loss and accumulation of pathological proteins, in various 
neurodegenerative diseases including AD and DLB (Lindberg et al., 2012; Xu et al., 2019). 
Alterations to this region have also been identified to underly aspects of the cognitive 
impairment observed in AD and DLB (Kobeleva et al., 2017; Berron et al., 2020). The present 
study is in agreement with previous findings that mPFC is vulnerable to α-synuclein and AD-
type pathology. However, the present study did not identify differences in the pathological 
burdens in relation to the presence or absence of cognitive fluctuations.  
The mPFC is a highly interconnected brain region which is involved in a number of large-
scale networks, including the default mode network (Li et al., 2014). Through the 
involvement of the mPFC in large-scale networks, and its implication in arousal (Zhang et al., 
2014) and attention (Riga et al., 2014), studies have investigated the role of the mPFC, and 
the networks it is part of, in alterations to consciousness (Franciotti et al., 2013; Lowther et 




2020). Although alterations to attentional networks, including reductions in default mode 
connectivity, involving the mPFC have been identified in DLB, the studies have not identified 
an association with cognitive fluctuations, although their role has not been dismissed 
(O'Dowd et al., 2019). Alterations to mPFC innervation has been observed in AD and DLB, 
with atrophy of the basal forebrain, which provides cholinergic innervations to the mPFC 
(Grothe et al., 2014), and more severe atrophy of the cholinergic neurons associated with 
alterations to arousal levels and maintenance (Kasanuki et al., 2018). Studies examining the 
mPFC in disorders of consciousness have also identified increases to thalamocortical 
connectivity to the mPFC is associated with recovery from a vegetative state (Jang et al., 
2020), with similar alterations reported for thalamocortical projections to the mPFC in DLB 
(Chabran et al., 2020).   
Although neuropathological and connectivity changes to the mPFC are hypothesised to play 
a role in alterations to arousal and awareness, that could clinically manifest as cognitive 
fluctuations, the data from the current study suggests that any alterations are not due to 
the direct presence of pathological accumulations within the synaptosomal or soluble 
enzyme fraction of the region. The present study identified no differences in the burden of 
pathology specific to the presence or absence of cognitive fluctuations in either of the two 
tissue fractions examined. Analysis further identified that no relationships between 
pathological protein sublocation and pathological burden were specific for the presence or 
absence of cognitive fluctuations. Together this data suggests that the presence of 
pathology within the mPFC is not directly related to the presence or absence of cognitive 
fluctuations. However, it is not possible to fully conclude that the accumulation of proteins 
in the mPFC have no role in cognitive fluctuations as it is possible that they indirectly 
influence alterations to arousal and attention, for example through altered trafficking of 
receptors or vesicles, or the sequestering of catalytic enzymes, as has been previously 
observed (Dugger and Dickson, 2010). Furthermore, it could be possible that there may be 
species of pathological protein that possess more pathological relevance than those 
examined in the present study. 
6.4.3 Neuronal sub-localisation of α-synuclein species 
Physiologically α-synuclein is thought to be in a dynamic equilibrium between a free, 




species have been thought to be cytoplasmic, however, recent evidence of α-synuclein’s 
membrane binding abilities has raised the question of whether cellular sub-localisation of 
pathology impacts upon aggregation and disease progression (Miraglia et al., 2018). 
Recently, studies have begun to investigate whether α-synuclein species in different 
subcellular localisations possess different conformations and toxic effects, utilising both in 
vivo (Colla et al., 2018) and post-mortem methods (Sanderson et al., 2020).  
Data from the present study identified that aggregated α-synuclein, measured by 5G4 
antibody, was present preferentially in the S2, microsome and soluble enzyme, fraction, in 
the nLBD with and without fluctuations and AD disease groups. The levels in the P2, crude 
synaptosomal and mitochondrial fraction, were observed not to differ from controls in all 
disease groups. The observations from the current study are in agreement with research by 
Colla et al. (2012a) who identified α-synuclein aggregates and oligomers were associated 
with microsomes in vivo. Further investigations by Colla et al. (2012b), identified that this 
microsomal accumulation of aggregated and oligomeric species preceded 
neurodegeneration in mouse models of synucleinopathies. Due to the sequential 
centrifugation of the tissue in order to produce a crude synaptosomal fraction, it is possible 
that larger α-synuclein aggregates, for example Lewy bodies, would be present in the P1, 
nuclei fraction, as they would sediment at lower spin speeds. As P1 was not analysed for the 
levels of α-synuclein burden, it is not possible to comment on all sizes of α-synuclein 
aggregates. The data collected from the current study in combination with previous findings 
could suggest that aggregated forms of α-synuclein are not present as readily in synapses 
compared to cytosolic or microsomal-associated locations, however it is beyond the scope 
of the current study to assess why or the effect that this distribution has on neuronal health.  
pS129 levels were identified not to be preferentially located in with the S2 or P2 fractions in 
the pathologically LBD groups, however, in the AD group pS129 was preferentially identified 
in the S2 fraction. The level of pS129 was also observed to be significantly higher in the 
pathologically LBD groups than both controls and AD, in both the P2 and S2 fractions. 
Differences in subcellular distribution, as observed between 5G4 and pS129, have been 
previously observed in DLB post-mortem tissue (Sanderson et al., 2020). In post-mortem 
DLB tissue a redistribution of membrane associated α-synuclein to cytosolic has been 




the different cellular compartments possessed different neurodegenerative effects 
(Sanderson et al., 2020). However, in the present study we could not compare the levels to 
controls due to the nature of the analysis where levels were expressed relative to controls. 
pS129 has been shown in vivo to bind to both mitochondria (Wang et al., 2019) and 
microsomes (Colla et al., 2018), which could suggest why pS129 was not preferentially 
located in one of the two fractions examined.  
Further research is required into the different toxic species of α-synuclein and their 
subcellular localisation to assess whether there is a specific pattern of redistribution that 
could relate to clinical features. 
6.4.4 Mitochondrial levels do not differ from controls in the synaptosomal fraction 
Mitochondrial impairment and the association of α-synuclein with mitochondrial 
membranes has been widely reported in synucleinopathies (Perier and Vila, 2012; Spano et 
al., 2015); mitochondrial dysfunction has also been reported in AD (Hawking, 2016). In the 
current study it was observed that in the P2, crude synaptosomal and mitochondrial, 
fraction there was no difference in the level of TOM20, a mitochondrial outer membrane 
marker, or the level of complex I marker relative to the level of mitochondria, 
NDUFB8:TOM20, in any of the experimental groups compared to controls. Previous studies 
have reported evidence for a decrease in the level of mitochondria in DLB, with a reduction 
in the level of complex I that is not merely a consequence of the loss of mitochondria 
(Garcia-Esparcia et al., 2017; Flønes et al., 2018). However, a study by Reeve et al. (2018) 
identified an increase in mitochondrial levels, which was hypothesised due to be impaired 
mitophagy. α-synuclein species have been observed to interact with membranes, including 
mitochondria (Wang et al., 2019), and have been shown to increase their permeability 
(Sanderson et al., 2020). Within the three fractions generated by the sequential 
centrifugations, VDAC a marker of mitochondria, was located in both the P1 and P2 
fractions. Alterations to mitochondrial membrane integrity, possibly through interaction 
with α-synuclein, could lead to the selection of only ‘healthy’ mitochondria within the P2 
pellet. Furthermore, membrane integrity in general has been proposed to be impaired in 
NDDs (Yu and Zhong, 2018), which could have further led to the selection of only healthy 
synaptosomes, supporting the lack of difference observed with the neurotransmitter 




mitochondrial markers in the other fractions is required to assess levels of mitochondrial 
impairment and to validate whether the sequential centrifugations selected for healthy 
mitochondria. 
6.4.5 Limitations 
The most influential limiting factors of the current study were the lack of analysis of SNAP25 
levels in all three fractions across the disease groups, as well as no analysis of a whole tissue 
fraction. Although, the crude synaptosomal fraction provides a technique to examine 
transporter and catalytic enzyme levels at the synapse, it is possible that due to alterations 
in synapses in neurodegenerative dementias, including alterations to membrane integrity 
(Yu and Zhong, 2018), the levels of synaptosomes in the different fractions are altered. 
Without analysis of the other fractions or a whole tissue fraction it is not possible to fully 
conclude how the results in the present study differ from previous studies. Further 
experiments are required to investigate the levels of synaptosomes within the different 
fractions in the different disease groups, this could help identify whether the number of 
synaptosomes in the disease groups is higher or lower than controls and provide a relative 
value for the protein analysis. Examination of a whole tissue fraction could help identify if 
reductions to protein levels that have been widely reported, for example ChAT, are also 
identified within the whole tissue fraction of the mPFC to assess whether a different 
method would have identified neurotransmitter reductions not identified by isolating 
synaptosomes.   
The study aimed to examine the monoaminergic ARAS projections into the mPFC, however, 
it was not possible to optimise the experimental protocol to examine the level of NET within 
this region. Further studies are required to investigate the levels of NET in the region. Also, 
to understand the full extent of monoaminergic dysfunction within the mPFC examination 
of receptor levels for both serotonin and noradrenaline would be required. 
The mPFC is a large heterogeneous region, with subregions possessing distinct and often 
opposing roles in cognitive processing, as well as different cellular compositions and 
neuronal connectivity (Bzdok et al., 2013; Marusak et al., 2016). In the current study only 
BA12 was examined. The differences in tissue level and subregion of the mPFC obtained 
could have influenced the data obtained. Further examinations into all regions of the mPFC 





The present study identified pathological changes related to the pathological diagnosis 
rather than the presence or absence of cognitive fluctuations. Although not specific for 
cognitive fluctuations the changes could contribute vulnerability to fluctuations, although 
not be directly causative. The absence of alterations to mitochondrial and neurotransmitter 
markers in the current study contradicted previous studies that had identified a reduction in 
the markers in neurodegenerative dementias. Further research is required into the 
synaptosomal fragmentation to assess whether ‘healthy’ synaptosomes and mitochondria 
were preferentially selected. This in turn could help examine the differences between 
‘healthy’ and ‘non-healthy’ mitochondria and synaptosomes in the mPFC in 





Chapter 7: General Discussion 
7.1 Introduction 
DLB is the second most common neurodegenerative dementia after AD, characterised by 
the presence of four core clinical features: cognitive fluctuations, parkinsonian extra-
pyramidal symptoms, RBD, and complex visual hallucinations (McKeith et al., 2017). DLB is 
neuropathologically characterised by the presence of Lewy body pathology, described by 
the extent of its distribution throughout the brain as neocortical, limbic, brainstem, 
amygdala-predominant or olfactory bulb only (McKeith et al., 2005). Although DLB is 
characterised by the presence of α-synuclein aggregates, 50-80% of patients have 
concomitant AD type pathology (Halliday et al., 2011; McKhann et al., 2011; Attems, 2017). 
80-90% of DLB patients experience cognitive fluctuations, although they are thought to be 
the least well characterised and understood of the four core clinical features (McKeith et al., 
2000b; Ballard et al., 2001; Matar et al., 2019). Fluctuating cognition has a profound 
negative impact on the patient’s quality of life and ability to function day to day (Gibb et al., 
1987; Yamamoto and Imai, 1988; Byrne et al., 1989; McKeith et al., 1992b; Zweig and 
Galvin, 2014). 
The ARAS, comprising various nuclei within the pons and midbrain, that project to the 
cortex, thalamus and basal forebrain, has been conceptually linked to cognitive fluctuations 
(Matar et al., 2019). Dysfunction to arousal/awareness, and attention have been 
hypothesised to underlie fluctuating cognition. Alterations to regions involved in the 
maintenance of arousal and awareness could lead to moments where patients appear to be 
unreceptive to external stimuli (Matar et al., 2019; O'Dowd et al., 2019). The LC, PPN, DR 
and mPFC have been implicated in these hypotheses, as constituent parts of the ARAS and 
therefore alterations to the regions could underlie the vulnerability to cognitive 
fluctuations.  
7.2 Pathology in the locus coeruleus does not relate to the presence or absence of 
cognitive fluctuations 
Investigation of the LC identified differences in the burden of alpha-synuclein, tau and 
amyloid-beta across the disease groups. However, the differences identified were related to 
pathological diagnosis and not to the presence or absence of cognitive fluctuations. 




pathologically AD cases the highest tau and amyloid-beta levels. Further analysis in the 
groups that possessed cognitive fluctuations revealed an association between tau burden in 
the LC and severity of cognitive fluctuations in the nLBD, but not DLB group. The association 
observed in the nLBD group could be suggestive that tau likely marks dysfunction and 
neuronal stress, and dysfunction and neuronal changes of the LC may be necessary but not 
in itself sufficient to elicit cognitive fluctuations.  
The lack of a specific pattern of pathological protein accumulation within the LC suggests a 
lack of involvement of LC protein inclusions in cognitive fluctuations in DLB. Although, 
investigation into possible functional impairments of the LC and noradrenergic system was 
beyond the remit of the study. There are a number of theories that could suggest why the 
data from the present study suggested a lack of involvement for LC protein inclusions in 
cognitive fluctuations in DLB. Firstly, it could be possible that alterations in other brain 
regions, excluding the LC, but including other components of the ARAS are required to 
predispose towards fluctuations in cognition. Secondly, it could be possible that pathological 
changes to the LC or the noradrenergic system as a whole predispose to cognitive 
fluctuations, with the mechanism that elicits the cognitive fluctuations caused by 
alterations, either pathological or neurochemical, in other brain regions. Cognitive 
fluctuations are variable by nature, thus it is likely that a combination of more subtle 
changes to networks, for example alterations to receptor levels or impaired synaptic 
neurotransmitter release, are related to cognitive fluctuations rather than static 
accumulations of pathology in the neuronal soma. Therefore, a third explanation could be 
that a collection of pathological or neurochemical changes in a brain network, such as the 
ARAS, creates a compromised system that may only manifest a clinically observable feature 
when a particular level of internal or external stress is placed upon it. 
Although, no specific pattern of accumulation of protein aggregates was observed for the 
presence or absence of cognitive fluctuations, a positive relationship was observed between 
the burden of tau in the LC and the severity of cognitive fluctuations. However, the 
relationship with severity of cognitive fluctuations was observed in only the nLBD and not 
the DLB with fluctuation group. Increased levels of tau within neurons of the LC could be an 
indirect measure of increased cellular dysfunction, including alterations to vesicular 




was not undertaken in the study. Alterations to the functioning of the noradrenergic system 
could partially underly the vulnerability for fluctuations by disrupting the ability of the 
nucleus to increase awareness and attention. As the LC is affected by tau at the early stages 
of pathological progression, it could be suggested that higher tau levels in the LC are 
suggestive of globally higher tau levels and thus higher global dysfunction within the diffuse 
networks hypothesised to underly cognitive fluctuations. It is unlikely that tau in the LC is 
the sole factor driving cognitive fluctuation severity as it would be expected that an 
association to be observed in the DLB group also if this was the case. 
7.3 Pedunculopontine nucleus pathological burden does not relate to the presence or 
absence of cognitive fluctuations 
Similarly, to the LC, differences were observed in the burden of pathological proteins in the 
PPN that were related to the pathological diagnosis and not the presence or absence of 
cognitive fluctuations. In addition, no associations were observed between the pathological 
burden in the PPN and severity of cognitive fluctuations in either the DLB or nLBD with 
fluctuation groups. Furthermore, the results demonstrated that there was no specific 
pattern related to the presence or absence of cognitive fluctuations seen for the 
relationship between PPN and LC pathology burden. 
The PPN has been described as a key centre in the ARAS, and is most active during waking 
and REM sleep (Jenkinson et al., 2009; Benarroch, 2013). Impairments to the arousal 
maintenance networks have been hypothesised to underlie a vulnerability that can lead to 
fluctuating cognition (Matar et al., 2019; O'Dowd et al., 2019). The PPN is thought to 
mediate its role in arousal through cholinergic projections to the thalamus (Benarroch, 
2013), studies have noted that loss of cholinergic neurons in the PPN leads to a decrease in 
cholinergic innervation to the thalamus in PD (Francis and Perry, 2007). Studies have also 
observed alterations to the cholinergic system in the thalamus relating to cognitive 
fluctuations; including preservation of thalamic nicotinic receptors in those with fluctuations 
compared to those without (Pimlott et al., 2006) and increased levels of acetylcholine 
precursors which were closely related to the presence and severity of fluctuations (Delli 
Pizzi et al., 2015). However, these changes could be independent from the pathological 
protein accumulation within the region, which would suggest why the present study did not 




of the cholinergic neurons in the PPN could aid in the understanding of whether 
neurotransmitter/neuron specific alterations are related to cognitive fluctuations. 
Although the PPN is a key component within the systems maintaining the high frequency 
EEG required for arousal, it is possible that the clinical phenotype of cognitive fluctuations 
could be a product of a network dysfunction. Dysfunction to the PPN could play a role, but 
not be the sole factor, within a dysfunctional ARAS network, suggesting why no associations 
were observed between PPN pathological burdens and the presence of cognitive 
fluctuations. This is supported by animal studies where lesions of the PPN did not have the 
expected effect on arousal levels, suggesting redundancy or flexibility to compensate within 
the system (Mahaffey and Garcia-Rill, 2015). Generation of fluctuations in cognition could 
rely upon a collection of alterations to a number of different brain regions, including those 
identified in the PPN, that in tandem elicit fluctuations but not in isolation. Changes to the 
thalamus, the main relay for PPN cholinergic neurons mediating arousal, could contribute to 
arousal-promoting signals not being able to elicit their desired effects. Furthermore, 
molecular and connectivity changes have been observed in the thalamus that have been 
related to cognitive fluctuations (Pimlott et al., 2006; Delli Pizzi et al., 2015), consistent with 
the suggestion that signals from the PPN may not be able to elicit their arousal effects on 
cortical regions.  
7.4 Cognitive fluctuations could be the result of dynamic serotonergic dysfunction 
In a similar manner to the results from the LC and PPN, differences in the burden of 
pathological proteins in the raphe were related to pathological diagnosis and not the 
presence or absence of cognitive fluctuations. Furthermore, analogously to the PPN no 
relationships were observed between the pathological burden in the raphe and the severity 
of cognitive fluctuations. However, analysis of TPH2 intensity in neurons with and without 
Lewy bodies identified differences that could relate to the severity of cognitive fluctuations. 
Together with the observation that a higher proportion of TPH2-positive neurons without 
Lewy bodies was associated with more severe cognitive fluctuations, dysfunction to the 
serotonergic system could underly vulnerability to cognitive fluctuations independent of 
local neurodegenerative pathology burden.  
The raphe forms part of the ventral ARAS pathway (Zeman, 2001), and has been implicated 




cognition has been hypothesised to reflect disturbed sleep-wake homeostasis leading to 
alterations in arousal (O'Dowd et al., 2019), consistent with alterations to sleep-wake 
architecture previously described in DLB (Pao et al., 2013). The raphe conveys its effect on 
arousal through serotonergic projections to various cortical and subcortical regions, 
including the basal forebrain and hypothalamus. Studies have identified atrophy of the basal 
forebrain (Grothe et al., 2014; Schumacher et al., 2020) and volumetric reductions in the 
hypothalamus associated with changes to arousal (Whitwell et al., 2007), in DLB. 
Furthermore, clinical features of DLB include depression and anxiety, suggestive of 
serotonergic dysfunction (McKeith et al., 2017). The present findings of variations in TPH2 
intensity in neurons with and without Lewy bodies, and the proportion of TPH2-posiitve 
neurons bearing Lewy bodies that related to the severity of cognitive fluctuations, likely 
indicates that serotonergic dysfunction could elicit vulnerability to cognitive fluctuations. 
Alterations to the serotonergic system could force other neurotransmitter systems in the 
ARAS, including the noradrenergic and cholinergic pathways, to compensate. Alterations to 
the noradrenergic pathways and cholinergic pathways have previously been identified in 
DLB, possibly indicating that these pathways may not be able to fully compensate for 
serotonergic dysfunction. The inability for the ARAS to reliably compensate for dysfunction 
in one of its constituent neurotransmitter systems could lead to a less dynamic modulation, 
which is not capable of handling variability in the load it is placed under, which could lead to 
lapses in cortical excitement, observed as clinical fluctuations. 
Similarly, to the PPN and LC the described alterations to the raphe are not likely to be 
exclusively responsible for cognitive fluctuations in DLB. The alterations to the raphe are 
likely to occur in unison with other changes in the ARAS. For example, imbalances between 
the monoaminergic and cholinergic systems would likely reduce the ability for the brain to 
dynamically control large scale networks that are required for the basis of consciousness 
(Matar et al., 2019). Fluctuations may be dependent on various changes that act in unison 
with those identified in the raphe, such as altered connectivity with higher order ARAS 
pathway structures. Alterations to the basal forebrain and hypothalamus for example, could 
further exacerbate serotonergic dysfunction, consequently leading to an ARAS system 
vulnerable to fluctuating cognition. Studies in the basal forebrain (Grothe et al., 2014; 




connectivity and volumetric reductions, that are consistent with the suggestion that 
numerous ARAS regions are impaired within DLB.  
7.5 Synaptosomal levels of neurotransmitter markers and pathology in the medial 
prefrontal cortex do not relate to the presence or absence of cognitive fluctuations 
Immunoblot assessment of synaptosomal and soluble enzyme fractions in the mPFC 
identified the burden of pathological proteins related to the pathological diagnosis rather 
than the presence or absence of cognitive fluctuations. Furthermore, analysis of 
synaptosomal levels of neurotransmitter markers, SERT, VMAT2 and ChAT, along with 
mitochondrial markers did not identify any differences in the experimental groups in 
comparison to controls. 
Previous studies have identified reductions to the neurotransmitter markers, SERT and 
ChAT, as well as mitochondrial markers in neurodegenerative disorders including DLB and 
AD (Tiraboschi et al., 2000; Ballard et al., 2002a; Flønes et al., 2018). The apparent 
preservation of neurotransmitter and mitochondrial markers could be through a 
preferential selection of ‘healthy’ synaptosomes and mitochondria in the fraction examined, 
as well as alterations to reserve pools of transporter proteins. However, even though there 
may be a preferential selection for ‘healthy’ synaptosomes, in the synaptosomal fraction 
analysed in the current study there were no alterations identified in the markers of ARAS 
projections in the disease groups compared to the controls. A lack of difference compared 
to the controls could suggest that there is no selective damage to ARAS-projecting 
synaptosomes. If there was selective damage or loss of ARAS-projecting synaptosomes it 
could be postulated that there would be a decrease in the ARAS projection markers, as a 
proportion of the total synaptosome pool and therefore would be an increase in ‘non-
healthy’ synaptosomes in the disease groups. Therefore, as analyses were measured relative 
to total protein content a decrease in the ARAS projection markers could have been 
expected. A further suggestion could be that all synaptosomes are equally vulnerable, not 
just those that are ARAS projecting. If all synaptosomes were reduced at the same rate, this 
could present as there being no difference between the disease groups and controls, due to 
the fact analysis was not quantified relative to the synaptosomal number. Examination of 
the other fractions, or the crude tissue homogenate, is required to fully assess whether 




that alterations in the mPFC solely contribute to the cortical vulnerability towards cognitive 
fluctuations and further alterations, including deafferentation of cholinergic and 
monoaminergic projections would be necessary in further cortical regions to create a 
propensity towards fluctuating cognition. Along with possible alterations to reserve pools of 
transporters, it is likely that subtle changes to receptors, including number, relative subtype 
expression and topographical location, both globally and neuronally, in the mPFC and other 
cortical regions may also be necessary to create a system vulnerable to cognitive 
fluctuations.  
7.6 Vulnerability across the ascending reticular activating system and its relationship 
to cognitive fluctuations  
The present series of studies has demonstrated that the presence of pathological protein 
accumulation within the ARAS is more specific for pathological diagnosis than the presence 
or absence of cognitive fluctuations. This is consistent with the idea that pathology in a 
single component of a distributed network may not be sufficient to account for the 
phenomenon, and that a collection of changes throughout the system could be necessary 
(Matar et al., 2019). The present series of studies have also identified alterations to the 
serotonergic neurotransmitter system that could relate to or create vulnerability to the 
presence of cognitive fluctuations. The raphe plays a complex role in the maintenance of 
arousal states, with lesions leading to permanent states of arousal and cortical depletion of 
serotonin having a sedative effect. Therefore, the present results could suggest that 
alterations that allow for a dynamic system, rather than a permanent diminished state, 
including alterations to neurotransmitter catalytic enzymes, could be more representative 
of the alterations required to create a vulnerability towards a transient clinical feature like 
cognitive fluctuations.  
Alpha-synuclein pathology was identified, in the pathologically LBD cases, in all regions 
examined. The regions investigated have all been implicated in modulating arousal through 
their connectivity with cortical regions and impairments to these nuclei have been 
speculated to play a role in the vulnerability towards cognitive fluctuations. However, levels 
of alpha-synuclein, and AD-type pathology were not different between the nLBD cases both 
with and without cognitive fluctuations. If cognitive fluctuations were to be purely the 




between the nLBD with and without cognitive fluctuations groups would have been 
observed. Therefore, the data from the histological studies of the three brainstem nuclei 
could suggest that perhaps different forms of pathological alterations, including presence 
and level of different alpha-synuclein species not specifically examined in the present 
studies or alterations to receptors may be necessary for the manifestation of cognitive 
fluctuations.   
The ARAS is a diffuse complex system comprised of a number of nuclei and 
neurotransmitter systems, with studies having identified a degree of redundancy with the 
system (Kovalzon, 2016b). Due to the level of redundancy within the ARAS it is suggested 
that all three key brainstem structures would need to be affected or that one region or 
neurotransmitter system would need to be severely affected so that parts of the ARAS are 
not able consistently undertake the role of the affected region, in order to elicit fluctuations 
in consciousness. If all three key brainstem regions were to be affected creating a 
vulnerability towards fluctuating cognition, it could be that regions contain a specific 
pattern of pathology. However, data from the present studies show a lack of associations 
between the pathological burdens of the three ARAS nuclei, specific to the groups with 
cognitive fluctuations. The lack of conserved associations in the fluctuation groups suggests 
that there is no topographical pattern of pathological burden that is specific for the 
presence of cognitive fluctuations. 
Two main hypotheses have been suggested to explain the aetiology of cognitive 
fluctuations; fluctuations as a disorder of attention and fluctuations as a disorder of arousal 
(Matar et al., 2019; O'Dowd et al., 2019). However, studies have suggested that cognitive 
fluctuations could be a disorder of both attention and arousal (Bliwise et al., 2014; Ferman 
et al., 2014). Data from the current studies could contribute new insights into the 
hypotheses surrounding cognitive fluctuations, as the current studies identified no 
relationships between the accumulation of pathological proteins and the presence or 
severity of cognitive fluctuations in the ARAS regions examined. This data could suggest that 
the presence of pathological aggregates alone in the regions is not sufficient to elicit 
cognitive fluctuations. It should be emphasised however that the lack of association with 
pathological burden does not suggest that the regions are not involved in the vulnerability 




changes could relate to the presence of cognitive fluctuations. However, the present series 
of studies primarily examined the alterations to arousal systems in relation to cognitive 
fluctuations. Although, the mPFC has been implicated in attentional as well as arousal 
systems. Therefore, it is possible that in order to elicit cognitive fluctuations impairments to 
both systems must occur in concert and alterations to the ARAS might represent only part of 
the vulnerability towards cognitive fluctuations. It is also plausible that a compromised 
system enables cognitive fluctuations to occur but additional dynamic factors, such as an 
increased load on the systems or variations to neurotransmitter vesicle pools, are required 
for a clinical feature to present.  
Cognitive fluctuations have already been postulated to be a product of alterations to 
multiple sites within a system, including the ARAS. It is possible that cognitive fluctuations 
are elicited by variable involvement in the different nodes of the affected network 
differentially in each individual, but that produces the same clinical phenotype, as Dugger et 
al. (2012) has postulated for RBD. This hypothesised individual variability within the same 
network could explain the difference observed clinically between the duration and 
frequency of cognitive fluctuations. Matar et al. (2019) hypothesised that cases that 
fluctuated frequently and for a short duration, compared to those who fluctuated 
infrequently but for a longer duration, could be representative of two different 
neuropathological aetiologies, although could elicit the same score for clinical severity via 
CAF. Variable involvement of arousal and attentional systems that could elicit fluctuating 
cognition could explain the lack of relationship to the presence or absence of cognitive 
fluctuations. Furthermore, results from the present study mainly identified pathological 
alterations related to the last CAF score, and not the average or maximum values. Within 
the present cohort a selection of cases possessed last CAF scores that were suggestive of a 
lack of cognitive fluctuations, although previous scores and clinical notes indicated that 
cognitive fluctuations had been present previously. The predominance for associations with 
last CAF score could be suggestive that the alterations that allow fluctuating cognition to 
occur could vary over the course of disease progression. Those cases which had a last CAF 
score indicative of a lack of cognitive fluctuation could have ‘lost’ the dynamic flexibility 
required to fluctuate, or due to the reversible nature of cognitive fluctuations, although 




maintain cortical arousal states. Together this could suggest that there is a high level of 
variability both between individuals and throughout the duration of disease progression in 
regard to the underlying neuropathological changes related to cognitive fluctuations. A high 
degree of variability would have hampered the ability of the present studies to identify 
specific changes that relate to the presence or absence of cognitive fluctuations.  
Overall the data suggests that the ARAS is subject to neurodegenerative changes, including 
the accumulation of pathological protein aggregates, however it is currently unclear how 
these could elicit a vulnerability towards cognitive fluctuations. Due to the degree of 
redundancy within networks, including the ARAS (Kovalzon, 2016b), pathology or structural 
alterations to individual components of a network are unlikely to relate to the presence of 
cognitive fluctuations. It is probable that a collection of pathological alterations, molecular 
and degenerative, to a number of network components contributes to the vulnerability to 
fluctuations.  
7.7 General strengths and limitations 
7.7.1 Strengths 
The primary strength of this study was the analysis of the same cases across all the ARAS 
regions examined. As there are multiple neurotransmitter systems that comprise the ARAS, 
it suggests that there is some level of redundancy within the system (Kovalzon, 2016b), 
further supported by animal lesion models, show that no pathway is essential for the 
maintenance of arousal (Jones, 2005b). Therefore, analysis of all regions in the same cases 
enabled the examination of the ARAS system as a whole in relation to cognitive fluctuations 
in DLB. 
A further strength of the study was that the cases included were clinically and pathologically 
well-characterised, with a consensus diagnosis based upon clinical and neuropathological 
features. The clinicopathological diagnosis ensured that all cases were not atypical in their 
clinical or neuropathological presentation and allowed the correct experimental fluctuation 
group categorisation that would not lead to anomalous results.  
Furthermore, due to the level of clinical information available from the NBTR, it was 
possible to ensure only DLB and nLBD cases with a history of cognitive fluctuations were 
included. The NBTR clinical information also meant it was possible to exclude cases that, 




these fluctuations were believed to be the result of or induced by medication changes. The 
extent of the clinical data further allowed for the inclusion of the AD and nLBD cases 
without a history of cognitive fluctuations. Additionally, the quantity of clinical data 
available allowed the assessment of the severity of cognitive fluctuations via maximum, 
average and last CAF score. As cognitive fluctuations are variable in clinical appearance the 
ability to use more than one measure of severity allows the capture the full range of 
variation of the clinical phenotype.   
The use of two disease control groups, nLBD and AD without cognitive fluctuations, is a 
further strength of the current studies. The inclusion of a nLBD without fluctuation group 
enabled specific comparisons to be undertaken in relation to cognitive fluctuations with the 
DLB and nLBD with fluctuations groups. The AD without cognitive fluctuations group further 
controlled for the effect of AD-type pathology in the regions analysed in the mixed AD/DLB 
cases. The inclusion of the non-fluctuating groups enabled the possible identification of a 
specific pattern or severity of pathological protein deposition, that could lead to a 
vulnerability towards cognitive fluctuations.  
The biochemical analysis of the mPFC utilised synaptosomal fragmentation, in order to 
determine the ‘functional’ levels of neurotransmitter markers.  A number of 
neurotransmitter markers, including vesicular transporters can be located at the synapse as 
well as in other neuronal compartments, therefore the fragmentation allowed the 
investigation of marker levels at the synaptic level compared with the whole tissue level.  
7.7.2 Limitations 
The present studies were limited by small cohort numbers, with a maximum of 14 per 
experimental fluctuation group. The specific inclusion of cases with well documented and 
assessed cognitive fluctuations meant that a number of possible cases were excluded from 
analysis; this included the exclusion of cases where fluctuations in cognition appeared to be 
related to medication and those that were uncooperative with neuropsychiatric testing intra 
vitam. A larger cohort size may have been better powered to identify relationships related 
to cognitive fluctuations. However, the study by Duggar et al. (2012) which undertook a 
similar analysis of the LC and PPN in relation to RBD utilised a maximum of 10 cases in the 




As the present series of studies were retrospective, not all cases utilised had been assessed 
for cognitive fluctuations. This limited the number of cases that could be utilised to test 
associations with severity of cognitive fluctuations, using CAF score. Although the number of 
cases is a limiting factor, a more prominent caveat is the CAF score itself. Some cases, which 
although had been recorded to clinically have cognitive fluctuations, had CAF scores of 0, 
which would suggest no fluctuations were present. The CAF consists of a series of 
informant-directed questionnaires regarding fluctuating confusion and impaired 
consciousness in the month prior to the assessment (Mainland, 2015). The cases that 
possessed CAF scores tended to come from clinical studies undertaken in conjunction with 
the NBTR, these cases were assessed annually with a number of neuropsychiatric including 
CAF. With CAF only being recorded annually, if a patient did not noticeably fluctuate within 
the month prior to the assessment, the presence of cognitive fluctuations would not be 
recorded within the score even if during the year severe and noticeable fluctuations had 
occurred. Along with CAF scores only being assessed annually, another caveat of the score is 
that due to the nature of the CAF scoring system, short duration but frequent fluctuations 
would receive the same score as longer duration, but more infrequent fluctuations; it is 
thought that these two different fluctuation patterns may be due to differing underlying 
pathological changes (Matar et al., 2019). A difference in fluctuation pattern could occur 
between the nLBD and DLB cases with fluctuations which could explain the association with 
tau in one group but not the other, however, until a more robust and frequent clinical 
assessment for clinical fluctuations is adopted into practice it will be difficult to fully probe 
into the pathological correlates for cognitive fluctuations. 
A further limitation of the histological studies was the lack of consistent level utilised to 
assess the three brainstem regions of the ARAS. Although the tissue analysed was obtained 
from the same NBTR tissue block for each of the three nuclei examined, the levels obtained 
for analysis could have possessed within block variations to the to the tissue section level. 
Previous studies have identified that different levels within the LC, PPN and raphe project to 
different anatomical regions, and have different effects on cognition and arousal (Ward and 
Gunn, 1976; Hornung, 2003; Hamani et al., 2016). As the blocks containing the LC, raphe 
and PPN are used for routine diagnostics sections had already been taken from the blocks 




A related limitation was that in the histological studies only one marker of alpha-synuclein 
was assessed. As research has suggested that Lewy bodies may be protective (Tompkins and 
Hill, 1997; Olanow et al., 2004; Tanaka et al., 2004; Shults, 2006) and more evidence 
suggests that different species of alpha-synuclein may play more of a role in the proteins 
neurotoxic effects (Lashuel et al., 2013), a pan alpha-synuclein marker (KM51) may not have 
assessed the levels of disease relevant alpha-synuclein. Human tissue is a valuable resource, 
therefore, examination of a wide number of alpha-synuclein species histologically could 
require exhaustive amounts of tissue, this is especially influential for the LC which is utilised 
for routine diagnostics where tissue is already limited for research use. 
nLBD and AD cases were utilised as non-fluctuating disease control groups. Although the use 
of nLBD allowed for examination of a pathologically high-grade Lewy body group that did 
not have fluctuations, its direct comparison to DLB was confounded by the presence of high-
grade AD-type pathology. Examination of nLBD with and without cognitive fluctuations 
allowed for comparison between the groups specifically in relation to cognitive fluctuations. 
However, the present study assumed that the cognitive fluctuations observed in mixed 
AD/DLB and DLB had the same aetiology, as changes specific to both fluctuating groups and 
not the two non-fluctuating groups would represent a fluctuation specific alteration. A more 
appropriate comparator would have been DLB cases without fluctuations, however as 
fluctuations are a core features identified in 80-90% of cases it would not be possible to 
obtain enough cases for meaningful analysis. 
7.8 Future directions 
7.8.1 Short-term studies 
Synaptosomal levels of ChAT and SERT assessed in the mPFC, were observed not to be 
significantly altered compared to control cases. The results obtained in Chapter 6 were in 
contradiction to a number of previously reported findings that have identified reduction in 
global cortical ChAT levels in both AD and DLB (Lippa et al., 1999; Tiraboschi et al., 2000). 
The lack of difference between the experimental fluctuation and control groups was 
hypothesised to be due to preferentially selection of ‘healthy’ synaptosomes during the 
fractionation processes. Therefore, to validate this hypothesis examination of SNAP25, as 
well as other synaptic markers, in all the fractions would be required to assess if whether in 




markers in the non-synaptosomal fraction. Furthermore, assessment of the other fractions 
for SERT and ChAT levels could identify whether the different experimental fluctuation 
groups have differing levels of the neurotransmitter markers in the ‘unhealthy’ synapses. An 
additional assessment of NET levels within the fractions should be undertaken to examine 
the integrity of noradrenergic projections to the mPFC, as no assessment could be 
undertaken in the current study due to being unable to ascertain a working protocol. 
Recent research has suggested that different species, including monomeric, oligomeric and 
post-translationally modified species of alpha-synuclein exist, with some likely having 
greater disease relevance that others (Lashuel et al., 2013; Alam et al., 2019; Mahul-Mellier 
et al., 2020). Therefore, the employment of a pan-alpha-synuclein antibody in the present 
studies, labelling both pathogenic and less pathogenic species, may have limited the ability 
to observe relationships between alpha-synuclein and cognitive fluctuations, which is a 
limitation of the current study These findings in conjunction with the notion that static 
pathological aggregate may not represent the pathological substrate required to elicit a 
transient clinical symptom, suggest other species of alpha-synuclein should be investigated. 
Therefore, quantifying the levels of different alpha-synuclein species, specifically in the 
synaptosomal fraction of the mPFC, could help identify species that are more relevant to the 
vulnerability of the ARAS to fluctuating cognition.  
The present studies did not include neuronal cell counts, in the LC, PPN or raphe. Therefore, 
cell counts for noradrenergic, cholinergic and serotonergic neurons in the LC, PPN and raphe 
respectively should be undertaken. Neuronal cell counts would enable further insight into 
changes within the ARAS nuclei that could relate to cognitive fluctuations, as suggested in 
Chapters 3 and 4.  
The results from current study of the raphe identified changes to serotonergic neurons 
containing Lewy bodies which could lead to serotonergic dysfunction that creates a 
predisposition to the generation of fluctuating cognition. Therefore, further investigations 
are warranted to examine the specific neuronal localisation of pathology within the LC and 
PPN. Analysis of whether alpha-synuclein pathology is preferentially located in 
noradrenergic or cholinergic neurons, and whether the presence of pathology leads to 
alterations in catalytic enzyme levels, could help further test the hypothesis that 




7.8.2 Medium and long-term studies 
The two main pathways of the ARAS, ventral and dorsal, project from the brainstem through 
the thalamus, dorsal, and hypothalamus and basal forebrain, ventral (Jones, 2003). 
Examination of these regions in the cases that have already had the brainstem ARAS nuclei 
analysed would allow a more comprehensive assessment of the ARAS as a whole. 
Assessment of pathological changes as well as alterations to neurotransmitter markers 
could identify whether changes throughout the ARAS are required in order to create a 
vulnerability towards cognitive fluctuations.  
Arousal has been speculated to be mediated by a wide array of different neurotransmitter 
receptors, including nicotinic, β- and α1-receptors, and 5-HT1A and 5-HT1B receptors 
(Berridge, 2008; Monti, 2011; Bloem et al., 2014). Examination of receptor levels via 
autoradiography could allow the identification of further neurotransmitter changes that 
could lead to the dynamic dysfunction required to elicit a transient clinical feature. 
Pathological examination of DLB patients who had undergone extensive clinical assessment 
of their cognitive fluctuations, for example EEG, MRI, and regular assessment of severity 
including CAF or DCFS would enable the pathological examination of alterations observed 
intra vitam. Furthermore, utilising cases that had undergone extensive neuropsychiatric 
testing could enable the examination of whether cases that have cognitive fluctuations that 
are short in duration but frequent have a similar, or different pathological underpinning to 
those with longer duration but less frequent fluctuations.  
The changes that occur in the different regions that comprise the ARAS are likely to underly 
a vulnerability to cognitive fluctuations in concert with each other (Matar et al., 2019). 
Therefore, computational modelling the specific changes observed within the regions 
examined, including deposition to pathological aggregates, alterations to neurotransmitter 
markers and receptors for example could provide a general overview of the status of the 
ARAS in cases with cognitive fluctuations compared to those without. Computational 
models obtained from pathological data could then be compared with EEG data to further 
understand the process that elicits cognitive fluctuations. 
7.9 Conclusion 
This study identified that the severity of protein aggregates in the ARAS was not associated 




patients have a pathologically compromised arousal system, but that this likely acts in 
concert with other mechanisms to elicit cognitive fluctuations. As cognitive fluctuations are 
transient, one may speculate that static protein aggregates are unlikely to underlie a clinical 
feature defined by variable clinical presence and it is likely that cognitive fluctuations are 
related to a global system failure rather than one specific change. Therefore, research 
should focus on obtaining a better clinical understanding and, the ability to quantify 
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